

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Behavioral and pharmaceutical interventions for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029265
Article Type:	Research
Date Submitted by the Author:	28-Jan-2019
Complete List of Authors:	James, Laura; University of Sydney, Saglimbene, Valeria; The University of Sydney, Sydney School of Public Health Wong, Germaine; The Children's Hospital at Westmead, Centre for Kidney Research Tong, Allison; The University of Sydney, Sydney School of Public Health Luu, Laurence; The University of Sydney, Sydney School of Public Health Craig, Jonathan; Flinders University Faculty of Medicine Nursing and Health Sciences, College of Medicine and Public Health, ; The Children's Hospital at Westmead, Centre for Kidney Research Howard, Kirsten; University of Sydney, School of Public Health Howell, Martin; University of Sydney - Camperdown and Darlington Campus, School of Public Health
Keywords:	skin cancer, melanoma, prevention, sun protection, sun protection behaviors

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Behavioral and pharmaceutical interventions for the prevention of skin cancers in solid organ**
5
6 **transplant recipients: a systematic review of randomized controlled trials**
7
8
9

10
11 **Authors full names and highest degree:**
12

13 Laura J. James, MPH^{1,2}, Valeria Saglimbene^{1,2,3}, MscMed^{1,2}, Germaine Wong, PhD^{1,2,4}, Allison Tong,
14 PhD^{1,2}, Laurence Don Wai Luu, BMedSc^{1,2}, Jonathan C. Craig, PhD⁵, Kirsten Howard, PhD¹, Martin
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Howell, PhD^{1,2}

22 **Institution of each author:**
23

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
¹Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney,
NSW 2006

²Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW 2145

³Diaverum Medical-Scientific Office, Lund, Sweden

⁴Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW 2145

⁵College of Medicine and Public Health, Flinders University, Adelaide, Australia

40 **Corresponding author:**
41

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Laura James

Centre for Kidney Research

The Children's Hospital at Westmead, Westmead, NSW 2145

Sydney, Australia

Phone: +61 2 9845 1482 Fax: +61 2 9845 1491

Email: laura.james@health.nsw.gov.au

Word count (abstract): 205

Word count (body): 3593

1
2 **Tables: 4** **Figures: 5**
3
4
5

6
7 **Key words:** skin cancer, melanoma, prevention, sun protection, sun protection behaviors, health
8
9 behavior
10

11 12 13 14 **Authorship**

15
16 LJJ, GW, AT, LL, JCC, MH designed the study; LJJ, VS, LL, MH conducted the data extraction and
17
18 analyses; all authors contributed to the interpretation of the analyses. LJJ drafted the manuscript;
19
20 all authors contributed to the writing and review of the manuscript.
21
22
23

24 25 26 **Disclosure**

27
28 The authors declare no conflicts of interest.
29
30
31

32 33 34 **Funding**

35
36 LJJ is supported by the National Health and Medical Research Council (NHMRC) Better Evidence
37
38 and Translation in Chronic Kidney Disease (BEAT-CKD) Program Grant (APP1092957). MH is
39
40 supported by the BEAT-CKD Program Grant (APP1092957). AT is supported by the NHMRC
41
42 Fellowship (APP1106716). The funding organizations had no role in the design and conduct of the
43
44 study; collection, management, analysis and interpretation of the data; preparation, review, or
45
46 approval of the manuscript.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abbreviations

AZA, azathioprine

BCC, basal cell carcinoma

CNI, calcineurin inhibitors

CI, confidence intervals

MAL, methyl aminolaevulinate cream

MD, mean difference

MMF, mycophenolate mofetil

mTORI, mammalian target of rapamycin inhibitors

NMSC, non-melanoma skin cancer

RCT, randomized controlled trial

RR, relative risk

SCC, squamous cell carcinoma

SMD, standardized mean difference

ABSTRACT

Objectives

Solid organ transplant recipients are at increased risk of skin cancer, affecting more than 50% of recipients. We aimed to determine the effectiveness of interventions for behavioral change for sun protection or skin cancer prevention in solid organ transplant recipients.

Design

Systematic review

Methods

Electronic databases were searched from inception to January 2018. We included randomized controlled trials that evaluated the effect of behavioral or pharmaceutical interventions on behavioral change or skin cancer prevention in solid organ transplant recipients. Risks of bias and evidence certainty were assessed using Cochrane and the GRADE framework.

Results

Twenty trials (n=2,295 participants) were included. The overall risk of bias was low or unclear and the quality of evidence was very low for all outcomes. Compared with standard care, behavioral interventions appear to improve sun protection behavior (N=3, n= 414, SMD 0.89, 95% CI -0.84-2.62, $I^2=98%$) and knowledge (N=4, n=489, SMD 0.50, 95% CI 0.12-0.87, $I^2=76%$). Compared with calcineurin inhibitors, conversion to mammalian target of rapamycin inhibitors may reduce the incidence of non-melanocytic skin cancer (N=5, n=1080, RR 0.46 95% CI 0.28-0.75, $I^2=72%$).

Conclusions

1
2 Behavioral and pharmaceutical preventive interventions may improve sun protective behavior and
3
4 knowledge, and reduce the incidence of non-melanocytic skin cancer, but the overall quality of the
5
6 evidence is very low and insufficient to guide decision-making and clinical practice.
7
8
9
10

11 **PROSPERO Registration number**

12
13
14 CRD420170639
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ARTICLE SUMMARY

Strengths and limitations

- A comprehensive review summarising evidence for interventions aimed at the behavioural change and skin cancer prevention in solid organ transplant recipients
- Few trials included important outcomes of skin cancer and none included melanoma or mortality
- The overall quality of evidence was very low for all outcomes and therefore insufficient to guide decision-making and clinical practice

1. INTRODUCTION

Skin cancer, including melanoma and nonmelanoma skin cancer (NMSC), is the most frequently diagnosed malignancy among solid organ transplant recipients, affecting more than 50% of post-transplantation recipients.^{1,2} The cumulative incidence of NMSC increases with time after transplantation, from 5-10% at 2 years to 40-80% at 20 years.²⁻⁴ Squamous cell carcinomas (SCC) account for 95% of skin cancers diagnosed, with an incidence of 65 to 250 times greater than the age and gender-matched general population.⁵⁻⁷ Once cancer develops, the excess risks of death from invasive and metastatic skin cancer, such as SCC and melanoma, are three times to nine times higher than the general population, with five-year overall survival of less than 30%.^{6,8-11}

Sun exposure behaviors remain the most significant and modifiable risk factor in the prevention of skin cancers in the general population.¹² However, with the dramatic increase in skin cancers in solid organ transplant recipients, pharmaceuticals have also been used to reduce and delay the development of skin cancer.^{12,13} Current recommendations for preventive strategies have often been extrapolated from guidelines in the general population, which may not be applicable to solid organ transplant recipients.¹⁴ For example, frequent skin self-examination and annual to biannual total body skin examination are generally recommended for the general population.¹⁴⁻¹⁶ Sun protective behaviors including use of sunscreen, protective clothing and limiting sun exposure during peak hours are potential measures for skin cancer prevention.^{3,4,10} Further, alteration of maintenance immunosuppression such as conversion to mammalian target of rapamycin inhibitors (mTORi) and secondary prevention using retinoid acitretin are recommended for management of skin cancers in high risk transplant recipients.¹⁵

1
2 The aim of this study is determine the effectiveness of interventions that promote behavioral
3
4 change and skin cancer prevention in solid organ transplant recipients.
5
6
7

8 **2. METHODS**

9

10
11 This systematic review followed a pre-specified protocol registered in PROSPERO
12
13 (CRD4201706392) and is reported in accordance with the Preferred Reporting Items for Systematic
14
15 Reviews and Meta-analyses (PRISMA) checklist.¹⁷ The study was exempt from approval from an
16
17 ethics' board. There was no patient or public involvement.
18
19
20
21

22 **2.1 Inclusion criteria**

23

24
25 All randomized controlled trials (RCTs) or quasi RCTs (allocated to trial arms by investigators) of
26
27 interventions for skin cancer prevention (both melanoma and non-melanoma skin cancer) in solid
28
29 organ transplant recipients were included. Behavioral interventions defined as any strategy used
30
31 to promote sun protective behavior including passive (e.g. pamphlets), active (e.g. group
32
33 workshops, counselling, dermatology clinic) and provision of sun protective equipment; and
34
35 pharmaceutical interventions (switch to mTOR inhibitors, photodynamic therapy, immune
36
37 response modifiers, nicotinamide and oral retinoids) and studies that reported skin cancer related
38
39 outcomes as their primary outcomes were included. Studies that did not report these outcomes as
40
41 primary end-points were excluded. Studies of interventions for the treatment of skin cancer were
42
43 excluded.
44
45
46
47
48
49

50 **2.2 Search strategies**

51

52
53 We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and
54
55 CINAHL from inception to January 2018 without language restriction, using search strategies
56
57
58
59
60

1
2 designed by a specialist information manager (Figure S1). Reference lists of included studies were
3
4 also searched.
5
6
7

8 **2.3 Data extraction**

9

10 Titles and abstracts were reviewed by two independent authors (LJJ & LL) and those that did not
11 meet the inclusion criteria were excluded. Full text articles were reviewed by 3 independent
12 reviewers (LJJ, VS, LL) and any disagreements were resolved by discussion. Data on study design,
13 geographic location, sample size, type of transplant, measurement of interventions, interventions
14 and comparators were extracted. We sought unclear or missing information from authors where
15 possible.
16
17
18
19
20
21
22
23
24
25

26 **2.4 Outcome measures**

27

28 The pre-specified outcome measures were incidence of precancerous and cancerous lesions, sun
29 protection behavior (including use of sunscreen, use of protective clothing including hats and
30 sunglasses, shade and sun avoidance), knowledge and attitude, skin self-examination, sun
31 exposure (including skin irritation, sunburn) and biologic measures (including measurement of
32 melanin index and sun damage assessment).
33
34
35
36
37
38
39
40
41
42

43 **2.5 Risk of bias and quality of evidence**

44

45 The risk of bias was assessed independently by LJJ and VS using the Cochrane risk of bias tool.¹⁸
46
47 The domains included in the assessment were: random sequence generation, allocation
48 concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete
49 outcome data, selective reporting, trial registration and industry involvement. Each criterion was
50 assigned a judgment of high, low or unclear risk of bias. Intention to treat and lost to follow up
51 were also assessed for each study. The quality of the evidence informing summary estimates for
52
53
54
55
56
57
58
59
60

1
2 each outcome was then assessed by LJJ using the Grading of Recommendations Assessment
3
4 Development and Evaluation (GRADE) guidelines.¹⁹
5
6
7

8 **2.6 Data synthesis and statistical analyses**

9
10 Continuous outcomes were summarized as mean difference (MD) or standardized mean
11
12 difference (SMD) and dichotomous outcomes as relative risk (RR). A MD/SMD greater than zero
13
14 and/or a RR greater than 1 could be interpreted as favoring the intervention group relative to the
15
16 control, unless specified elsewhere. Risk estimates were reported with 95% confidence intervals
17
18 (CI), using random-effects meta-analysis. We considered P values <0.05 to be statistically
19
20 significant. We quantified the heterogeneity using the I² statistic. An I² value of <25% was
21
22 considered to represent low heterogeneity and >75% as high heterogeneity. When sufficient data
23
24 were available, possible sources of heterogeneity were investigated using subgroup analysis based
25
26 on pre-specified study characteristics including sample size, trial duration, setting and overall risk
27
28 of bias. Funnel plots were planned to evaluate small study effects when at least ten studies were
29
30 included in meta-analysis. All analyses were conducted using Review Manager version 5.3
31
32 software.
33
34
35
36
37
38
39
40

41 **3. RESULTS**

42 **3.1 Study selection**

43
44
45 The literature search identified 1099 articles, of which, 854 were excluded after abstract and title
46
47 review. Full text assessment of 78 studies found 21 eligible articles for inclusion (Figure 1).
48
49
50
51

52 **3.2 Studies characteristics**

53
54
55 We included 21 reports of 20 RCTs, including 2,295 participants (Figure 1). The study
56
57 characteristics are summarized in Table 1 and Table 2. The median number of participants was 44
58
59 (range 17 to 824) and the median follow-up duration was 10 months (range 1 day to 36 months).
60

1
2 All studies included kidney transplant recipients, with some also including heart transplant
3 recipients (n=1), liver, heart, pancreas, lung, heart/lung and other transplants (n=1), and lung and
4 liver transplant recipients (n=2). In total, 15 of 21 (76%) studies provided sufficient data for the
5 meta-analyses. Six studies did not meet final criteria for meta-analysis as they had the same
6 sample of participants (n=1),²⁰ or did not provide data that was able to be meta-analyzed (n=5).²¹⁻
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3.3 Risk of bias and quality of the evidence

Overall studies were at low or unclear risk of bias for many domains (Figure 2; Figure S2).

Allocation concealment was adequate in 7 (35%) of 20 studies, and unclear in 12 (60%) studies.

Participants were blinded in 4 (20%), and outcome assessors were blinded in 10 (50%). Intention to treat analyses were used in 6 (30%) studies and 256 (11%) patients were lost to follow-up. A total of 3 (15%) studies had incomplete outcome data, and all studies were at low risk for selective reporting. Seven studies (35%) reported industry involvement in authorship, design, or data analysis, and of the 16 trials requiring trial registration, only 9 (56%) reported accordingly.

The overall quality of the evidence was very low for all outcomes (Table S1) due to limitations in study design, heterogeneity in the intervention and outcomes measures, the very small sample size of individual studies and the small number of studies for each specific outcome. Obtaining an overall summary estimate was difficult for many outcomes due to the variability in the analytical methods and reporting in individual studies. In particular, assessment of reporting of sun protection behavior and sun protection knowledge was not possible as outcomes were inconsistent and there was large diversity of interventions used (e.g. written education material versus a mobile app program). Furthermore, formal testing of publication bias was not performed due to insufficient data.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3.4 Interventions

The interventions in the included studies were grouped in three broad categories, behavioral (n=6), switch to mTOR inhibitors (n=6), and other pharmaceutical interventions (photodynamic therapy, immune response modifiers, oral retinoids and nicotinamide) (n=9). Studies of behavioral interventions used passive methods of delivery including written educational material (n=2), both written educational material and text messages (n=1), mobile app programs (n=2) and a video (n=1).

All six studies of immunosuppression compared mTORis (sirolimus) to calcineurin inhibitors (CNI) based therapies.

Four of the eight studies of other pharmaceutical interventions assessed the effect of photodynamic therapy using methyl aminolevinate creams compared to placebo (n=1), no treatment to contralateral area (n=2) or a topical immune response modifier cream (n=1). Three studies assessed oral retinoid using acitretin compared to placebo (n=1), lower dose (n=1) or a drug free period (n=1), one study assessed nicotinamide compared to placebo and a single study assessed the benefits of topical immune response modifier compared to placebo in kidney transplant recipients.

3.5 Effect of behavioural interventions on sun protection outcomes

Sun protection behavior

Sun protection behavior, defined as hours spent outdoors per week, use of sunscreen, wearing protective clothing and seeking shade, was assessed in three trials²⁶⁻²⁸. Educational workbooks,²⁶ educational workbooks and text messages²⁷ and a mobile app program²⁸ were compared with standard care. Patients who received behavioral interventions reported improved sun protection

1
2 behavior scores²⁶⁻²⁸ (3 studies, 414 participants, SMD 0.89, 95% CI -0.84-2.62, I² 98%) (Table 3;
3
4 Figure 3). A single trial assessed a standardised and validated educational workbook and found an
5
6 improvement in the proportion of participants engaging in skin self-examination after one month
7
8 (75 participants, RR 4.14, 95% CI 2.22-7.72).²⁹ One trial assessed a mobile app program and
9
10 reported a reduction in daily hours spent outdoors among the intervention group (170
11
12 participants, SMD -6.12, 95% CI -7.11 to -5.13).²⁸
13
14
15
16
17

18 Sun protection knowledge

19
20 The effectiveness of educational workbooks, text messages, mobile app programs and videos on
21
22 sun protection knowledge was assessed in 6 studies^{20,24,26-29}, four of which provided data for a
23
24 meta-analysis. There was an improvement in knowledge scores (4 studies, 489 participants, SMD
25
26 0.50, 95% CI 0.12-0.87, I² 76%) in the intervention group compared to standard care (Figure 4).²⁶⁻²⁹
27
28 One study compared an interactive visual representation of the educational program with
29
30 standard information pamphlets and found that knowledge of sun protection improved among
31
32 those who received the educational video.²⁴
33
34
35
36
37
38
39

40 Sun protection attitude

41
42 Three studies assessed sun protective attitude after receiving an educational workbook, text
43
44 messages or a mobile app program over a period of 0.5 months to 1.5 months.²⁷⁻²⁹ Compared to
45
46 standard care, there was an overall improvement in scores of concern about developing cancer (3
47
48 studies, 348 participants, SMD 1.85, 95% CI 1.59-2.11, I² 96%).²⁷⁻²⁹ Two studies involving 273
49
50 participants reported an improvement in scores of understanding the personal risk of skin cancer
51
52 (SMD 0.61, 95% CI -0.60-1.82, I² 96%), adherence to sun protection (SMD 0.77 95% CI -0.14-1.68, I²
53
54 92%) and willingness or intention to change behavior (SMD 1.70, 95% CI -1.68-5.07, I² 99%).^{27,28} A
55
56 single study involving 75 participants also reported an improvement in scores of ability to
57
58
59
60

1
2 recognize a potential skin cancer (MD 1.80, 95% CI 1.35-2.25), importance of skin self-examination
3
4 (MD 1.05, 95% CI 0.61-1.49) and having a partner help for skin self-examination (MD 1.59, 95% CI
5
6 1.10-2.08).²⁹ Another single study reported an improvement in the importance of engaging in sun
7
8 protection (measured using 5-point Likert scale) (101 participants, MD 7.00, 95% CI 2.94-11.06).²⁷
9
10

11 12 13 14 Skin complications and biologic measures

15
16 Two trials of behavioral interventions in 271 kidney transplant recipients compared a mobile app
17
18 or an educational workbook and text messages to standard care on reported skin complications
19
20 and biologic measures of sun exposure.^{27,28} The intervention group experienced a reduced
21
22 incidence of skin irritation (a culturally relevant term for sun exposure³⁰) (RR 1.00, 95% CI 0.89-
23
24 1.13, I² 95%) or sunburn (RR 3.19, 95% CI 2.47-4.10, I² 99%). They also had a decreased melanin
25
26 index (right forearm, SMD -0.42, 95% CI -0.66 to -0.18; cheek SMD -0.25, 95% CI -0.64 to -0.15) and
27
28 reduced severity of sun damage (SMD -0.13, 95% CI -0.40 to 0.13) on sun exposed areas
29
30 (measured using clinical images of chronic sun damage and scored 1-10).
31
32
33
34

35 36 37 **3.6 Effect of pharmaceutical interventions on skin cancer prevention**

38
39
40 The incidence and responses of pre-cancerous lesions were measured only in trials of
41
42 pharmaceutical interventions (Table 4). These included the switch to mTOR inhibitors (n=1),³¹
43
44 photodynamic therapy (n=2)^{32,33} and immune response modifiers (n=1)³⁴ to current treatment,
45
46 lower dose or no treatment. The incidence of non-melanocytic skin cancers (NMSC) was assessed
47
48 in nine pharmaceutical studies.^{1,31,34-40} None included melanoma as an outcome.
49
50
51
52
53
54
55

56 Topical/local interventions

57
58
59
60

1
2 One trial of 14 participants compared an immune response modifier, 5% imiquimod cream with
3
4 placebo and found a reduction in the incidence of skin dysplasia (RR 2.14, 95% CI 0.31-14.65), skin
5
6 atypia (RR 3.00, 95% CI 0.47-19.35), and viral warts (RR 7.00, 95% CI 0.46-106.10).³⁴
7
8
9

10
11 One Danish study of 26 kidney transplant recipients compared photodynamic therapy with no
12
13 treatment and reported a relative reduction by approximately 40% in the incidence of NMSC on
14
15 the treated area (RR 0.59, 95% CI 0.34-21.03, p 0.06).⁴⁰ A lower incidence of SCC was also reported
16
17 in one trial comparing two areas of skin using an immune response modifier and placebo (14
18
19 participants, RR 0.09, 95% CI 0.001-1.70).³⁴ Two trials comparing photodynamic therapy to an
20
21 immune response modifier or photodynamic therapy to placebo in recipients with diagnosed
22
23 keratoses reported a complete response rate of 60% compared to 24% in the control group (50
24
25 participants, RR 5.03, 95% CI 0.14-176.17, I² 85%).^{32,33} Further, one trial which was not included in
26
27 the meta-analysis, reported a higher cumulative incidence of actinic keratosis lesions in untreated
28
29 skin (63%) compared with skin treated by photodynamic therapy (28%).²³
30
31
32
33
34
35
36
37
38

39 Systemic interventions

40
41
42
43 mTORis therapy reduced the incidence of NMSC compared to CNIs maintenance therapy (5 trials,
44
45 1082 participants, RR 0.46, 95% CI 0.28-0.75, I² 72%) (Figure 5).^{1,31,35,37,39} However evidence was
46
47 limited due to short follow-up periods, variability in dosing of mTORis and significant rates of loss
48
49 to follow up. A single trial involving 21 patients reported a reduction in the overall incidence of
50
51 SCC by 49% in the conversion arm, but reported a drop out rate of 77% and follow-up time of less
52
53 than 2 years.²¹ Further, a single trial which compared mTORi conversion from CNI based therapy
54
55 reported a significant improvement in skin dysplasia (32 participants, RR 24.35, 95% CI 1.55-
56
57
58
59
60 381.99).³¹

1
2
3
4 Two trials comparing an oral retinoid, acitretin, with placebo or a drug free period reported an
5 increased lower risk of both SCCs and BCCs (46 participants, RR 0.40, 95% CI 0.19-0.85, p 0.02; RR
6 0.50, 95% CI 0.14-1.76³⁸) or development of a new skin cancer (19 participants, RR 0.22, 95% CI
7 0.06-0.90). However, there were no differences in the incidence of new SCCs.³⁶ One trial, which
8 was not included in the meta-analysis, showed approximately a 50% reduction in the incidence of
9 actinic keratosis which compared a high dose to a low dose of acitretin.²²
10
11
12
13
14
15
16
17
18
19
20

21 One Australian trial of 22 kidney transplant recipients compared nicotinamide with placebo and
22 reported an estimated relative rate difference of 0.35 (95% CI -0.62 to 0.74), 0.67 (95% CI -0.40 to
23 0.90) and 0.07 (95% CI -1.51 to 0.65) for NMSC, BCCs and SCCs respectively.²⁵
24
25
26
27
28
29

30 **3.6 Subgroup analysis**

31
32 Study size, trial duration, setting and risk of bias did not modify the effects of CNIs and mTORIs on
33 skin cancer incidences (Figure S3). Sources of heterogeneity for other treatment effects could not
34 be explored due to insufficient data.
35
36
37
38
39

40 **4. DISCUSSION**

41
42 Skin cancers (both non-melanoma and melanoma) are major causes of morbidity and mortality in
43 solid organ transplant recipients. Despite this, trials of interventions aimed at preventing skin
44 cancer in solid organ transplant recipients are few in number (20 trials), small with half comprising
45 of 50 patients or less, of short duration (48% have <12 months follow up) and 52% do not include
46 incidence of skin cancer as an outcome. Our review included 21 reports of 20 trials involving 2,295
47 transplant recipients, who were predominately kidney transplant recipients. The studies covered a
48 broad range of interventions, including behavioral to improve sun protection behavior and
49
50
51
52
53
54
55
56
57
58
59
60

1
2 pharmaceutical (immunosuppression, photodynamic therapy, oral retinoid, nicotinamide and
3
4 topical immune response modifiers) to evaluate precancerous lesion response and cancer
5
6 incidence. None of the behavioral intervention studies included precancerous lesions or skin
7
8 cancer incidence as outcomes. Although interventions showed plausible improvements to sun
9
10 protection behaviors, precancerous lesion responses and cancer incidence, there was considerable
11
12 variability across interventions types, variability in outcomes assessed and outcome estimates.
13
14 Overall, the current evidence for interventions for skin cancer prevention in solid organ transplant
15
16 recipients is of very low quality and is insufficient to guide decision-making and clinical practice.
17
18
19
20
21
22
23

24 Although behavioral interventions appeared to improve sun protection attitude, knowledge and
25
26 behavior, there were inconsistencies detected and none of these studies included skin cancer as
27
28 an outcome. Due to limited number of studies, we were unable to compare specific behavioral
29
30 interventions (e.g. mobile app vs. written education) to ascertain the most effective method of
31
32 delivering sun protection education. While there may be some modest benefits in the reduction in
33
34 cancer incidence (for NMSC) among solid organ transplant recipients who were converted to
35
36 mTORIs compared to those on CNI maintenance, there was substantial heterogeneity across the
37
38 studies that was unable to be explained by subgroup analyses. Heterogeneity may be attributed to
39
40 the absence of long term follow up, large discontinuation rates owing to adverse events and
41
42 variability in the doses of mTORIs. Pharmaceutical interventions (switch to mTOR inhibitors,
43
44 photodynamic therapy, immune response modifiers) showed a reduction in precancerous lesions
45
46 compared to standard care or a comparator group. However uncertainty exists in the treatment
47
48 effects and there were too few studies, interventions were incomparable, follow-up times were
49
50 variable and considerable loss to follow up for some studies to conclude that the benefits are
51
52 sustainable.
53
54
55
56
57
58
59
60

1
2 Previous systematic reviews have evaluated the impact of behavioral interventions on skin cancer
3
4 prevention in the general population,⁴¹ and concluded that computer programs may increase sun
5
6 protective behaviors, and 'appearance-focused' interventions may decrease sun tanning and UV
7
8 exposure in adolescents and young women, respectively. Reviews conducted in other populations
9
10 at high-risk including outdoor workers,⁴² family history, personal history and phenotypic factors⁴³
11
12 have found similar improvement in sun protective behaviors, including use of sunscreen, as well as
13
14 a decreased incidence of keratoses. A systematic review of the benefits and harms of oral
15
16 retinoids for the prevention of skin cancer among high risk transplant recipients led to inconclusive
17
18 results on the effect of acitretin due to the small number of included trials.⁴⁴
19
20
21
22
23
24
25

26 Despite the inclusion of all interventions aimed at the prevention of skin cancer in solid organ
27
28 transplant recipients and the comprehensive systematic search for eligible studies, there are some
29
30 potential limitations. Due to the heterogeneity of the studies, the high risk of bias, the potential
31
32 for reporting bias and imprecision in the point estimates of individual studies, there is a high
33
34 degree of uncertainty in the estimate of the effect of skin cancer prevention interventions.
35
36 Further, given the small number of studies included in the meta-analysis, we were unable to
37
38 perform any detailed subgroup analyses or assess for publication bias. Finally, few trials included
39
40 the important outcomes of skin cancer and none included melanoma or mortality.
41
42
43
44
45
46
47

48 Although behavioral change is a simple strategy, long-term adherence remains challenging.
49
50 While behavioral counseling has been shown to increase sun protective behaviors in non-
51
52 transplant populations,⁴¹ there is no direct evidence to show that the behavioral change led to a
53
54 reduction in morbidity and mortality. Previous studies have suggested that transplant recipients
55
56 do not practice sun protective behaviors regularly,⁴⁵⁻⁴⁷ were less likely to use sunscreen⁴⁸ and that
57
58 patients have to perceive skin cancer as being an important risk to be motivated to change
59
60

1
2 behavior.^{49,50} However, studies on risk perception of transplant recipients remain conflicting.

3
4 Given this complexity and the observed inconsistencies in the existing trials, process evaluations
5
6 including facilitators and barriers to behavioral change should be included in future trials. Such
7
8 evaluations could include the use of qualitative methodology to support the trial design, ascertain
9
10 the perspectives of participants on the intervention and evaluate the implementation.^{51,52}
11
12
13
14
15

16 We suggest that further strategies for skin cancer prevention in transplant recipients require a
17
18 multifaceted and individualized approach. Transplant recipients are likely to benefit from early
19
20 implementation of education, particularly before transplantation occurs and recipients may be
21
22 preoccupied with other health needs related to transplantation. Although recipients understand
23
24 the importance of ongoing education for the ability to self-manage their disease, they may
25
26 experience difficulty in concentrating and learning new knowledge, and are often unable to look
27
28 beyond their graft and the anxiety/fear of graft loss.⁵³⁻⁵⁵ Interventions should be integrated into
29
30 routine appointments and tailored to meet the individual needs of patients. This would be best
31
32 achieved through a shared decision-making approach to identify the patient's preferences and
33
34 priorities and thereby enhance the likelihood of success of self-management and prevention.⁵⁶
35
36
37
38
39
40
41
42

43 Additional large-scale and high-quality RCTs are needed to demonstrate the effectiveness of
44
45 interventions used to prevent skin cancer in transplant recipients in terms of patient important
46
47 outcomes, in particular morbidity and mortality associated with skin cancer. Determining patient's
48
49 preferences for prevention and management of skin cancer are also warranted to ensure
50
51 interventions and outcomes for trials are relevant to patient needs and priorities and better
52
53 support patient-centered treatment decisions.⁵⁷ Evidence of the efficacy of sun protective
54
55 behavior interventions need to be strengthened, with use of measures that are homogenous,
56
57
58 reliable and validated.
59
60

1
2
3
4 Preventative measures including behavioral, switch to mTOR inhibitors and other pharmaceuticals
5
6
7 may improve skin cancer outcomes for solid organ transplant recipients. However, the overall
8
9 quality of evidence is of very low and insufficient to guide decision-making and clinical practice.
10
11
12 Future robust studies that are well powered, have long-term follow up, and use clinical and
13
14 patient important outcome measures in a consistent manner are required to therefore optimize
15
16
17 outcomes for solid organ transplant recipients.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. *N Engl J Med*. 2012;367(4):329-339.
2. Harwood CA, Mesher D, McGregor JM, et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2013;13(1):119-129.
3. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. *The British journal of dermatology*. 2002;147(5):950-956.
4. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S. Skin cancer in organ transplant recipients--where do we stand today? *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2008;8(11):2192-2198.
5. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med*. 2003;348(17):1681-1691.
6. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. *J Am Acad Dermatol*. 2002;47(1):1-20.
7. Garrett GL, Blanc PD, Boscardin J, et al. Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. *JAMA dermatology*. 2017;153(3):296-303.
8. Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. *Archives of dermatology*. 2003;139(3):301-306.
9. ANZDATA Registry. *38th Report, Chapter 10: Cancer*. Adelaide, Australia. : Australia and New Zealand Dialysis and Transplant Registry;2016. Available at: <http://www.anzdata.org.au>.
10. Chapman JR, Webster AC, Wong G. Cancer in the Transplant Recipient. *Cold Spring Harb Perspect Med*. 2013;3(7):a015677.
11. Garrett GL, Lowenstein SE, Singer JP, He SY, Arron ST. Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013. *J Am Acad Dermatol*. 2016;75(1):106-112.

- 1 12. Ibrahim SF, Brown MD. Tanning and cutaneous malignancy. *Dermatol Surg.* 2008;34(4):460-474.
- 2
- 3 13. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in
4 transplant recipients. *Clinical transplantation.* 2005;19(6):726-734.
- 5
- 6
- 7 14. Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the
8 evidence? *Clinical journal of the American Society of Nephrology : CJASN.* 2008;3 Suppl 2:S87-S100.
- 9
- 10
- 11 15. Chadban SJ, Barraclough KA, Campbell SB, et al. KHA-CARI guideline: KHA-CARI adaptation of the
12 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *Nephrology.*
13
14 2012;17(3):204-214.
- 15
- 16
- 17 16. Acuna SA, Huang JW, Scott AL, et al. Cancer Screening Recommendations for Solid Organ Transplant
18 Recipients: A Systematic Review of Clinical Practice Guidelines. *American journal of transplantation :*
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
19. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic
Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Medicine.* 2009;6(7):e1000097.
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- 207
- 208
- 209
- 210
- 211
- 212
- 213
- 214
- 215
- 216
- 217
- 218
- 219
- 220
- 221
- 222
- 223
- 224
- 225
- 226
- 227
- 228
- 229
- 230
- 231
- 232
- 233
- 234
- 235
- 236
- 237
- 238
- 239
- 240
- 241
- 242
- 243
- 244
- 245
- 246
- 247
- 248
- 249
- 250
- 251
- 252
- 253
- 254
- 255
- 256
- 257
- 258
- 259
- 260
- 261
- 262
- 263
- 264
- 265
- 266
- 267
- 268
- 269
- 270
- 271
- 272
- 273
- 274
- 275
- 276
- 277
- 278
- 279
- 280
- 281
- 282
- 283
- 284
- 285
- 286
- 287
- 288
- 289
- 290
- 291
- 292
- 293
- 294
- 295
- 296
- 297
- 298
- 299
- 300
- 301
- 302
- 303
- 304
- 305
- 306
- 307
- 308
- 309
- 310
- 311
- 312
- 313
- 314
- 315
- 316
- 317
- 318
- 319
- 320
- 321
- 322
- 323
- 324
- 325
- 326
- 327
- 328
- 329
- 330
- 331
- 332
- 333
- 334
- 335
- 336
- 337
- 338
- 339
- 340
- 341
- 342
- 343
- 344
- 345
- 346
- 347
- 348
- 349
- 350
- 351
- 352
- 353
- 354
- 355
- 356
- 357
- 358
- 359
- 360
- 361
- 362
- 363
- 364
- 365
- 366
- 367
- 368
- 369
- 370
- 371
- 372
- 373
- 374
- 375
- 376
- 377
- 378
- 379
- 380
- 381
- 382
- 383
- 384
- 385
- 386
- 387
- 388
- 389
- 390
- 391
- 392
- 393
- 394
- 395
- 396
- 397
- 398
- 399
- 400
- 401
- 402
- 403
- 404
- 405
- 406
- 407
- 408
- 409
- 410
- 411
- 412
- 413
- 414
- 415
- 416
- 417
- 418
- 419
- 420
- 421
- 422
- 423
- 424
- 425
- 426
- 427
- 428
- 429
- 430
- 431
- 432
- 433
- 434
- 435
- 436
- 437
- 438
- 439
- 440
- 441
- 442
- 443
- 444
- 445
- 446
- 447
- 448
- 449
- 450
- 451
- 452
- 453
- 454
- 455
- 456
- 457
- 458
- 459
- 460
- 461
- 462
- 463
- 464
- 465
- 466
- 467
- 468
- 469
- 470
- 471
- 472
- 473
- 474
- 475
- 476
- 477
- 478
- 479
- 480
- 481
- 482
- 483
- 484
- 485
- 486
- 487
- 488
- 489
- 490
- 491
- 492
- 493
- 494
- 495
- 496
- 497
- 498
- 499
- 500
- 501
- 502
- 503
- 504
- 505
- 506
- 507
- 508
- 509
- 510
- 511
- 512
- 513
- 514
- 515
- 516
- 517
- 518
- 519
- 520
- 521
- 522
- 523
- 524
- 525
- 526
- 527
- 528
- 529
- 530
- 531
- 532
- 533
- 534
- 535
- 536
- 537
- 538
- 539
- 540
- 541
- 542
- 543
- 544
- 545
- 546
- 547
- 548
- 549
- 550
- 551
- 552
- 553
- 554
- 555
- 556
- 557
- 558
- 559
- 560
- 561
- 562
- 563
- 564
- 565
- 566
- 567
- 568
- 569
- 570
- 571
- 572
- 573
- 574
- 575
- 576
- 577
- 578
- 579
- 580
- 581
- 582
- 583
- 584
- 585
- 586
- 587
- 588
- 589
- 590
- 591
- 592
- 593
- 594
- 595
- 596
- 597
- 598
- 599
- 600
- 601
- 602
- 603
- 604
- 605
- 606
- 607
- 608
- 609
- 610
- 611
- 612
- 613
- 614
- 615
- 616
- 617
- 618
- 619
- 620
- 621
- 622
- 623
- 624
- 625
- 626
- 627
- 628
- 629
- 630
- 631
- 632
- 633
- 634
- 635
- 636
- 637
- 638
- 639
- 640
- 641
- 642
- 643
- 644
- 645
- 646
- 647
- 648
- 649
- 650
- 651
- 652
- 653
- 654
- 655
- 656
- 657
- 658
- 659
- 660
- 661
- 662
- 663
- 664
- 665
- 666
- 667
- 668
- 669
- 670
- 671
- 672
- 673
- 674
- 675
- 676
- 677
- 678
- 679
- 680
- 681
- 682
- 683
- 684
- 685
- 686
- 687
- 688
- 689
- 690
- 691
- 692
- 693
- 694
- 695
- 696
- 697
- 698
- 699
- 700
- 701
- 702
- 703
- 704
- 705
- 706
- 707
- 708
- 709
- 710
- 711
- 712
- 713
- 714
- 715
- 716
- 717
- 718
- 719
- 720
- 721
- 722
- 723
- 724
- 725
- 726
- 727
- 728
- 729
- 730
- 731
- 732
- 733
- 734
- 735
- 736
- 737
- 738
- 739
- 740
- 741
- 742
- 743
- 744
- 745
- 746
- 747
- 748
- 749
- 750
- 751
- 752
- 753
- 754
- 755
- 756
- 757
- 758
- 759
- 760
- 761
- 762
- 763
- 764
- 765
- 766
- 767
- 768
- 769
- 770
- 771
- 772
- 773
- 774
- 775
- 776
- 777
- 778
- 779
- 780
- 781
- 782
- 783
- 784
- 785
- 786
- 787
- 788
- 789
- 790
- 791
- 792
- 793
- 794
- 795
- 796
- 797
- 798
- 799
- 800
- 801
- 802
- 803
- 804
- 805
- 806
- 807
- 808
- 809
- 810
- 811
- 812
- 813
- 814
- 815
- 816
- 817
- 818
- 819
- 820
- 821
- 822
- 823
- 824
- 825
- 826
- 827
- 828
- 829
- 830
- 831
- 832
- 833
- 834
- 835
- 836
- 837
- 838
- 839
- 840
- 841
- 842
- 843
- 844
- 845
- 846
- 847
- 848
- 849
- 850
- 851
- 852
- 853
- 854
- 855
- 856
- 857
- 858
- 859
- 860
- 861
- 862
- 863
- 864
- 865
- 866
- 867
- 868
- 869
- 870
- 871
- 872
- 873
- 874
- 875
- 876
- 877
- 878
- 879
- 880
- 881
- 882
- 883
- 884
- 885
- 886
- 887
- 888
- 889
- 890
- 891
- 892
- 893
- 894
- 895
- 896
- 897
- 898
- 899
- 900
- 901
- 902</

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22. de Sevaux RG, Smit JV, de Jong EM, van de Kerkhof PC, Hoitsma AJ. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. *J Am Acad Dermatol*. 2003;49(3):407-412.
23. Togsverd-Bo K, Omland SH, Wulf HC, Sorensen SS, Haedersdal M. Primary prevention of skin dysplasia in renal transplant recipients with photodynamic therapy: a randomized controlled trial. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2015;15(11):2986-2990.
24. Trinh N, Novice K, Lekakh O, Means A, Tung R. Use of a brief educational video administered by a portable video device to improve skin cancer knowledge in the outpatient transplant population. *Dermatol Surg*. 2014;40(11):1233-1239.
25. Chen AC, Martin AJ, Dalziel RA, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. *The British journal of dermatology*. 2016;175(5):1073-1075.
26. Clowers-Webb HE, Christenson LJ, Phillips PK, et al. Educational outcomes regarding skin cancer in organ transplant recipients: Randomized intervention of intensive vs standard education. *Archives of dermatology*. 2006;142(6):712-718.
27. Robinson JK, Guevara Y, Gaber R, et al. Efficacy of a sun protection workbook for kidney transplant recipients: a randomized controlled trial of a culturally sensitive educational intervention. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2014;14(12):2821-2829.
28. Robinson JK, Friedewald JJ, Desai A, Gordon EJ. A randomized controlled trial of a mobile medical app for kidney transplant recipients: effect on use of sun protection. *Transplant Direct*. 2016;2(1):1.
29. Robinson JK, Turrisi R, Mallett KA, et al. Efficacy of an educational intervention with kidney transplant recipients to promote skin self-examination for squamous cell carcinoma detection. *Archives of dermatology*. 2011;147(6):689-695.

- 1 30. Robinson JK, Joshi KM, Ortiz S, Kundu RV. Melanoma knowledge, perception, and awareness in
2 ethnic minorities in Chicago: recommendations regarding education. *Psycho-oncology*. 2011;20(3):313-
3 320.
- 4
5
6
7 31. Salgo R, Gossmann J, fer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal
8 transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective,
9 randomized, assessor-blinded, controlled clinical trial. *American journal of transplantation : official journal
10 of the American Society of Transplantation and the American Society of Transplant Surgeons*.
11 2010;10(6):1385-1393.
- 12
13
14
15
16
17 32. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic
18 therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. *The
19 British journal of dermatology*. 2004;151(1):196-200.
- 20
21
22
23
24
25
26
27 33. Togsverd-Bo K, Halldin C, Sandberg C, et al. Photodynamic therapy is more effective than
28 imiquimod for actinic keratosis in organ transplant recipients – a randomized intra-individual controlled
29 trial. *The British journal of dermatology*. 2017.
- 30
31
32
33
34
35 34. Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod
36 cream for the treatment of skin dysplasia in high-risk renal transplant recipients: Randomized, double-
37 blind, placebo-controlled trial. *Archives of dermatology*. 2005;141(8):985-993.
- 38
39
40
41
42 35. Alberu J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients
43 converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the
44 CONVERT trial. *Transplantation*. 2011;92(3):303-310.
- 45
46
47
48
49 36. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of
50 keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-
51 controlled study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*.
52 1995;13(8):1933-1938.
- 53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
37. Campbell S, Walker R, Tai S, Jiang Q, Russ G. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2012;12(5):1146-1156.
38. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. *Austral J Dermatol*. 2002;43(4):269-273.
39. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2013;31(10):1317-1323.
40. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. *Acta Derm Venereol*. 2006;86(1):25-28.
41. Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2011;154(3):190-201.
42. Horsham C, Auster J, Sendall MC, et al. Interventions to decrease skin cancer risk in outdoor workers: update to a 2007 systematic review. *BMC research notes*. 2014;7:10.
43. Wu YP, Aspinwall LG, Conn BM, Stump T, Grahmann B, Leachman SA. A systematic review of interventions to improve adherence to melanoma preventive behaviors for individuals at elevated risk. *Preventive medicine*. 2016;88:153-167.
44. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. *The British journal of dermatology*. 2005;152(3):518-523.
45. Iannacone MR, Pandeya N, Isbel N, et al. Sun Protection Behavior in Organ Transplant Recipients in Queensland, Australia. *Dermatology (Basel, Switzerland)*. 2015;231(4):360-366.

- 1 46. Imko-Walczuk B, Graczyk M, Korban M, Kielbowicz M, Debska-Slizien A, Rutkowski B. Impact of Skin
2 Cancer Awareness on Prophylactic Behavior Among Renal Transplant Recipients. *Transplantation*
3 *proceedings*. 2016;48(5):1526-1531.
4
5
6
7 47. Thomas BR, Barnabas A, Agarwal K, et al. Patient perception of skin-cancer prevention and risk after
8 liver transplantation. *Clinical and experimental dermatology*. 2013;38(8):851-856.
9
10
11 48. Robinson JK, Rigel DS. Sun protection attitudes and behaviors of solid-organ transplant recipients.
12 *Dermatol Surg*. 2004;30(4 Pt 2):610-615.
13
14
15 49. Robinson JK, Friedewald J, Gordon EJ. Perceptions of Risk of Developing Skin Cancer for Diverse
16 Audiences: Enhancing Relevance of Sun Protection to Reduce the Risk. *Journal of cancer education : the*
17 *official journal of the American Association for Cancer Education*. 2016;31(1):153-157.
18
19
20 50. Skiveren J, Mortensen EL, Haedersdal M. Sun protective behaviour in renal transplant recipients. A
21 qualitative study based on individual interviews and the Health Belief Model. *The Journal of dermatological*
22 *treatment*. 2010;21(6):331-336.
23
24
25 51. Lewin S, Glenton C, Oxman AD. Use of qualitative methods alongside randomised controlled trials
26 of complex healthcare interventions: methodological study. *BMJ (Clinical research ed)*. 2009;339:b3496.
27
28
29 52. Oakley A, Strange V, Bonell C, Allen E, Stephenson J. Process evaluation in randomised controlled
30 trials of complex interventions. *BMJ (Clinical research ed)*. 2006;332(7538):413-416.
31
32
33 53. Buldukoglu K, Kulakac O, Kececioglu N, Alkan S, Yilmaz M, Yucetin L. Recipients' perceptions of their
34 transplanted kidneys. *Transplantation*. 2005;80(4):471-476.
35
36
37 54. Jamieson NJ, Hanson CS, Josephson MA, et al. Motivations, Challenges, and Attitudes to Self-
38 management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. *American journal*
39 *of kidney diseases : the official journal of the National Kidney Foundation*. 2016;67(3):461-478.
40
41
42 55. Urstad KH, Wahl AK, Andersen MH, Oyen O, Fagermoen MS. Renal recipients' educational
43 experiences in the early post-operative phase--a qualitative study. *Scandinavian journal of caring sciences*.
44 2012;26(4):635-642.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 56. Gordon EJ, Butt Z, Jensen SE, et al. Opportunities for shared decision making in kidney
2 transplantation. *American journal of transplantation : official journal of the American Society of*
3 *Transplantation and the American Society of Transplant Surgeons*. 2013;13(5):1149-1158.
4
5
6
7 57. O'Hare AM, Rodriguez RA, Bowling CB. Caring for patients with kidney disease: shifting the
8 paradigm from evidence-based medicine to patient-centered care. *Nephrology, dialysis, transplantation :*
9 *official publication of the European Dialysis and Transplant Association - European Renal Association*.
10
11
12
13
14
15 2016;31(3):368-375.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of included studies (n=21)

Characteristics	N (%)
Type of transplant	
Kidney	17 (81.0)
Multiple*	4 (19.0)
Sex	
≥ 50% Male	19 (90.5)
< 50% Male	1 (4.8)
Not specified	1 (4.8)
Age (mean)	
< 60	11 (52.4)
≥ 60	5 (23.8)
Not specified	5 (23.8)
Sample size	
10 – 50	11 (52.4)
50 – 100	3 (14.3)
100 – 200	5 (23.8)
>200	2 (9.5)
Setting	
Single center	8 (38.1)
Multi center	12 (57.1)
Not specified	1 (4.8)
Country of origin	
Australia	3 (14.3)
Denmark	4 (19.0)
France	1 (4.8)
Germany	1 (4.8)
Netherlands	2 (9.5)
New Zealand	2 (9.5)
Switzerland	1 (4.8)
Sweden	1 (4.8)
United Kingdom	3 (14.3)
United States	7 (33.3)
Other†	1 (4.8)
Intervention Type	
Behavioral	6 (28.6)
Switch to mTOR inhibitors	6 (28.6)
Photodynamic therapy	4 (19.0)
Oral retinoid	3 (14.3)
Nictotinamide	1 (4.8)
Topical immune response modifier	1 (4.8)
Duration of follow up	
<12 months	10 (47.6)
12 months	4 (19.0)
24 months	5 (23.8)
>24 months	1 (4.8)
Not specified	1 (4.8)
Year of publication	
1995 – 1999	1 (4.8)
2000 – 2004	3 (14.3)
2005 – 2009	4 (19.0)
2010 – 2014	8 (38.1)
2015 – 2017	5 (23.8)

* Kidney, liver and lung (n=2); kidney and heart (n=1); Kidney and multiple other types (n=1) – see text

† 111 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, United States), South Africa, and South America (Argentina, Brazil, Chile)

Table 2. Characteristics of individual studies

Study	N	Type of transplant	Setting	Type of intervention	Measures	Intervention	Comparator	Primary outcomes	Time (mths)
Behavioral interventions (n=6)									
4 Clowers- 5 Webb 6 2006 ²⁶ 7	202	Kidney, liver, heart, pancreas, lung, heart/lung, other [§]	Single centre, United States	Behavioral	Self-reported questionnaire	Repetitive written material	Standard care	Knowledge & behavior	10
8 Robinson 9 2011 ²⁹ 10	75	Kidney	United States	Behavioral	Self-reported questionnaire	Workbook	Standard care	Knowledge & behavior	1
11 Robinson 12 2014 ²⁷ 13	101	Kidney	Single centre, United States	Behavioral	Self-reported questionnaire	Workbook Text messages	Standard care	Knowledge & behavior	1.5
14 Robinson 15 2015 ^{20†} 16	170	Kidney	Multi-centre, United States	Behavioral	Self-reported questionnaire	Mobile app program	Standard care	Knowledge & behavior	0.5
17 Robinson 18 2016 ²⁸ 19 20	170	Kidney	Multi-centre, United States	Behavioral	Self-reported questionnaire	Mobile app program	Standard care	Knowledge & behavior	1.5
21 Trinh 22 2014 ^{24*} 23	100	Kidney, liver, lung	Single centre, United States	Behavioral	Self-reported questionnaire	Video	Pamphlet	Knowledge	1 day
Switch to mTOR inhibitors (n=6)									
25 Alberu 26 2011 ³⁵ 27 28	830	Kidney	Multi centre [§]	Switch to mTOR inhibitors	Investigator reported adverse events	Conversion to sirolimus	CNI	Cancer Incidence	24
29 Campbell 30 2009 ³⁷ 31 32 33	86	Kidney	Multi centre, Australia, New Zealand, United States	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	CNI	Cancer Incidence	12
34 Carroll 35 2013 ^{21*} 36	32	Kidney	Multi centre, UK	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to prednisolone & sirolimus	CNI/AZA	Cancer incidence	24
37 Euvrard 38 2012 ¹ 39	120	Kidney	Multi centre, France	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	CNI	Cancer incidence	24
40 Hoogendijk- 41 van den 42 Akker 43	155	Kidney	Multi centre, Netherlands, UK	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	AZA/MMF/ CNI	Cancer incidence	24

6/mjopen-2029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> by guest on April 17, 2024. Protected by copyright.

2013³⁹

1 Salgo 2 2010 ³¹ 3 4	44	Kidney	Single centre, Germany	Switch to mTOR inhibitors	Physical examination +/- biopsy Clinical photographs	Conversion to sirolimus and prednisone	AZA/MMF/ CNI	Precancerous skin dysplasia incidence	12
5 Pharmaceutical interventions – Photodynamic therapy (n=4); oral retinoids (n=3); nicotinamide (n=1); 5% imiquimod cream (n=1)									
6 Bavinck 7 1995 ³⁶ 8 9 10 11	44	Kidney	Multi centre, Netherlands	Oral retinoid	Physical examination +/- biopsy	Acitretin	Placebo	Cancer incidence precancerous lesion reduction	6
12 Brown 13 2005 ³⁴ 14 15 16 17	21	Kidney	Multi centre, UK	Topical immune response modifier cream	Physical examination +/- biopsy Clinical mapping and photographs	5% Imiquimod cream	Placebo	Reduction of precancerous lesions	4
18 Chen 19 2016 ^{25*} 20 21	22	Kidney	Single centre, Australia	Nicotinamide	Physical examination	Nicotinamide	Placebo	Cancer incidence	6
22 de Sevaux 23 2003 ^{22*} 24 25	26	Kidney	Single centre, Netherlands	Oral retinoid	Physical examination +/- biopsy	High dose acitretin	Low dose acitretin	Cancer and precancerous incidence	12
26 Dragieva 27 2004 ³² 28 29	17	Kidney, heart	Single centre, Switzerland	Photodynamic therapy	Physical examination +/- biopsy Clinical photographs	Methyl aminolevulinate cream	Placebo	Precancerous lesion response	4
30 George 31 2002 ³⁸ 32 33	23	Kidney	Multi centre, Australia	Oral retinoid	Physical examination Annual radiological evaluation	Acitretin	Drug free period	Cancer incidence	24
34 Togsverd- 35 Bo 2015 ^{23*†} 36 37	25	Kidney	Single centre, Denmark	Photodynamic therapy	Physical examination Clinical photographs	Methyl aminolevulinate cream	No treatment contralateral area	Actinic keratosis incidence	36
38 Togsverd- 39 Bo 2017 ^{33†} 40 41	35	Kidney, lung, liver	Multi-centre, Denmark and Sweden	Photodynamic therapy	Physical examination Questionnaire/Diary	Methyl aminolevulinate cream	5% imiquimoid cream	Actinic keratosis lesion response	6

30

Wulf 2006 ^{40†}	27	Kidney	Multi centre, Denmark and Netherlands	Photodynamic therapy	Clinical mapping and photographs	Methyl aminolevulinate cream	No treatment contralateral area	Cancer incidence	12
-----------------------------	----	--------	---	-------------------------	-------------------------------------	------------------------------------	---------------------------------------	---------------------	----

2
3 Excluded from analyses – no meaningful data to extract

4 Randomized controlled areas of skin on individuals

5 Excluded from analyses – same participants as Robinson 2016

6 11 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, United States), South Africa, and South America (Argentina, Brazil, Chile)

7 Abbreviations: CNI, Calcineurin inhibitor; AZA, Azathioprine; MMF, Mycophenolate mofetil

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

6/bmjopen/2019/029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

Table 3. Effect of behavioral interventions on sun protection outcomes

Outcome	Studies	Participants	Weighted MD ^a /SMD ^b [95% CI]	Relative risk	P	I ²	Intervention	Comparator
BEHAVIORAL INTERVENTION (n=5)								
SUN PROTECTION BEHAVIOR								
General sun protection behavior	3	414	0.89 [-0.84, 2.62]		0.31	98%	Workbook, text messages, mobile app program	Standard care
Skin self-examination								
1 month after visit	1	75		4.14 [2.22, 7.72]	<0.001	—	Workbook	Standard care
If checked, concerned	1	42		6.43 [0.42, 98.58]	0.18	—		
If concerned, saw dermatologist	1	12		Not estimable ^c		—		
Decrease daily hours outdoors	1	170	-1.84 [-2.20, -1.48] ^d		<0.001	—	Mobile app program	Standard care
SUN PROTECTION KNOWLEDGE								
	4	489	0.50 [0.12, 0.87]		0.01	76%	Workbook, text messages, mobile app program	Standard care
SUN PROTECTION ATTITUDE								
Concern about developing skin cancer	3	348	1.88 [0.96, 2.80]		<0.001	92%	Workbook, text messages, mobile app program	Standard care
Recognise personal risk	2	273	0.61 [-0.60, 1.82]		0.32	96%	Workbook and text messages, mobile app program	Standard care
Confidence in ability to perform sun protection	2	273	0.77 [-0.14, 1.68]		0.10	92%		
Willingness/intention to change behavior	2	273	1.70 [-1.68, 5.07]		0.32	99%		
Knowledge of significance of skin cancer, relevance of sun protection, risk of having a tan	1	101	0.67 [0.27, 1.07]		0.001	—	Workbook and text messages	Standard care
Confidence in ability to recognise a skin cancer	1	75	1.76 [1.23, 2.30]		<0.001	—	Workbook	Standard care
Importance of skin self-examination	1	75	1.08 [0.60, 1.57]		<0.001	—		
Importance of partner help for skin self-examination	1	75	1.44 [0.93, 1.95]		<0.001	—		
COMPLICATIONS								
Skin irritation								

BMJ Open

None	2	271		1.00 [0.89, 1.13]	0.95	95%
> 1	2	271		0.77 [0.43, 1.36]	0.36	89%
Sunburn (past week)						
None	2	271		3.19 [2.47, 4.10]	<0.001	99%
> 1	2	271		2.68 [1.81, 3.96]	<0.001	95%

BIOLOGIC MEASURES

Melanin index - RU arm (sun protected)	2	271	0.12 [-0.12, 0.35]		0.34	0%
Melanin index - R forearm (sun exposed)	2	271	-0.42 [-0.66, -0.18] ^d		0.001	0%
Cheek (sun exposed)	2	271	-0.25 [-0.64, 0.15] ^d		0.22	61%
Sun damage assessment - R forearm	2	271	-0.13 [-0.40, 0.13] ^d		0.33	16%

^aMean difference
^bStandardised mean difference
^cUnable to estimate due to absence of comparator group
^dReduction of outcome of interest represents an improvement

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

For peer review only

Table 4. Effect of pharmaceutical interventions on skin cancer prevention

Outcome	Studies	Participants	Relative risk	P	I ²	Intervention	Comparator
SWITH TO mTOR INHIBITORS (n=5)							
<u>PRE-CANCEROUS LESIONS</u>							
Skin dysplasia							
Any improvement	1	32	24.35 [1.55, 381.99]	0.02	—	Sirolimus	CNI ^b
Unchanged	1	32	0.85 [0.28, 2.61]	0.78	—		
Any worsening	1	32	0.04 [0.00, 0.66]	0.02	—		
<u>CANCEROUS LESIONS</u>							
SCC ^d /BCC ^e incidence	5	1082	0.46 [0.28, 0.75]	0.002	72%	Sirolimus	CNI
PHOTODYNAMIC THERAPY (n=3)							
<u>PRE-CANCEROUS LESIONS</u>							
Actinic keratosis reduction (1-2 sessions)							
Complete response	2	50 ^a	5.03 [0.14, 176.17]	0.37	85%	MAL ^c	Placebo, Imiquimod 5% cream
Partial response	1	17 ^a	7.00 [0.39, 125.99]	0.19	—	MAL	Placebo
No reduction	1	17 ^a	0.09 [0.02, 0.40]	0.002	—		
<u>CANCEROUS LESIONS</u>	1	26 ^a	0.59 [0.34, 1.03]	0.06	—	MAL	No treatment
IMMUNE RESPONSE MODIFIERS (n=1)							
<u>PRE-CANCEROUS LESIONS</u>							
Reduced skin atypia							
	1	14 ^a	3.00 [0.47, 19.35]	0.25	—	Imiquimod 5% cream	Placebo
Reduced dysplasia							
	1	14 ^a	2.14 [0.31, 14.65]	0.44	—		
Reduced keratoses							
	1	14 ^a	2.14 [0.31, 14.65]	0.44	—		
Reduced no. viral warts							
	1	14 ^a	7.00 [0.46, 106.10]	0.16	—		
<u>CANCEROUS LESIONS</u>							
SCC incidence							
Treated (cream vs. placebo)	1	14 ^a	0.09 [0.01, 1.70]	0.11	—	Imiquimod 5% cream	Placebo
Untreated (control site)	1	14 ^a	0.43 [0.08, 2.37]	0.33	—		
ORAL RETINOIDS (n=2)							
<u>CANCEROUS LESIONS</u>							
Decreased incidence:							
> 1 SCC	1	46 ^a	0.40 [0.19, 0.85]	0.02	—	Acitretin	Drug free period
> 1 BCC	1	46 ^a	0.50 [0.14, 1.76]	0.28	—		

New skin cancer	1	19 ^a	0.22 [0.06, 0.90]	0.03	—	Acitretin	Placebo
-----------------	---	-----------------	-------------------	------	---	-----------	---------

^aControl is the contralateral or similar area of skin on the same participant

^bCalcineurin inhibitor

^cMethyl aminolaevulinate cream

^dSquamous cell carcinoma

^eBasal cell carcinoma

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

1
2
3 **Figure legends**
4

5
6 Figure 1. Study selection
7

8 Figure 2. Risk of bias of included studies
9

10 Figure 3. Behavioral interventions – Sun protection behavior (general)
11

12 Figure 4. Behavioral interventions – Sun protection knowledge
13

14 Figure 5. Switch to mTOR inhibitors – Non melanoma skin cancer incidence
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1. Study selection




Figure 1. Study selection

254x190mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 2. Risk of bias of included studies


254x190mm (72 x 72 DPI)



277x73mm (72 x 72 DPI)



274x79mm (72 x 72 DPI)



274x90mm (72 x 72 DPI)

Figure S1. Search Strategy

1. exp Neoplasms, Basal Cell/
2. basal cell carcinoma.ti,ab.
3. exp Neoplasms, Squamous Cell/
4. squamous cell carcinoma.ti,ab.
5. nonmelanom*.ti,ab.
6. non melanom*.ti,ab.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Melanoma/
9. melanoma*.ti,ab.
10. Skin Neoplasms/
11. skin cancer*.ti,ab.
12. 8 or 9 or 10 or 11
13. 7 or 12
14. sun exposure.ti,ab.
15. sun exposed.ti,ab.
16. Sunburn/
17. sunburn.ti,ab.
18. sunbath*.ti,ab.
19. Sunlight/
20. Ultraviolet Rays/
21. solar radiation.ti,ab.
22. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
23. sunlamp*.ti,ab.
24. sunbed*.ti,ab.
25. tanning bed*.ti,ab.
26. tanning booth*.ti,ab.
27. tanning salon*.ti,ab.
28. tanning device.ti,ab.
29. artificial light*.ti,ab.
30. artificial uv.ti,ab.

- 1 31. indoor tan*.ti,ab.
- 2
- 3 32. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
- 4
- 5 33. Sunscreening Agents/
- 6
- 7 34. sunscreen.ti,ab.
- 8
- 9 35. 33 or 34
- 10
- 11 36. 22 or 32 or 35
- 12
- 13 37. 13 and 36
- 14 38. exp Organ Transplantation/
- 15
- 16 39. solid organ transplant*.mp.
- 17
- 18 40. transplant recipient*.tw.
- 19
- 20 41. exp Immunosuppression/
- 21
- 22 42. Immunocompromised Host/
- 23
- 24 43. 38 or 39 or 40 or 41 or 42
- 25
- 26 44. 37 and 43
- 27
- 28 45. 38 or 39 or 40
- 29
- 30 46. 13 and 45
- 31 47. randomized controlled trial.pt.
- 32
- 33 48. controlled clinical trial.pt.
- 34
- 35 49. randomized.ab.
- 36
- 37 50. placebo.ab.
- 38
- 39 51. Clinical Trials as Topic/
- 40
- 41 52. randomly.ab.
- 42
- 43 53. (crossover or cross-over).tw.
- 44
- 45 54. trial.ti.
- 46
- 47 55. 50 or 48 or 47 or 54 or 51 or 53 or 49 or 52
- 48
- 49 56. Animals/ not (animals/ and Humans/)
- 50
- 51 57. 55 not 56
- 52
- 53 58. 46 and 57
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Figure S2. Risk of bias in individual studies

Study	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Alberu 2011	+	?	-	-	+	+
Bavlnck 1995	?	?	+	?	+	+
Brown 2005	?	?	+	+	+	+
Campbell 2012	+	+	-	+	+	+
Carroll 2012	?	?	-	+	+	+
Chen 2016	+	?	+	+	+	+
Clowers-Webb 2006	?	?	-	?	+	+
de Saveaux 2003	?	+	-	?	+	+
Dragljeva 2004	?	?	+	?	+	+
Euvrand 2012	?	?	-	?	+	+
George 2002	?	?	-	?	+	+
Hoogendijk-van den Akker 2013	?	+	-	+	-	+
Robinson 2011	?	?	-	?	+	+
Robinson 2014	+	+	-	+	+	+
Robinson 2016	?	+	-	+	+	+
Salgo 2012	?	?	-	+	-	+
Togswend-Bo 2015	+	+	?	+	+	+
Togswend-Bo 2017	+	+	-	?	+	+
Trinh 2014	+	?	?	?	+	+
WuJr 2006	+	-	-	+	+	+

only

Table S1. Assessment of quality of studies using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system.


Quality of assessment (Decrease in quality score)						
Number of studies	Risk of bias/Quality of evidence	Inconsistency	Indirectness	Imprecision	Publication bias	Quality
Sun protection behavior						
5 RCTs ^{20,26-29}	Serious study limitations (-1) Randomisation unclear ^{20,26,28,29} Participants not blinded or well described ^{20,26-29} Concealment of allocation not described. ^{26,29}	Important inconsistency (-1) Analysed in subgroups. heterogeneity (I ² =99%) ²⁶⁻²⁸	Indirectness (-1) Diverse interventions (written vs. electronic), varying duration (2 weeks to 10 months) Same sample of participants ^{20,28}	Serious imprecision (-1) Small sample size, CIs crosses the null	Uncertain Unable to determine. Small number of studies, large heterogeneity	Very low
Sun protection knowledge						
6 RCTs ^{20,24,26-29}	Serious limitations (-1) Randomisation unclear ^{20,26,28,29} Participants not blinded or well described ^{20,24,26-29} Concealment of allocation not described ^{24,29}	Important inconsistency (-1) Heterogeneity (I ² 85%)	Indirectness (-1) Diverse interventions (written vs. electronic), varying duration (1 day to 10 months) Same sample ^{20,28}	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity	Very low
Sun protection attitude						
4 RCTs ^{20,27-29}	Serious limitations (-1) Randomisation unclear ^{20,28,29} Participants not blinded or well described ^{20,27-29} Concealment of allocation not described ^{28,29}	Important inconsistency (-1) Wide variation in the effect estimates, heterogeneity (I ² 97%).	Indirectness (-1) Diverse interventions (written vs. electronic), Similar duration. Same sample ^{20,28}	Serious imprecision (-1) Small sample size, small number of events	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low

6/bmjopen-7 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

Complications (skin irritation, sunburn)							
1 2 3 4 5 6	2 RCTs ^{27,28}	Serious limitations (-1) Participants not blinded ^{27,28}	Important inconsistency (-1) Heterogeneity (I ² =95-99%) Analysed in subgroups. Similar effect estimates.	Indirectness (-1) Diverse interventions (written vs. electronic), similar duration.	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low
Biologic measures (melanin index, sun damage)							
8 9 10 11 12 13 14	2 RCTs ^{27,28}	Serious limitations (-1) Randomisation unclear ²⁸ Participants not blinded ^{27,28}	Important inconsistency (-1) Analysed in subgroups. Heterogeneity (I ² 60%)	Indirectness (-1) Different interventions (written vs. electronic), similar duration.	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low
Pre-cancerous incidence							
16 17 18 19 20 21 22 23	4 RCTs ^{23,31-34}	Serious limitations (-1) Randomisation or allocation unclear ^{31,32,34} Participants not blinded or well described ^{23,31-34}	Important inconsistency (-1) Analysed in subgroups.	Indirectness (-1) Diverse interventions, varying duration	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Large heterogeneity.	Very low
Cancer incidence							
26 27 28 29 30 31 32 33 34 35 36	10 RCTs ^{1,25,31,34-40}	Serious limitations (-1) Randomisation unclear ^{1,36,38,39} Allocation concealment not used or unclear ^{1,25,35,36,38,40} Participants not blinded. ^{1,31,35,37-40}	Important inconsistency (-1) Majority of participants came from 1 study ³⁵ Small sample ^{1,25,31,34,36-40}	Indirectness (-1) Diverse interventions (immunosuppression, photodynamic therapy, immune response modifier, retinoid, nicotinamide), varying duration	Serious imprecision (-1) Majority of participants from one trial (n=551), small number of events	Uncertain Unable to determine. Large heterogeneity.	Very low

6/bmjopen-2019-029265 or 17 March 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2021 by guest. Protected by copyright.

Figure S3. Subgroup analyses of immunosuppression conversion interventions on skin can





PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICCO, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-14
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-14
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16-17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	2

1136/bmjopen-2019-029265 on May 20, 2020. Downloaded from http://bmjopen.bmj.com/ on April 27, 2024 by guest. Protected by copyright.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Behavioral and pharmaceutical interventions for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029265.R1
Article Type:	Original research
Date Submitted by the Author:	10-Dec-2019
Complete List of Authors:	James, Laura; University of Sydney, Saglimbene, Valeria; The University of Sydney, Sydney School of Public Health Wong, Germaine; The Children's Hospital at Westmead, Centre for Kidney Research Tong, Allison; The University of Sydney, Sydney School of Public Health Luu, Laurence; The University of Sydney, Sydney School of Public Health Craig, Jonathan; Flinders University Faculty of Medicine Nursing and Health Sciences, College of Medicine and Public Health, ; The Children's Hospital at Westmead, Centre for Kidney Research Howard, Kirsten; University of Sydney, School of Public Health Howell, Martin; University of Sydney - Camperdown and Darlington Campus, School of Public Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Public health
Keywords:	skin cancer, melanoma, prevention, sun protection, sun protection behaviors

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Behavioral and pharmaceutical interventions for the prevention of skin cancers in solid organ**
5
6 **transplant recipients: a systematic review of randomized controlled trials**
7
8
9

10
11 **Authors full names and highest degree:**
12

13 Laura J. James, MPH^{1,2}, Valeria Saglimbene^{1,2}, MscMed^{1,2}, Germaine Wong, PhD^{1,2,3}, Allison Tong,
14
15
16 PhD^{1,2}, Laurence Don Wai Luu, BMedSc^{1,2}, Jonathan C. Craig, PhD⁴, Kirsten Howard, PhD¹, Martin
17
18
19 Howell, PhD^{1,2}
20

21
22 **Institution of each author:**
23

24
25 ¹Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney,
26
27 NSW 2006
28

29
30 ²Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW 2145
31

32
33 ³Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW 2145
34

35
36 ⁴College of Medicine and Public Health, Flinders University, Adelaide, Australia
37

38 **Corresponding author:**
39

40
41 Laura James

42
43 Centre for Kidney Research

44
45 The Children's Hospital at Westmead, Westmead, NSW 2145

46
47 Sydney, Australia
48

49
50 Phone: +61 2 9845 1482 Fax: +61 2 9845 1491
51

52
53 Email: laura.james@health.nsw.gov.au
54

55
56 **Word count (abstract):** 205
57

58
59 **Word count (body):** 3593
60

Tables: 4 **Figures:** 5

1
2
3
4 **Key words:** skin cancer, melanoma, prevention, sun protection, sun protection behaviors, health
5
6 behavior
7
8
9

10 11 **Authorship**

12 LJJ, GW, AT, LL, JCC, KH, MH designed the study; LJJ, VS, LL, MH conducted the data extraction and
13
14 analyses; all authors contributed to the interpretation of the analyses. LJJ drafted the manuscript;
15
16 all authors contributed to the writing and review of the manuscript.
17
18
19
20
21
22

23 24 **Disclosure**

25
26 The authors declare no conflicts of interest.
27
28
29

30 31 **Data availability statement**

32
33 No additional data available.
34
35
36
37

38 39 **Funding**

40
41 LJJ is supported by the National Health and Medical Research Council (NHMRC) Better Evidence
42
43 and Translation in Chronic Kidney Disease (BEAT-CKD) Program Grant (APP1092957). MH is
44
45 supported by the BEAT-CKD Program Grant (APP1092957). AT is supported by the NHMRC
46
47 Fellowship (APP1106716). The funding organizations had no role in the design and conduct of the
48
49 study; collection, management, analysis and interpretation of the data; preparation, review, or
50
51 approval of the manuscript.
52
53
54
55
56
57
58
59
60

Abbreviations

AZA, azathioprine

BCC, basal cell carcinoma

CNI, calcineurin inhibitors

CI, confidence intervals

MAL, methyl aminolaevulinate cream

MD, mean difference

MMF, mycophenolate mofetil

mTORI, mammalian target of rapamycin inhibitors

NMSC, non-melanoma skin cancer

RCT, randomized controlled trial

RR, relative risk

SCC, squamous cell carcinoma

SMD, standardized mean difference

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives

Solid organ transplant recipients are at increased risk of skin cancer, affecting more than 50% of recipients. We aimed to determine the effectiveness of interventions for behavioral change for sun protection or skin cancer prevention in solid organ transplant recipients.

Design

Systematic review

Data sources

Electronic databases were searched from inception to January 2018.

Eligibility Criteria

We included randomized controlled trials that evaluated the effect of behavioral or pharmaceutical interventions on behavioral change or skin cancer prevention in solid organ transplant recipients.

Data extraction and synthesis

Risks of bias and evidence certainty were assessed using Cochrane and the GRADE framework.

Results

1
2 Twenty trials (n=2,295 participants) were included. It is uncertain whether behavioral
3
4 interventions improve sun protection behavior (N=3, n= 414, SMD 0.89, 95% CI -0.84-2.62, I²
5 =98%) and knowledge (N=4, n=489, SMD 0.50, 95% CI 0.12-0.87, I²= 76%) as the quality of evidence
6
7 is very low. We are uncertain of the effects of mammalian target of rapamycin inhibitors on the
8
9 incidence of non-melanocytic skin cancer (N=5, n=1080, RR 0.46 95% CI 0.28-0.75, I²=72%) as the
10
11 quality of evidence is very low.
12
13
14
15
16
17
18

19 **Conclusions**

20
21 Behavioral and pharmaceutical preventive interventions may improve sun protective behavior and
22
23 knowledge, and reduce the incidence of non-melanocytic skin cancer, but the overall quality of the
24
25 evidence is very low and insufficient to guide decision-making and clinical practice.
26
27
28
29
30

31 **PROSPERO Registration number**

32
33 CRD42017063962
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Strengths and limitations

- A comprehensive review conducted using methods outlined by Cochrane Collaboration including GRADE to assess risk of bias and evidence certainty
- Inclusion of a broad range of interventions, including behavioral to improve sun protection behavior and pharmaceutical (immunosuppression, photodynamic therapy, oral retinoid, nicotinamide and topical immune response modifiers) to evaluate precancerous lesion response and cancer incidence
- Difficulty obtaining an overall summary estimate for many outcomes due to the variability in the analytical methods and reporting in individual studies
- Unable to perform detailed subgroup analyses or assess for publication bias due to small number of studies
- Few trials included the important outcomes of skin cancer and none included melanoma or mortality.

1. INTRODUCTION

Skin cancer, including melanoma and nonmelanoma skin cancer (NMSC), is the most frequently diagnosed malignancy among solid organ transplant recipients, affecting more than 50% of post-transplantation recipients.^{1,2} The cumulative incidence of NMSC increases with time after transplantation, from 5-10% at 2 years to 40-80% at 20 years.²⁻⁴ Compared to the general population, there is a higher rate of squamous cell carcinoma (SCC) to basal cell carcinoma (BCC), with an incidence of 65 to 250 times greater than the age and gender-matched general population.⁵⁻⁸ Once cancer develops, management options are limited as immunotherapy may be unsuitable as it may lead to graft rejection.^{9,10} Although registry data shows improvement in survival rates of transplant recipients as a result of improved transplantation techniques and management of immunosuppression, there is a greater burden of skin cancer and cancer related mortality.¹¹ The excess risk of death from invasive and metastatic skin cancer, such as SCC and melanoma, are three times to nine times higher than the general population, with five-year overall survival of less than 30%.^{6,12-15}

Sun exposure behaviors remain the most significant and modifiable risk factor in the prevention of skin cancers in the general population.¹⁶ However, with the dramatic increase in skin cancers in solid organ transplant recipients, pharmaceuticals have also been used to reduce and delay the development of skin cancer.^{16,17} Current recommendations for preventive strategies have often been extrapolated from guidelines in the general population, which may not be applicable to solid organ transplant recipients.^{18,19} For example, frequent skin self-examination and annual to biannual total body skin examination are generally recommended for the general population.¹⁸⁻²⁰ Sun protective behaviors including use of sunscreen, protective clothing and limiting sun exposure during peak hours of high UV index days are potential measures for skin cancer prevention.^{3,4,14}

1
2 Further, alteration of maintenance immunosuppression such as conversion to mammalian target
3
4 of rapamycin inhibitors (mTORi) and secondary prevention using retinoid acitretin are
5
6 recommended for management of skin cancers in high risk transplant recipients.²⁰
7
8
9

10
11 The aim of this study is determine the effectiveness of interventions that promote behavioral
12
13 change and skin cancer prevention in solid organ transplant recipients.
14
15
16

17 **2. METHODS**

18
19 This systematic review followed a pre-specified protocol registered in PROSPERO
20
21 (CRD42017063962) and is reported in accordance with the Preferred Reporting Items for
22
23 Systematic Reviews and Meta-analyses (PRISMA) checklist.²¹ The study was exempt from approval
24
25 from an ethics' board.
26
27
28
29
30
31

32 **2.1 Inclusion criteria**

33
34 All randomized controlled trials (RCTs) or quasi RCTs (allocated to trial arms by investigators) of
35
36 interventions for skin cancer prevention (both melanoma and non-melanoma skin cancer) in solid
37
38 organ transplant recipients were included. Behavioral interventions defined as any strategy used
39
40 to promote sun protective behavior including passive (e.g. pamphlets), active (e.g. group
41
42 workshops, counselling, dermatology clinic) and provision of sun protective equipment; and
43
44 pharmaceutical interventions (switch to mTOR inhibitors, photodynamic therapy, immune
45
46 response modifiers, nicotinamide and oral retinoids) and studies that reported skin cancer related
47
48 outcomes as their primary outcomes were included. Studies that did not report these outcomes as
49
50 primary end-points were excluded. Studies of interventions for the treatment of skin cancer were
51
52 excluded.
53
54
55
56
57
58
59
60

2.2 Search strategies

We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and CINAHL from inception to November 2019 without language restriction, using search strategies designed by a specialist information manager (see Medline search strategy in Figure S1). Reference lists of included studies were also searched.

2.3 Data extraction

Titles and abstracts were reviewed by two independent authors (LJJ & LL) and those that did not meet the inclusion criteria were excluded. Full text articles were reviewed by 3 independent reviewers (LJJ, VS, LL) and any disagreements were resolved by discussion. Data on study design, geographic location, sample size, type of transplant, measurement of interventions, interventions and comparators were extracted. We sought unclear or missing information from authors where possible.

2.4 Outcome measures

The pre-specified outcome measures were incidence of precancerous and cancerous lesions, sun protection behavior (including use of sunscreen, use of protective clothing including hats and sunglasses, shade and sun avoidance), knowledge and attitude, skin self-examination, sun exposure (including skin irritation, sunburn) and biologic measures (including measurement of melanin index and sun damage assessment).

2.5 Risk of bias and quality of evidence

The risk of bias was assessed independently by LJJ and VS using the Cochrane risk of bias tool.²²

The domains included in the assessment were: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, trial registration and industry involvement. Each criterion was

1
2 assigned a judgment of high, low or unclear risk of bias. Intention to treat and lost to follow up
3
4 were also assessed for each study. The quality of the evidence informing summary estimates for
5
6 each outcome was then assessed by LJJ using the Grading of Recommendations Assessment
7
8 Development and Evaluation (GRADE) guidelines.²³
9
10

11 12 13 **2.6 Data synthesis and statistical analyses** 14

15 Continuous outcomes were summarized as mean difference (MD) or standardized mean
16
17 difference (SMD) and dichotomous outcomes as relative risk (RR). A MD/SMD greater than zero
18
19 and/or a RR greater than 1 could be interpreted as favoring the intervention group relative to the
20
21 control, unless specified elsewhere. Risk estimates were reported with 95% confidence intervals
22
23 (CI), using random-effects meta-analysis. We considered P values <0.05 to be statistically
24
25 significant. We quantified the heterogeneity using the I² statistic. An I² value of <25% was
26
27 considered to represent low heterogeneity and >75% as high heterogeneity. When sufficient data
28
29 were available, possible sources of heterogeneity were investigated using subgroup analysis based
30
31 on pre-specified study characteristics including sample size, trial duration, setting and overall risk
32
33 of bias. Funnel plots were planned to evaluate small study effects when at least ten studies were
34
35 included in meta-analysis. All analyses were conducted using Review Manager version 5.3
36
37 software.
38
39
40
41
42
43
44
45
46
47

48 **2.7 Patient and public involvement** 49

50 There was no patient or public involvement.
51
52
53
54
55
56
57
58
59
60

3. RESULTS

3.1 Study selection

The literature search identified 1280 articles, of which, 1201 were excluded after abstract and title review. Full text assessment of 79 studies found 22 eligible articles for inclusion (Figure 1).

3.2 Studies characteristics

We included 22 reports of 20 RCTs, including 2,295 participants (Figure 1). The study characteristics are summarized in Table 1 and Table 2. The median number of participants was 44 (range 17 to 830) and the median follow-up duration was 10 months (range 1 day to 60 months). All studies included kidney transplant recipients, with some also including heart transplant recipients (n=1), liver, heart, pancreas, lung, heart/lung and other transplants (n=1), and lung and liver transplant recipients (n=2). In total, 15 of 21 (76%) studies provided sufficient data for the meta-analyses. Six studies did not meet final criteria for meta-analysis as they had the same sample of participants (n=1),²⁴ or did not provide data that was able to be meta-analyzed (n=5).²⁵⁻²⁹

3.3 Risk of bias and quality of the evidence

Overall studies were at low or unclear risk of bias for many domains (Figure 2; Figure S2). Random sequence generation and allocation concealment were unclear in most studies (n=12, 60%).

Blinding of participants was not done in most studies (n=16, 80%) and blinding of outcome assessors was only reporting in half of the studies (n=10). Intention to treat analyses were used in 6 (30%) studies and 6 studies (30%) had a high loss to follow-up. A total of 3 (15%) studies had incomplete outcome data, and all studies were at low risk for selective reporting. Seven studies (35%) reported industry involvement in authorship, design, or data analysis, and of the 16 trials requiring trial registration, only 9 (56%) reported accordingly.

1
2
3
4 The overall quality of the evidence was very low for all outcomes (Table S1) due to limitations in
5
6 study design, heterogeneity in the intervention and outcomes measures, the very small sample
7
8 size of individual studies and the small number of studies for each specific outcome. Obtaining an
9
10 overall summary estimate was difficult for many outcomes due to the variability in the analytical
11
12 methods and reporting in individual studies. In particular, assessment of reporting of sun
13
14 protection behavior and sun protection knowledge was not possible as outcomes were
15
16 inconsistent and there was large diversity of interventions used (e.g. written education material
17
18 versus a mobile app program). Furthermore, formal testing of publication bias was not performed
19
20 due to insufficient data.
21
22
23
24
25
26

27 **3.4 Interventions**

28
29
30 The interventions in the included studies were grouped in three broad categories, behavioral
31
32 (n=6), switch to mTOR inhibitors (n=6), and other pharmaceutical interventions (photodynamic
33
34 therapy, immune response modifiers, oral retinoids and nicotinamide) (n=9). Studies of behavioral
35
36 interventions used passive methods of delivery including written educational material (n=2), both
37
38 written educational material and text messages (n=1), mobile app programs (n=2) and a video
39
40 (n=1).
41
42
43
44
45
46

47 All six studies of immunosuppression compared mTORis (sirolimus) to calcineurin inhibitors (CNI)
48
49 based therapies.
50
51

52
53 Four of the eight studies of other pharmaceutical interventions assessed the effect of
54
55 photodynamic therapy using methyl aminolevinate creams compared to placebo (n=1), no
56
57 treatment to contralateral area (n=2) or a topical immune response modifier cream (n=1). Three
58
59 studies assessed oral retinoid using acitretin compared to placebo (n=1), lower dose (n=1) or a
60

1
2 drug free period (n=1), one study assessed nicotinamide compared to placebo and a single study
3
4 assessed the benefits of topical immune response modifier compared to placebo in kidney
5
6 transplant recipients.
7
8
9

10 **3.5 Effect of behavioural interventions on sun protection outcomes**

11 Sun protection behavior

12
13 Sun protection behavior, defined as hours spent outdoors per week, use of sunscreen, wearing
14
15 protective clothing and seeking shade, was assessed in three trials³⁰⁻³². Educational workbooks,³⁰
16
17 educational workbooks and text messages³¹ and a mobile app program³² were compared with
18
19 standard care. Patients who received behavioral interventions reported improved sun protection
20
21 behavior scores³⁰⁻³² (3 studies, 414 participants, SMD 0.89, 95% CI -0.84-2.62, I² 98%) (Table 3;
22
23 Figure 3). We are uncertain of the effects of behavioural interventions on sun protection behavior
24
25 due to very low quality of evidence. A single trial assessed a standardised and validated
26
27 educational workbook and found an improvement in the proportion of participants engaging in
28
29 skin self-examination after one month (75 participants, RR 4.14, 95% CI 2.22-7.72).³³ One trial
30
31 assessed a mobile app program and reported a reduction in daily hours spent outdoors among the
32
33 intervention group (170 participants, MD -6.12, 95% CI -7.11 to -5.13).³²
34
35
36
37
38
39
40
41
42
43
44

45 Sun protection knowledge

46
47 The effectiveness of educational workbooks, text messages, mobile app programs and videos on
48
49 sun protection knowledge was assessed in 6 studies^{24 28 30-33}, four of which provided data for a
50
51 meta-analysis. There was an improvement in knowledge scores (4 studies, 489 participants, SMD
52
53 0.50, 95% CI 0.12-0.87, I² 76%) in the intervention group compared to standard care (Figure 4).³⁰⁻³³
54
55
56 One study compared an interactive visual representation of the educational program with
57
58
59
60

1
2 standard information pamphlets and found that knowledge of sun protection improved among
3
4 those who received the educational video.²⁸
5
6
7

8 9 Sun protection attitude

10
11 Three studies assessed sun protective attitude after receiving an educational workbook, text
12
13 messages or a mobile app program over a period of 0.5 months to 1.5 months.³¹⁻³³ Compared to
14
15 standard care, there was an overall improvement in scores of concern about developing cancer (3
16
17 studies, 348 participants, SMD 1.85, 95% CI 1.59-2.11, I² 96%).³¹⁻³³ Two studies involving 273
18
19 participants reported an improvement in scores of understanding the personal risk of skin cancer
20
21 (SMD 0.61, 95% CI -0.60-1.82, I² 96%), adherence to sun protection (SMD 0.77 95% CI -0.14-1.68, I²
22
23 92%) and willingness or intention to change behavior (SMD 1.70, 95% CI -1.68-5.07, I² 99%).^{31 32}
24
25 We are uncertain of the effects of behavioural interventions on sun protection attitude due to
26
27 very low quality of evidence. A single study involving 75 participants also reported an
28
29 improvement in scores of ability to recognize a potential skin cancer (MD 1.80, 95% CI 1.35-2.25),
30
31 importance of skin self-examination (MD 1.05, 95% CI 0.61-1.49) and having a partner help for skin
32
33 self-examination (MD 1.59, 95% CI 1.10-2.08).³³ Another single study reported an improvement in
34
35 the importance of engaging in sun protection (measured using 5-point Likert scale) (101
36
37 participants, MD 7.00, 95% CI 2.94-11.06).³¹
38
39
40
41
42
43
44
45

46 Skin complications and biologic measures

47
48 Two trials of behavioral interventions in 271 kidney transplant recipients compared a mobile app
49
50 or an educational workbook and text messages to standard care on reported skin complications
51
52 and biologic measures of sun exposure.^{31 32} The intervention group experienced a reduced
53
54 incidence of skin irritation (a culturally relevant term for sun exposure³⁴) (RR 1.00, 95% CI 0.89-
55
56 1.13, I² 95%) or sunburn (RR 3.19, 95% CI 2.47-4.10, I² 99%). They also had a decreased melanin
57
58
59
60

1
2 index (right forearm, SMD -0.42, 95% CI -0.66 to -0.18; cheek SMD -0.25, 95% CI -0.64 to -0.15) and
3
4 reduced severity of sun damage (SMD -0.13, 95% CI -0.40 to 0.13) on sun exposed areas
5
6 (measured using clinical images of chronic sun damage and scored 1-10).
7
8
9

10 **3.6 Effect of pharmaceutical interventions on skin cancer prevention**

11
12
13
14 The incidence and responses of pre-cancerous lesions were measured only in trials of
15
16 pharmaceutical interventions (Table 4). These included the switch to mTOR inhibitors (n=1),³⁵
17
18 photodynamic therapy (n=2)^{36 37} and immune response modifiers (n=1)³⁸ to current treatment or
19
20 placebo. The incidence of non-melanocytic skin cancers (NMSC) was assessed in nine
21
22 pharmaceutical studies.^{1 35 38-44} None included melanoma as an outcome.
23
24
25
26
27
28
29

30 Topical/local interventions

31
32 One trial of 14 participants compared an immune response modifier, 5% imiquimod cream with
33
34 placebo and found a reduction in the incidence of skin dysplasia (RR 2.14, 95% CI 0.31-14.65), skin
35
36 atypia (RR 3.00, 95% CI 0.47-19.35), and viral warts (RR 7.00, 95% CI 0.46-106.10).³⁸
37
38
39
40
41

42 One Danish study of 26 kidney transplant recipients compared photodynamic therapy with no
43
44 treatment and reported a relative reduction by approximately 40% in the incidence of NMSC on
45
46 the treated area (RR 0.59, 95% CI 0.34-21.03, p 0.06).⁴⁴ A lower incidence of SCC was also reported
47
48 in one trial comparing two areas of skin using an immune response modifier and placebo (14
49
50 participants, RR 0.09, 95% CI 0.001-1.70).³⁸ Two trials comparing photodynamic therapy to an
51
52 immune response modifier or photodynamic therapy to placebo in recipients with diagnosed
53
54 keratoses reported a complete response rate of 60% compared to 24% in the control group (50
55
56 participants, RR 5.03, 95% CI 0.14-176.17, I² 85%).^{36 37} We are uncertain of the effects of
57
58
59
60

1
2 photodynamic therapy on incidence of precancerous lesions due to very low quality of evidence.
3
4 Further, one trial which was not included in the meta-analysis, reported a higher cumulative
5
6 incidence of actinic keratosis lesions in untreated skin (63%) compared with skin treated by
7
8 photodynamic therapy (28%).²⁷
9
10

11 12 13 14 Systemic interventions 15

16
17
18 mTORis therapy reduced the incidence of NMSC compared to CNIs maintenance therapy (5 trials,
19
20 1082 participants, RR 0.46, 95% CI 0.28-0.75, I² 72%) (Figure 5).^{1 35 39 41 43} However evidence was
21
22 limited due to short follow-up periods, variability in dosing of mTORis and significant rates of loss
23
24 to follow up, and therefore we are uncertain of the effects of mTORis on skin cancer incidence due
25
26 to very low quality of evidence. A single trial involving 21 patients reported a reduction in the
27
28 overall incidence of SCC by 49% in the conversion arm, but reported a drop out rate of 77% and
29
30 follow-up time of less than 2 years.²⁵ Further, a single trial which compared mTORi conversion
31
32 from CNI based therapy reported a significant improvement in skin dysplasia (32 participants, RR
33
34 24.35, 95% CI 1.55-381.99).³⁵
35
36
37
38
39
40
41
42

43 Two trials comparing an oral retinoid, acitretin, with placebo or a drug free period reported an
44
45 increased lower risk of both SCCs and BCCs (46 participants, RR 0.40, 95% CI 0.19-0.85, p 0.02; RR
46
47 0.50, 95% CI 0.14-1.76)⁴² or development of a new skin cancer (19 participants, RR 0.22, 95% CI
48
49 0.06-0.90). However, there were no differences in the incidence of new SCCs.⁴⁰ One trial, which
50
51 was not included in the meta-analysis, showed approximately a 50% reduction in the incidence of
52
53 actinic keratosis which compared a high dose to a low dose of acitretin.²⁶
54
55
56
57
58
59
60

1
2 One Australian trial of 22 kidney transplant recipients compared nicotinamide with placebo and
3
4 reported an estimated relative rate difference of 0.35 (95% CI -0.62 to 0.74), 0.67 (95% CI -0.40 to
5
6 0.90) and 0.07 (95% CI -1.51 to 0.65) for NMSC, BCCs and SCCs respectively.²⁹
7
8
9

10 **3.7 Subgroup analysis**

11
12 Study size, trial duration, setting and risk of bias did not modify the effects of CNIs and mTORIs on
13
14 skin cancer incidences (Figure S3). Sources of heterogeneity for other treatment effects could not
15
16 be explored due to insufficient data.
17
18
19

20 **4 DISCUSSION**

21
22 Skin cancers (both non-melanoma and melanoma) are major causes of morbidity and mortality in
23
24 solid organ transplant recipients. Despite this, trials of interventions aimed at preventing skin
25
26 cancer in solid organ transplant recipients are few in number (20 trials), small with half comprising
27
28 of 50 patients or less, of short duration (48% have <12 months follow up) and 52% do not include
29
30 incidence of skin cancer as an outcome. Our review included 22 reports of 20 trials involving 2,295
31
32 transplant recipients, who were predominately kidney transplant recipients. The studies covered a
33
34 broad range of interventions, including behavioral to improve sun protection behavior and
35
36 pharmaceutical (immunosuppression, photodynamic therapy, oral retinoid, nicotinamide and
37
38 topical immune response modifiers) to evaluate precancerous lesion response and cancer
39
40 incidence. None of the behavioral intervention studies included precancerous lesions or skin
41
42 cancer incidence as outcomes. Although interventions showed plausible improvements to sun
43
44 protection behaviors, precancerous lesion responses and cancer incidence, there was considerable
45
46 variability across interventions types, variability in outcomes assessed and outcome estimates.
47
48 Overall, the current evidence for interventions for skin cancer prevention in solid organ transplant
49
50 recipients is of very low quality and is insufficient to guide decision-making and clinical practice.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Although behavioral interventions appeared to improve sun protection attitude, knowledge and
5
6 behavior, there were inconsistencies detected and none of these studies included skin cancer as
7
8 an outcome. Due to limited number of studies, we were unable to compare specific behavioral
9
10 interventions (e.g. mobile app vs. written education) to ascertain the most effective method of
11
12 delivering sun protection education. While there may be some modest benefits in the reduction in
13
14 cancer incidence (for NMSC) among solid organ transplant recipients who were converted to
15
16 mTORIs compared to those on CNI maintenance, there was substantial heterogeneity across the
17
18 studies that was unable to be explained by subgroup analyses. Heterogeneity may be attributed to
19
20 the absence of long term follow up, large discontinuation rates owing to adverse events and
21
22 variability in the doses of mTORIs. Pharmaceutical interventions (switch to mTOR inhibitors,
23
24 photodynamic therapy, immune response modifiers) showed a reduction in precancerous lesions
25
26 compared to standard care or a comparator group. However uncertainty exists in the treatment
27
28 effects and there were too few studies, interventions were incomparable, follow-up times were
29
30 variable and considerable loss to follow up for some studies to conclude that the benefits are
31
32 sustainable.
33
34
35
36
37
38
39
40
41
42

43 Previous systematic reviews have evaluated the impact of behavioral interventions on skin cancer
44
45 prevention in the general population,⁴⁵ and concluded that computer programs may increase sun
46
47 protective behaviors, and 'appearance-focused' interventions may decrease sun tanning and UV
48
49 exposure in adolescents and young women, respectively. Reviews conducted in other populations
50
51 at high-risk including outdoor workers,⁴⁶ family history, personal history and phenotypic factors⁴⁷
52
53 have found similar improvement in sun protective behaviors, including use of sunscreen, as well as
54
55 a decreased incidence of keratoses. A systematic review of the benefits and harms of oral
56
57
58
59
60

1
2 retinoids for the prevention of skin cancer among high risk transplant recipients led to inconclusive
3
4 results on the effect of acitretin due to the small number of included trials.⁴⁸
5
6
7

8
9 Despite the inclusion of all interventions aimed at the prevention of skin cancer in solid organ
10
11 transplant recipients and the comprehensive systematic search for eligible studies, there are some
12
13 potential limitations. Due to the heterogeneity of the studies, the high risk of bias, the potential
14
15 for reporting bias and imprecision in the point estimates of individual studies, there is a high
16
17 degree of uncertainty in the estimate of the effect of skin cancer prevention interventions. All
18
19 studies of behavioral interventions were undertaken in United States, with 4 by the same authors,
20
21 whilst most pharmacological intervention studies were conducted in Europe. There were also
22
23 large discontinuation rates owing to adverse events in trials of mTORIs. Further, given the small
24
25 number of studies included in the meta-analysis, we were unable to perform any detailed
26
27 subgroup analyses to explore heterogeneity or assess for publication bias. While we were unable
28
29 to show and assess publication bias using standard statistical tests, we would suggest the
30
31 observed heterogeneity may also be attributed to potential publication and reporting biases. It is
32
33 difficult to quantify the extent of such bias in this review, but one would expect research with
34
35 'positive' findings that indicate an intervention works, such as behavioral interventions improve
36
37 sun protection, are more likely to be published more than one, in high impact journals and more
38
39 likely to be cited. Finally, few trials included patient important outcomes associated with skin
40
41 cancer and none included melanoma or mortality.
42
43
44
45
46
47
48
49
50

51
52
53 The use of pharmaceutical and immunosuppression therapy remains complex. Not only has mTORI
54
55 therapy shown benefits in lowering the risk of skin cancer, early conversion to mTORI therapy
56
57 from CNIs has also shown promising effects in reducing cancer rates.^{49 50} On the contrary, overall
58
59 mortality is higher and discontinuation following adverse events is more common in patients who
60

1
2 receive mTORI therapy.^{49 50} Several RCTs showed a higher rate of patients reporting adverse
3
4 events or drug discontinuation with sirolimus,^{1 41 43} demonstrating concern of its clinical
5
6 usefulness.⁴⁹ Nicotinamide may also offer benefits to reducing skin cancer incidence by 20% and is
7
8 relatively safe with minimal side effects. The protective effect of nicotinamide on skin cancer
9
10 incidence in kidney transplant recipients is currently being explored in a phase 3 randomised
11
12 controlled trial.
13
14
15
16
17
18

19 Although behavioral change is a simple strategy, long-term adherence remains challenging.

20
21 While behavioral counseling has been shown to increase sun protective behaviors in non-
22
23 transplant populations,⁴⁵ there is no direct evidence to show that the behavioral change led to a
24
25 reduction in morbidity and mortality. Previous studies have suggested that transplant recipients
26
27 do not practice sun protective behaviors regularly,⁵¹⁻⁵³ were less likely to use sunscreen⁵⁴ and that
28
29 patients have to perceive skin cancer as being an important risk to be motivated to change
30
31 behavior.^{55 56} However, studies on risk perception of transplant recipients remain conflicting.
32
33
34
35
36 Given this complexity and the observed inconsistencies in the existing trials, process evaluations
37
38 including facilitators and barriers to behavioral change should be included in future trials. Such
39
40 evaluations could include the use of qualitative methodology to support the trial design, ascertain
41
42 the perspectives of participants on the intervention and evaluate the implementation.^{57 58}
43
44
45
46
47

48 We suggest that further strategies for skin cancer prevention in transplant recipients require a
49
50 multifaceted and individualized approach. Transplant recipients are likely to benefit from early
51
52 implementation of education, particularly before transplantation occurs and recipients may be
53
54 preoccupied with other health needs related to transplantation. Although recipients understand
55
56 the importance of ongoing education for the ability to self-manage their disease, they may
57
58 experience difficulty in concentrating and learning new knowledge, and are often unable to look
59
60

1
2 beyond their graft and the anxiety/fear of graft loss.⁵⁹⁻⁶¹ Interventions should be integrated into
3
4 routine appointments and tailored to meet the individual needs of patients. This would be best
5
6 achieved through a shared decision-making approach to identify the patient's preferences and
7
8 priorities and thereby enhance the likelihood of success of self-management and prevention.⁶²
9
10

11
12
13
14 Additional large-scale and high-quality RCTs are needed to demonstrate the effectiveness of
15
16 interventions used to prevent skin cancer in transplant recipients in terms of patient important
17
18 outcomes, in particular morbidity and mortality associated with skin cancer. Determining patient's
19
20 preferences for prevention and management of skin cancer are also warranted to ensure
21
22 interventions and outcomes for trials are relevant to patient needs and priorities and better
23
24 support patient-centered treatment decisions.⁶³ Evidence of the efficacy of sun protective
25
26 behavior interventions need to be strengthened, with use of measures that are homogenous,
27
28 reliable and validated.
29
30
31
32
33
34
35

36 Preventative measures including behavioral, switch to mTOR inhibitors and other pharmaceuticals
37
38 may improve skin cancer outcomes for solid organ transplant recipients. However, the overall
39
40 quality of evidence is of very low and insufficient to guide decision-making and clinical practice.
41
42 Future robust studies that are well powered, have long-term follow up, and use clinical and
43
44 patient important outcome measures in a consistent manner are required to therefore optimize
45
46 outcomes for solid organ transplant recipients.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. *N Engl J Med* 2012;367(4):329-39.
2. Harwood CA, Mesher D, McGregor JM, et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. *Am J Transplant* 2013;13(1):119-29. doi: 10.1111/j.1600-6143.2012.04292.x [published Online First: 2012/10/18]
3. Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. *Br J Dermatol* 2002;147(5):950-6. [published Online First: 2002/11/02]
4. Ulrich C, Kanitakis J, Stockfleth E, et al. Skin cancer in organ transplant recipients--where do we stand today? *Am J Transplant* 2008;8(11):2192-8. doi: 10.1111/j.1600-6143.2008.02386.x [published Online First: 2008/09/11]
5. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med* 2003;348(17):1681-91. doi: 10.1056/NEJMra022137 [published Online First: 2003/04/25]
6. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. *J Am Acad Dermatol* 2002;47(1):1-20. doi: <https://doi.org/10.1067/mjd.2002.125579>
7. Garrett GL, Blanc PD, Boscardin J, et al. Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. *JAMA Dermatol* 2017;153(3):296-303. doi: 10.1001/jamadermatol.2016.4920 [published Online First: 2017/01/18]
8. Green AC, Olsen CM. Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. *Acta Derm Venereol* 2015;95(8):923-27.
9. Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. *J Immunother Cancer* 2019;7(1):106.
10. Hassan NA, Abudayyeh A, Shah M, et al. The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature: American Society of Clinical Oncology, 2018.

- 1 11. Au EH, Chapman JR, Craig JC, et al. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and
2 after Kidney Transplant. *J Am Soc Nephrol* 2019;30(3):471-80.
- 3
4
5 12. Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ
6 transplant recipients: a multicenter collaborative study. *Arch Dermatol* 2003;139(3):301-6. [published
7
8
9 Online First: 2003/03/08]
- 10
11
12 13. ANZDATA Registry. 38th Report, Chapter 10: Cancer. Adelaide, Australia. : Australia and New Zealand
13
14 Dialysis and Transplant Registry, 2016.
- 15
16
17 14. Chapman JR, Webster AC, Wong G. Cancer in the Transplant Recipient. *Cold Spring Harb Perspect Med*
18
19 2013;3(7):a015677. doi: 10.1101/cshperspect.a015677
- 20
21
22 15. Garrett GL, Lowenstein SE, Singer JP, et al. Trends of skin cancer mortality after transplantation in the
23
24 United States: 1987 to 2013. *J Am Acad Dermatol* 2016;75(1):106-12. doi: 10.1016/j.jaad.2016.02.1155
25
26 [published Online First: 2016/04/14]
- 27
28
29 16. Ibrahim SF, Brown MD. Tanning and cutaneous malignancy. *Dermatologic Surgery* 2008;34(4):460-74.
30
31 doi: 10.1111/j.1524-4725.2007.34092.x [published Online First: 2008/02/06]
- 32
33
34 17. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant
35
36 recipients. *Clin Transplant* 2005;19(6):726-34. doi: 10.1111/j.1399-0012.2005.00412.x [published Online
37
38 First: 2005/11/30]
- 39
40
41 18. Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence?
42
43 *Clin J Am Soc Nephrol* 2008;3 Suppl 2:S87-S100. doi: 10.2215/CJN.03320807
- 44
45
46 19. Acuna SA, Huang JW, Scott AL, et al. Cancer Screening Recommendations for Solid Organ Transplant
47
48 Recipients: A Systematic Review of Clinical Practice Guidelines. *Am J Transplant* 2017;17(1):103-14. doi:
49
50 10.1111/ajt.13978 [published Online First: 2016/08/31]
- 51
52
53 20. Chadban SJ, Barraclough KA, Campbell SB, et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO
54
55 Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *Nephrology* 2012;17(3):204-14. doi:
56
57 10.1111/j.1440-1797.2011.01559.x
- 58
59
60

- 1 21. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-
2
3 Analyses: The PRISMA Statement. *PLOS Medicine* 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097
4
5 22. edited by Julian PTH, Sally G. Cochrane handbook for systematic reviews of interventions: Chichester,
6
7 West Sussex ; Hoboken NJ : John Wiley & Sons 2008.
8
9
10 23. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and
11
12 strength of recommendations. *BMJ* 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD [published
13
14 Online First: 2008/04/26]
15
16
17 24. Robinson JK, Friedewald JJ, Desai A, et al. Response across the health-literacy spectrum of kidney
18
19 transplant recipients to a sun-protection education program delivered on tablet computers: randomized
20
21 controlled trial. *JMIR Cancer* 2015;1(2):e8.
22
23
24 25. Carroll RP, Hester J, Wood KJ, et al. Conversion to sirolimus in kidney transplant recipients with
25
26 squamous cell cancer and changes in immune phenotype. *Nephrol Dial Transplant* 2013;28(2):462-65.
27
28
29 26. de Sevaux RG, Smit JV, de Jong EM, et al. Acitretin treatment of premalignant and malignant skin
30
31 disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of
32
33 acitretin. *J Am Acad Dermatol* 2003;49(3):407-12. [published Online First: 2003/09/10]
34
35
36 27. Togsverd-Bo K, Omland SH, Wulf HC, et al. Primary prevention of skin dysplasia in renal transplant
37
38 recipients with photodynamic therapy: a randomized controlled trial. *Am J Transplant* 2015;15(11):2986-
39
40
41 90. doi: <https://dx.doi.org/10.1111/ajt.13358>
42
43
44 28. Trinh N, Novice K, Lekakh O, et al. Use of a brief educational video administered by a portable video
45
46 device to improve skin cancer knowledge in the outpatient transplant population. *Dermatologic Surgery*
47
48 2014;40(11):1233-9. doi: <https://dx.doi.org/10.1097/DSS.000000000000148>
49
50
51 29. Chen AC, Martin AJ, Dalziel RA, et al. A phase II randomized controlled trial of nicotinamide for skin
52
53 cancer chemoprevention in renal transplant recipients. *Br J Dermatol* 2016;175(5):1073-75. doi:
54
55 10.1111/bjd.14662 [published Online First: 2016/10/30]
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30. Clowers-Webb HE, Christenson LJ, Phillips PK, et al. Educational outcomes regarding skin cancer in organ transplant recipients: Randomized intervention of intensive vs standard education. *Arch Dermatol* 2006;142(6):712-8. doi: 10.1001/archderm.142.6.712 [published Online First: 2006/06/21]
31. Robinson JK, Guevara Y, Gaber R, et al. Efficacy of a sun protection workbook for kidney transplant recipients: a randomized controlled trial of a culturally sensitive educational intervention. *Am J Transplant* 2014;14(12):2821-29.
32. Robinson JK, Friedewald JJ, Desai A, et al. A randomized controlled trial of a mobile medical app for kidney transplant recipients: effect on use of sun protection. *Transplant Direct* 2016;2(1):1.
33. Robinson JK, Turrisi R, Mallett KA, et al. Efficacy of an educational intervention with kidney transplant recipients to promote skin self-examination for squamous cell carcinoma detection. *Arch Dermatol* 2011;147(6):689-95. doi: <https://dx.doi.org/10.1001/archdermatol.2011.10>
34. Robinson JK, Joshi KM, Ortiz S, et al. Melanoma knowledge, perception, and awareness in ethnic minorities in Chicago: recommendations regarding education. *Psychooncology* 2011;20(3):313-20. doi: 10.1002/pon.1736 [published Online First: 2010/09/30]
35. Salgo R, Gossman J, fer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. *Am J Transplant* 2010;10(6):1385-93.
36. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. *Br J Dermatol* 2004;151(1):196-200.
37. Togsverd-Bo K, Halldin C, Sandberg C, et al. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients – a randomized intra-individual controlled trial. *Br J Dermatol* 2017 doi: 10.1111/bjd.15884

- 1 38. Brown VL, Atkins CL, Ghali L, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin
2
3 dysplasia in high-risk renal transplant recipients: Randomized, double-blind, placebo-controlled trial. *Arch*
4
5 *Dermatol* 2005;141(8):985-93.
6
7
8 39. Alberu J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted
9
10 to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
11
12 *Transplantation* 2011;92(3):303-10.
13
14
15 40. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic
16
17 skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled
18
19 study. *J Clin Oncol* 1995;13(8):1933-8. doi: 10.1200/jco.1995.13.8.1933 [published Online First:
20
21 1995/08/01]
22
23
24 41. Campbell S, Walker R, Tai S, et al. Randomized controlled trial of sirolimus for renal transplant
25
26 recipients at high risk for nonmelanoma skin cancer. *Am J Transplant* 2012;12(5):1146-56.
27
28
29 42. George R, Weightman W, Russ GR, et al. Acitretin for chemoprevention of non-melanoma skin cancers
30
31 in renal transplant recipients. *Austral J Dermatol* 2002;43(4):269-73.
32
33
34 43. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al. Two-year randomized controlled
35
36 prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive
37
38 squamous cell carcinomas to sirolimus. *J Clin Oncol* 2013;31(10):1317-23.
39
40
41 44. Wulf HC, Pavel S, Stender I, et al. Topical photodynamic therapy for prevention of new skin lesions in
42
43 renal transplant recipients. *Acta Derm Venereol* 2006;86(1):25-28.
44
45
46 45. Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the
47
48 U.S. Preventive Services Task Force. *Ann Intern Med* 2011;154(3):190-201. doi: 10.7326/0003-4819-154-3-
49
50 201102010-00009 [published Online First: 2011/02/02]
51
52
53 46. Horsham C, Auster J, Sendall MC, et al. Interventions to decrease skin cancer risk in outdoor workers:
54
55 update to a 2007 systematic review. *BMC Res Notes* 2014;7:10. doi: 10.1186/1756-0500-7-10 [published
56
57 Online First: 2014/01/09]
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
47. Wu YP, Aspinwall LG, Conn BM, et al. A systematic review of interventions to improve adherence to melanoma preventive behaviors for individuals at elevated risk. *Prev Med* 2016;88:153-67. doi: 10.1016/j.ypmed.2016.04.010 [published Online First: 2016/04/20]
48. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. *Br J Dermatol* 2005;152(3):518-23. doi: 10.1111/j.1365-2133.2005.06347.x [published Online First: 2005/03/25]
49. Howard MD, Su JC, Chong AH. Skin cancer following solid organ transplantation: a review of risk factors and models of care. *Am J Clin Dermatol* 2018;19(4):585-97.
50. Lim W, Eris J, Kanellis J, et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. *Am J Transplant* 2014;14(9):2106-19.
51. Iannacone MR, Pandeya N, Isbel N, et al. Sun Protection Behavior in Organ Transplant Recipients in Queensland, Australia. *Dermatology* 2015;231(4):360-6. doi: 10.1159/000439428 [published Online First: 2015/09/30]
52. Imko-Walczuk B, Graczyk M, Korban M, et al. Impact of Skin Cancer Awareness on Prophylactic Behavior Among Renal Transplant Recipients. *Transplant Proc* 2016;48(5):1526-31. doi: 10.1016/j.transproceed.2015.11.040 [published Online First: 2016/08/09]
53. Thomas BR, Barnabas A, Agarwal K, et al. Patient perception of skin-cancer prevention and risk after liver transplantation. *Clin Exp Dermatol* 2013;38(8):851-6. doi: 10.1111/ced.12159 [published Online First: 2013/06/21]
54. Robinson JK, Rigel DS. Sun protection attitudes and behaviors of solid-organ transplant recipients. *Dermatologic Surgery* 2004;30(4 Pt 2):610-5. doi: 10.1111/j.1524-4725.2004.30145.x [published Online First: 2004/04/06]

- 1 55. Robinson JK, Friedewald J, Gordon EJ. Perceptions of Risk of Developing Skin Cancer for Diverse
2
3 Audiences: Enhancing Relevance of Sun Protection to Reduce the Risk. *J Cancer Educ* 2016;31(1):153-7. doi:
4
5 10.1007/s13187-015-0885-1 [published Online First: 2015/07/26]
6
7 56. Skiveren J, Mortensen EL, Haedersdal M. Sun protective behaviour in renal transplant recipients. A
8
9 qualitative study based on individual interviews and the Health Belief Model. *J Dermatolog Treat*
10
11 2010;21(6):331-6. doi: 10.3109/09546630903410166 [published Online First: 2010/06/10]
12
13
14 57. Lewin S, Glenton C, Oxman AD. Use of qualitative methods alongside randomised controlled trials of
15
16 complex healthcare interventions: methodological study. *BMJ* 2009;339:b3496. doi: 10.1136/bmj.b3496
17
18 [published Online First: 2009/09/12]
19
20
21 58. Oakley A, Strange V, Bonell C, et al. Process evaluation in randomised controlled trials of complex
22
23 interventions. *BMJ* 2006;332(7538):413-6. doi: 10.1136/bmj.332.7538.413 [published Online First:
24
25 2006/02/18]
26
27
28 59. Buldukoglu K, Kulakac O, Kececioglu N, et al. Recipients' perceptions of their transplanted kidneys.
29
30 *Transplantation* 2005;80(4):471-6. [published Online First: 2005/08/27]
31
32
33 60. Jamieson NJ, Hanson CS, Josephson MA, et al. Motivations, Challenges, and Attitudes to Self-
34
35 management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. *Am J Kidney Dis*
36
37 2016;67(3):461-78. doi: 10.1053/j.ajkd.2015.07.030 [published Online First: 2015/09/16]
38
39
40 61. Urstad KH, Wahl AK, Andersen MH, et al. Renal recipients' educational experiences in the early post-
41
42 operative phase--a qualitative study. *Scand J Caring Sci* 2012;26(4):635-42. doi: 10.1111/j.1471-
43
44 6712.2012.00972.x [published Online First: 2012/03/16]
45
46
47 62. Gordon EJ, Butt Z, Jensen SE, et al. Opportunities for shared decision making in kidney transplantation.
48
49 *Am J Transplant* 2013;13(5):1149-58. doi: 10.1111/ajt.12195 [published Online First: 2013/03/16]
50
51
52 63. O'Hare AM, Rodriguez RA, Bowling CB. Caring for patients with kidney disease: shifting the paradigm
53
54 from evidence-based medicine to patient-centered care. *Nephrol Dial Transplant* 2016;31(3):368-75. doi:
55
56 10.1093/ndt/gfv003 [published Online First: 2015/02/01]
57
58
59
60

1 64. Dantal J, Morelon E, Rostaing L, et al. Sirolimus for Secondary Prevention of Skin Cancer in Kidney
2
3 Transplant Recipients: 5-Year Results. *Journal of Clinical Oncology* 2018;36(25):2612-20. doi:
4
5 10.1200/jco.2017.76.6691
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of included studies (n=20)

Characteristics	N (%)
Type of transplant	
Kidney	16 (80)
Multiple*	4 (20)
Sex	
≥ 50% Male	18 (90)
< 50% Male	1 (5)
Not specified	1 (5)
Age (mean)	
< 60	10 (50)
≥ 60	5 (25)
Not specified	5 (25)
Sample size	
10 – 50	11 (55)
50 – 100	3 (15)
100 – 200	4 (20)
>200	2 (10)
Setting	
Single center	8 (40)
Multi center	11 (55)
Not specified	1 (5)
Country of origin	
Australia	3 (15)
Denmark	4 (20)
France	1 (5)
Germany	1 (5)
Netherlands	2 (10)
New Zealand	2 (10)
Switzerland	1 (5)
Sweden	1 (5)
United Kingdom	3 (15)
United States	6 (30)
Other†	1 (5)
Intervention Type	
Behavioral	5 (25)
Switch to mTOR inhibitors	6 (30)
Photodynamic therapy	4 (20)
Oral retinoid	3 (15)
Nictotinamide	1 (5)
Topical immune response modifier	1 (5)
Duration of follow up	
<12 months	9 (45)
12 months	4 (20)
24 months	5 (25)
>24 months	1 (5)
Not specified	1 (5)
Year of publication	
1995 – 1999	1 (5)
2000 – 2004	3 (15)
2005 – 2009	4 (20)
2010 – 2014	8 (40)
2015 – 2017	4 (20)

* Kidney, liver and lung (n=2); kidney and heart (n=1); Kidney and multiple other types (n=1) – see text

† 111 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, United States), South Africa, and South America (Argentina, Brazil, Chile)

Table 2. Characteristics of individual studies

Study	N	Type of transplant	Setting	Type of intervention	Measures	Intervention	Comparator	Primary outcomes	Time (mths)
Behavioral interventions (n=6)									
4 Clowers- 5 Webb 6 2006 ³⁰	202	Kidney, liver, heart, pancreas, lung, heart/lung, other [§]	Single centre, United States	Behavioral	Self-reported questionnaire	Repetitive written material	Standard care	Knowledge & behavior	10
8 Robinson 9 2011 ³³	75	Kidney	United States	Behavioral	Self-reported questionnaire	Workbook	Standard care	Knowledge & behavior	1
10 Robinson 11 2014 ³¹	101	Kidney	Single centre, United States	Behavioral	Self-reported questionnaire	Workbook Text messages	Standard care	Knowledge & behavior	1.5
14 Robinson 15 2015 ^{24†}	170	Kidney	Multi-centre, United States	Behavioral	Self-reported questionnaire	Mobile app program	Standard care	Knowledge & behavior	0.5
17 Robinson 18 2016 ³²	170	Kidney	Multi-centre, United States	Behavioral	Self-reported questionnaire	Mobile app program	Standard care	Knowledge & behavior	1.5
21 Trinh 22 2014 ^{28*}	100	Kidney, liver, lung	Single centre, United States	Behavioral	Self-reported questionnaire	Video	Pamphlet	Knowledge	1 day
Switch to mTOR inhibitors (n=7)									
25 Alberu 26 2011 ³⁹	830	Kidney	Multi centre [§]	Switch to mTOR inhibitors	Investigator reported adverse events	Conversion to sirolimus	CNI	Cancer incidence	24
29 Campbell 30 2012 ⁴¹	86	Kidney	Multi centre, Australia, New Zealand, United States	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	CNI	Cancer incidence	12
34 Carroll 35 2013 ^{25*}	32	Kidney	Multi centre, UK	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to prednisolone & sirolimus	CNI/AZA	Cancer incidence	24
37 Euvrard 38 2012 ¹⁶⁴	120	Kidney	Multi centre, France	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	CNI	Cancer incidence	24
40 Hoogendijk- 41 van den 42 Akker	155	Kidney	Multi centre, Netherlands, UK	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	AZA/MMF/ CNI	Cancer incidence	24

6/mjopen-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> by guest on April 17, 2024. Protected by copyright.

2013⁴³

1 Salgo 2 2010 ³⁵ 3 4	44	Kidney	Single centre, Germany	Switch to mTOR inhibitors	Physical examination +/- biopsy Clinical photographs	Conversion to sirolimus and prednisone	AZA/MMF/ CNI	Precancerous skin dysplasia incidence	12
5 Pharmaceutical interventions – Photodynamic therapy (n=4); oral retinoids (n=3); nicotinamide (n=1); 5% imiquimod cream (n=1)									
6 Bavinck 7 1995 ⁴⁰ 8 9 10 11	44	Kidney	Multi centre, Netherlands	Oral retinoid	Physical examination +/- biopsy	Acitretin	Placebo	Cancer incidence precancerous lesion reduction	6
12 Brown 13 2005 ³⁸ 14 15 16 17	21	Kidney	Multi centre, UK	Topical immune response modifier cream	Physical examination +/- biopsy Clinical mapping and photographs	5% Imiquimod cream	Placebo	Reduction of precancerous lesions	4
18 Chen 19 2016 ^{29*} 20 21	22	Kidney	Single centre, Australia	Nicotinamide	Physical examination	Nicotinamide	Placebo	Cancer incidence	6
22 de Sevaux 23 2003 ^{26*} 24 25	26	Kidney	Single centre, Netherlands	Oral retinoid	Physical examination +/- biopsy	High dose acitretin	Low dose acitretin	Cancer and precancerous incidence	12
26 Dragieva 27 2004 ³⁶ 28 29	17	Kidney, heart	Single centre, Switzerland	Photodynamic therapy	Physical examination +/- biopsy Clinical photographs	Methyl aminolevulinate cream	Placebo	Precancerous lesion response	4
30 George 31 2002 ⁴² 32 33	23	Kidney	Multi centre, Australia	Oral retinoid	Physical examination Annual radiological evaluation	Acitretin	Drug free period	Cancer incidence	24
34 Togsverd- 35 Bo 2015 ^{27*†} 36 37	25	Kidney	Single centre, Denmark	Photodynamic therapy	Physical examination Clinical photographs	Methyl aminolevulinate cream	No treatment contralateral area	Actinic keratosis incidence	36
38 Togsverd- 39 Bo 2017 ^{37†} 40 41	35	Kidney, lung, liver	Multi-centre, Denmark and Sweden	Photodynamic therapy	Physical examination Questionnaire/Diary	Methyl aminolevulinate cream	5% imiquimoid cream	Actinic keratosis lesion response	6

32

Wulf 2006 ^{44†}	27	Kidney	Multi centre, Denmark and Netherlands	Photodynamic therapy	Clinical mapping and photographs	Methyl aminolevulinate cream	No treatment contralateral area	Cancer incidence	12
-----------------------------	----	--------	---	-------------------------	-------------------------------------	------------------------------------	---------------------------------------	---------------------	----

2
3 Excluded from analyses – no meaningful data to extract

4 Randomized controlled areas of skin on individuals

5 Excluded from analyses – same participants as Robinson 2016

6 11 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, United States), South Africa, and South America (Argentina, Brazil, Chile

7 Abbreviations: CNI, Calcineurin inhibitor; AZA, Azathioprine; MMF, Mycophenolate mofetil

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

For peer review only

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

Table 3. Effect of behavioral interventions on sun protection outcomes

Outcome	Studies	Participants	Weighted MD ^a /SMD ^b [95% CI]	Relative risk	P	I ²	Intervention	Comparator
BEHAVIORAL INTERVENTION (n=5)								
SUN PROTECTION BEHAVIOR								
General sun protection behavior	3	414	0.89 [-0.84, 2.62]		0.31	98%	Workbook, text messages, mobile app program	Standard care
Skin self-examination								
1 month after visit	1	75		4.14 [2.22, 7.72]	<0.001	90%	Workbook	Standard care
If checked, concerned	1	42		6.43 [0.42, 98.58]	0.18	99%		
If concerned, saw dermatologist	1	12		Not estimable ^c		99%		
Decrease daily hours outdoors	1	170	-6.12 [-7.11, -5.13] ^d		<0.001	99%	Mobile app program	Standard care
SUN PROTECTION KNOWLEDGE								
	4	489	0.50 [0.12, 0.87]		0.01	76%	Workbook, text messages, mobile app program	Standard care
SUN PROTECTION ATTITUDE								
Concern about developing skin cancer	3	348	1.88 [0.96, 2.80]		<0.001	92%	Workbook, text messages, mobile app program	Standard care
Recognise personal risk	2	273	0.61 [-0.60, 1.82]		0.32	96%	Workbook and text messages, mobile app program	Standard care
Confidence in ability to perform sun protection	2	273	0.77 [-0.14, 1.68]		0.10	92%		
Willingness/intention to change behavior	2	273	1.70 [-1.68, 5.07]		0.32	99%		
Knowledge of significance of skin cancer, relevance of sun protection, risk of having a tan	1	101	7.00 [2.94, 11.06]		0.001	99%	Workbook and text messages	Standard care
Confidence in ability to recognise a skin cancer	1	75	1.80 [1.35, 2.25]		<0.001	99%	Workbook	Standard care
Importance of skin self-examination	1	75	1.05 [0.61, 1.49]		<0.001	99%		
Importance of partner help for skin self-examination	1	75	1.59 [1.10, 2.08]		<0.001	99%		

COMPLICATIONS

1	Skin irritation								
2	None	2	271	1.00 [0.89, 1.13]	0.95	95%	Workbook and text messages, mobile app program	Standard care	
3	> 1	2	271	0.77 [0.43, 1.36]	0.36	89%			
4	Sunburn (past week)								
5	None	2	271	3.19 [2.47, 4.10]	<0.001	99%			
6	> 1	2	271	2.68 [1.81, 3.96]	<0.001	95%			

BIOLOGIC MEASURES

10	Melanin index - RU arm (sun protected)	2	271	0.12 [-0.12, 0.35]	0.34	0%	Workbook and text messages, mobile app program	Standard care
11	Melanin index - R forearm (sun exposed)	2	271	-0.42 [-0.66, -0.18] ^d	0.001	0%		
12	Cheek (sun exposed)	2	271	-0.25 [-0.64, 0.15] ^d	0.22	61%		
13	Sun damage assessment - R forearm	2	271	-0.13 [-0.40, 0.13] ^d	0.33	16%		

^aMean difference

^bStandardised mean difference

^cUnable to estimate due to absence of comparator group

^dReduction of outcome of interest represents an improvement

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

For peer review only

Table 4. Effect of pharmaceutical interventions on skin cancer prevention

Outcome	Studies	Participants	Relative risk	P	I ²	Intervention	Comparator
SWITH TO mTOR INHIBITORS (n=5)							
<u>PRE-CANCEROUS LESIONS</u>							
Skin dysplasia							
Any improvement	1	32	24.35 [1.55, 381.99]	0.02	0.0	Sirolimus	CNI ^b
Unchanged	1	32	0.85 [0.28, 2.61]	0.78	0.0		
Any worsening	1	32	0.04 [0.00, 0.66]	0.02	0.0		
<u>CANCEROUS LESIONS</u>							
SCC ^d /BCC ^e incidence	5	1082	0.46 [0.28, 0.75]	0.002	72%	Sirolimus	CNI
≥1 SCC	1	53	0.64 (0.35, 1.17)	0.15	N/A		
Skin cancer (excluding SCC)	1	53	0.74 (0.49, 1.14)	0.17	N/A		
Skin cancer (including SCC)	1	53	0.85 (0.61, 1.17)	0.32	N/A		
Skin cancer with BCC	1	53	0.89 (0.45, 1.78)	0.75	N/A		
PHOTODYNAMIC THERAPY (n=3)							
<u>PRE-CANCEROUS LESIONS</u>							
Actinic keratosis reduction (1-2 sessions)							
Complete response	2	50 ^a	5.03 [0.14, 176.17]	0.37	85%	MAL ^c	Placebo, Imiquimod 5% cream
Partial response	1	17 ^a	7.00 [0.39, 125.99]	0.19	N/A	MAL	Placebo
No reduction	1	17 ^a	0.09 [0.02, 0.40]	0.002	N/A		
<u>CANCEROUS LESIONS</u>	1	26 ^a	0.59 [0.34, 1.03]	0.06	N/A	MAL	No treatment
IMMUNE RESPONSE MODIFIERS (n=1)							
<u>PRE-CANCEROUS LESIONS</u>							
Reduced skin atypia							
	1	14 ^a	3.00 [0.47, 19.35]	0.25	N/A	Imiquimod 5% cream	Placebo
Reduced dysplasia	1	14 ^a	2.14 [0.31, 14.65]	0.44	N/A		
Reduced keratoses	1	14 ^a	2.14 [0.31, 14.65]	0.44	N/A		
Reduced no. viral warts	1	14 ^a	7.00 [0.46, 106.10]	0.16	N/A		

CANCEROUS LESIONS

SCC incidence

1	Treated (cream vs. placebo)	1	14 ^a	0.09 [0.01, 1.70]	0.11	N/A	Imiquimod 5% cream	Placebo
2								
3								
4	Untreated (control site)	1	14 ^a	0.43 [0.08, 2.37]	0.33	N/A		
5								

ORAL RETINOIDS (n=2)

CANCEROUS LESIONS

Decreased incidence:

10	> 1 SCC	1	46 ^a	0.40 [0.19, 0.85]	0.02	N/A	Acitretin	Drug free period
11								
12	> 1 BCC	1	46 ^a	0.50 [0.14, 1.76]	0.28	N/A		
13								
14	New skin cancer	1	19 ^a	0.22 [0.06, 0.90]	0.03	N/A	Acitretin	Placebo
15								

^aControl is the contralateral or similar area of skin on the same participant

^bCalcineurin inhibitor

^cMethyl aminolaevulinate cream

^dSquamous cell carcinoma

^eBasal cell carcinoma

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

For peer review only

1
2
3 **Figure legends**
4

5
6 Figure 1. Study selection
7

8 Figure 2. Risk of bias of included studies
9


10 Figure 3. Behavioral interventions – Sun protection behavior (general)
11

12
13 Figure 4. Behavioral interventions – Sun protection knowledge
14

15 Figure 5. Switch to mTOR inhibitors – Non melanoma skin cancer incidence
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


Figure 1. PRISMA Flowchart



209x297mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Risk of bias in included studies




297x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




209x279mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



209x279mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



209x279mm (300 x 300 DPI)

Figure S1. Search Strategy

1. exp Neoplasms, Basal Cell/
2. basal cell carcinoma.ti,ab.
3. exp Neoplasms, Squamous Cell/
4. squamous cell carcinoma.ti,ab.
5. nonmelanom*.ti,ab.
6. non melanom*.ti,ab.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Melanoma/
9. melanoma*.ti,ab.
10. Skin Neoplasms/
11. skin cancer*.ti,ab.
12. 8 or 9 or 10 or 11
13. 7 or 12
14. exp Organ Transplantation/
15. solid organ transplant*.mp.
16. transplant recipient*.tw.
17. exp Immunosuppression/
18. Immunocompromised Host/
19. 14 or 15 or 16 or 17 or 18
20. 13 and 19
21. randomized controlled trial.pt.
22. controlled clinical trial.pt.
23. randomized.ab.
24. placebo.ab.
25. Clinical Trials as Topic/
26. randomly.ab.
27. (crossover or cross-over).tw.
28. trial.ti.
29. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. Animals/ not (animals/ and Humans/)

1 31. 29 not 30

2
3 32. 20 and 31
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure S2. Risk of bias and key findings in individual studies

Study, year	Random sequence generation	Allocation concealment	Blinding participants & personnel	Blinding outcome assessors	Incomplete outcome data	Selective reporting	Intervention & comparator	Outcome RR/MD/SMD (95% CI)	
Behavioral Interventions (n=6)									
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Clowers-Webb 2006 ³⁰	Unclear	Unclear	High	Unclear	High	Low	Repetitive written material vs. standard care	General behavior SMD -0.30 (-0.63, 0.03) Knowledge SMD 0.07 (-0.26, 0.40)
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44	Robinson 2011 ³³	Unclear	Unclear	Unclear	Unclear	Low	Low	Workbook vs. standard care	Skin self examination (1 month) RR 4.14 (2.22, 7.72) Knowledge SMD 1.05 (0.57, 1.54) Concern about developing cancer SMD 0.95 (0.47, 1.43) Confidence to recognize cancer MD 1.80 (1.35, 2.25) Importance of skin self-examination MD 1.05 (0.61, 1.49) Importance of partner to help for skin self-examination MD 1.59 (1.10, 2.08)
45 46	Robinson 2014 ³¹	Low	Low	High	Low	Low	Low	Workbook & text messages vs. standard care	General behavior SMD 0.32 (-0.07, 0.71) Knowledge SMD 0.65 (0.25, 1.05) Concern about developing cancer SMD 2.73 (2.19, 3.27) Recognize personal risk SMD -0.01 (0.40, 0.38) Confidence in sun protection SMD 0.30 (-0.09, 0.68) Willingness/intention to change behaviour SMD -0.02 (-0.41, 0.36) Importance of skin cancer/sun protection/having a tan MD 7.00 (2.94, 11.06) Skin irritation none RR 1.37 (1.16, 1.63) Skin irritation >1 RR 0.15 (0.03, 0.61) Sunburn none RR 1.30 (1.12, 1.52) Sunburn >1 RR 0.17 (0.04, 0.72) Melanin index - RU arm (sun protected) SMD 0.23

1 2 3 4	Hoogendijk- van den Akker 2013 ⁴³	Unclear	Low	High	Low	High	Low	Sirolimus vs CNI/MMF/AZA	Cancer incidence RR 0.13 (0.02, 0.99)
5 6 7 8 9 10	Salgo 2010 ³⁵	Unclear	Unclear	High	Low	High	Low	Sirolimus vs CNI/MMF/AZA	Cancer incidence RR 0.13 (0.02, 0.95) Skin dysplasia Any improvement RR 24.35 (1.55, 381.99) Unchanged RR 0.85 (0.28, 2.61) Any worsening RR 0.04 (0.00, 0.66)
11	Pharmaceutical interventions – Photodynamic therapy (n=4); oral retinoids (n=3); 5% imiquimod cream (n=1)								
12 13 14	Bavinck 1995 ⁴⁰	Unclear	Unclear	Low	Unclear	Low	Low	Acitretin vs. placebo	Cancer incidence RR 0.22 (0.06, 0.90)
15 16 17 18 19 20 21 22 23	Brown 2005 ³⁸	Unclear	Unclear	Low	Low	Low	Low	5% Imiquimod cream vs. placebo	Cancer incidence SCC treated RR 0.09 (0.01, 1.70) SCC untreated RR 0.43 (0.08, 2.37) Reduced skin atypia RR 3.00 (0.47, 19.35) Reduced dysplasia RR 2.14 (0.31, 14.65) Reduced keratosis RR 2.14 (0.31, 14.65) Reduced no. viral warts RR 07.00 (0.46, 106.10)
24 25	Chen 2016 ²⁹	Low	Unclear	Low	Low	Low	Low	Nicotinamide vs. placebo	
26 27 28 29	de Sevaux 2003 ²⁶	Unclear	Low	High	Unclear	Low	Low	High dose acitretin vs. low dose acitretin	
30 31 32 33 34	Dragieva 2004 ³⁶	Unclear	Unclear	Low	Unclear	Low	Low	Methyl aminolevulinate cream vs. placebo	Actinic keratosis reduction Complete response RR 27.00 (1.73, 420.67) Partial reduction RR 7.00 (0.39, 125.99) No reduction RR 0.09 (0.02, 0.40)
35 36 37 38	George 2002 ⁴²	Unclear	Unclear	High	Unclear	Low	Low	Acitretin vs. drug free period	Cancer incidence >1 SCC RR 0.40 (0.19, 0.85) >1 SCC RR 0.50 (0.14, 1.76)
39 40 41 42 43 44	Togsverd-Bo 2015 ^{27*}	Low	Low	Unclear	Low	Low	Low	Methyl aminolevulinate cream vs. no treatment	

1	Togsverd-Bo 2017 ^{37†}	Low	Low	High	Unclear	Low	Low	Methyl aminolevulinate cream vs. 5% Imiquimod cream	Actinic keratosis reduction Complete response RR 1.42 (0.81, 2.48)
2									
3									
4									
5	Wulf 2006 ^{44†}	Low	High	High	Low	Low	Low	Methyl aminolevulinate cream vs. no treatment	Cancer incidence RR 0.59 (0.34, 1.03)
6									
7									
8									
9									

10 *Excluded from analyses – no meaningful data to extract

11 †Randomized controlled areas of skin on individuals

12 ‡Excluded from analyses – same participants as Robinson 2016

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

6/bmjopen-2019-029266 on 17 May 2020. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

Quality of assessment (Decrease in quality score)						
Number of studies	Risk of bias/Quality of evidence	Inconsistency	Indirectness	Imprecision	Publication bias	Quality
Sun protection behavior						
5 RCTs ^{24 30-33}	Serious study limitations (-1) Randomisation unclear ^{24 30 32 33} Participants not blinded or well described ^{24 30-33} Concealment of allocation not described. ^{30 33}	Important inconsistency (-1) Analysed in subgroups. heterogeneity (I ² =99%) ³⁰⁻³²	Indirectness (-1) Diverse interventions (written vs. electronic), varying duration (2 weeks to 10 months) Same sample of participants ^{24 32}	Serious imprecision (-1) Small sample size, CIs crosses the null	Uncertain Unable to determine. Small number of studies, large heterogeneity	Very low
Sun protection knowledge						
6 RCTs ^{24 28 30-33}	Serious limitations (-1) Randomisation unclear ^{24 30 32 33} Participants not blinded or well described ^{24 28 30-33} Concealment of allocation not described ^{28 33}	Important inconsistency (-1) Heterogeneity (I ² 85%)	Indirectness (-1) Diverse interventions (written vs. electronic), varying duration (1 day to 10 months) Same sample ^{24 32}	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity	Very low
Sun protection attitude						
4 RCTs ^{24 31-33}	Serious limitations (-1) Randomisation unclear ^{24 32 33} Participants not blinded or well described ^{24 31-33} Concealment of allocation	Important inconsistency (-1) Wide variation in the effect estimates, heterogeneity (I ² 97%).	Indirectness (-1) Diverse interventions (written vs. electronic), Similar duration. Same sample ^{24 32}	Serious imprecision (-1) Small sample size, small number of events	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low

6/bmjopen-7 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

not described^{32 33}**Complications (skin irritation, sunburn)**

2 RCTs ^{31 32}	Serious limitations (-1) Participants not blinded ^{31 32}	Important inconsistency (-1) Heterogeneity ($I^2=95-99\%$) Analysed in subgroups. Similar effect estimates.	Indirectness (-1) Diverse interventions (written vs. electronic), similar duration.	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low
-------------------------	--	---	---	--	---	-----------------

Biologic measures (melanin index, sun damage)

2 RCTs ^{31 32}	Serious limitations (-1) Randomisation unclear ³² Participants not blinded ^{31 32}	Important inconsistency (-1) Analysed in subgroups. Heterogeneity ($I^2 60\%$)	Indirectness (-1) Different interventions (written vs. electronic), similar duration.	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low
-------------------------	---	---	---	--	---	-----------------

Pre-cancerous incidence

4 RCTs ^{27 35-38}	Serious limitations (-1) Randomisation or allocation unclear ^{35 36 38} Participants not blinded or well described ^{27 35-38}	Important inconsistency (-1) Analysed in subgroups.	Indirectness (-1) Diverse interventions, varying duration	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Large heterogeneity.	Very low
----------------------------	--	---	---	--	--	-----------------


Cancer incidence

10 RCTs ^{1 29 35 38-44}	Serious limitations (-1) Randomisation unclear ^{1 40 42 43} Allocation concealment not used or unclear ^{1 29 39 40 42 44} Participants not blinded. ^{1 35 39 41-44}	Important inconsistency (-1) Majority of participants came from 1 study ³⁹ Small sample ^{1 29 35 38 40-44}	Indirectness (-1) Diverse interventions (immunosuppression, photodynamic therapy, immune response modifier, retinoid, nicotinamide), varying duration	Serious imprecision (-1) Majority of participants from one trial (n=551), small number of events	Uncertain Unable to determine. Large heterogeneity.	Very low
----------------------------------	--	---	---	--	--	-----------------

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Figure S3. Subgroup analyses of immunosuppression conversion interventions on skin cancer incidence





PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICCO, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-14
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-14
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16-17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	2

1136/bmjopen-2019-029265 on May 2020. Downloaded from http://bmjopen.bmj.com/ on April 27, 2024 by guest. Protected by copyright.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Behavioral and pharmaceutical interventions for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029265.R2
Article Type:	Original research
Date Submitted by the Author:	29-Jan-2020
Complete List of Authors:	James, Laura; University of Sydney, Saglimbene, Valeria; The University of Sydney, Sydney School of Public Health Wong, Germaine; The Children's Hospital at Westmead, Centre for Kidney Research Tong, Allison; The University of Sydney, Sydney School of Public Health Luu, Laurence; The University of Sydney, Sydney School of Public Health Craig, Jonathan; Flinders University Faculty of Medicine Nursing and Health Sciences, College of Medicine and Public Health, ; The Children's Hospital at Westmead, Centre for Kidney Research Howard, Kirsten; University of Sydney, School of Public Health Howell, Martin; University of Sydney - Camperdown and Darlington Campus, School of Public Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Public health
Keywords:	skin cancer, melanoma, prevention, sun protection, sun protection behaviors

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Behavioral and pharmaceutical interventions for the prevention of skin cancers in solid organ**
5
6 **transplant recipients: a systematic review of randomized controlled trials**
7
8
9

10
11 **Authors full names and highest degree:**
12

13 Laura J. James, MPH^{1,2}, Valeria Saglimbene^{1,2}, MscMed^{1,2}, Germaine Wong, PhD^{1,2,3}, Allison Tong,
14
15
16 PhD^{1,2}, Laurence Don Wai Luu, BMedSc^{1,2}, Jonathan C. Craig, PhD⁴, Kirsten Howard, PhD¹, Martin
17
18
19 Howell, PhD^{1,2}
20

21
22 **Institution of each author:**
23

24
25 ¹Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney,
26
27 NSW 2006
28

29
30 ²Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW 2145
31

32
33 ³Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW 2145
34

35
36 ⁴College of Medicine and Public Health, Flinders University, Adelaide, Australia
37

38 **Corresponding author:**
39

40 Laura James
41

42
43 Centre for Kidney Research
44

45
46 The Children's Hospital at Westmead, Westmead, NSW 2145
47

48
49 Sydney, Australia
50

51
52 Phone: +61 2 9845 1482 Fax: +61 2 9845 1491
53

54
55 Email: laura.james@health.nsw.gov.au
56

57 **Word count (abstract):** 205
58

59 **Word count (body):** 3593
60

Tables: 4 **Figures:** 5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Key words: skin cancer, melanoma, prevention, sun protection, sun protection behaviors, health behavior

Authorship

LJJ, GW, AT, LL, JCC, KH, MH designed the study; LJJ, VS, LL, MH conducted the data extraction and analyses; all authors contributed to the interpretation of the analyses. LJJ drafted the manuscript; all authors contributed to the writing and review of the manuscript.

Disclosure

The authors declare no conflicts of interest.

Data availability statement

No additional data available.

Funding

LJJ is supported by the National Health and Medical Research Council (NHMRC) Better Evidence and Translation in Chronic Kidney Disease (BEAT-CKD) Program Grant (APP1092957). MH is supported by the BEAT-CKD Program Grant (APP1092957). AT is supported by the NHMRC Fellowship (APP1106716). The funding organizations had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review, or approval of the manuscript.

Abbreviations

AZA, azathioprine

BCC, basal cell carcinoma

CNI, calcineurin inhibitors

CI, confidence intervals

MAL, methyl aminolaevulinate cream

MD, mean difference

MMF, mycophenolate mofetil

mTORI, mammalian target of rapamycin inhibitors

NMSC, non-melanoma skin cancer

RCT, randomized controlled trial

RR, relative risk

SCC, squamous cell carcinoma

SMD, standardized mean difference

ABSTRACT

Objectives

Solid organ transplant recipients are at increased risk of skin cancer, affecting more than 50% of recipients. We aimed to determine the effectiveness of interventions for behavioral change for sun protection or skin cancer prevention in solid organ transplant recipients.

Design

Systematic review

Data sources

Electronic databases were searched from inception to November 2019.

Eligibility Criteria

We included randomized controlled trials that evaluated the effect of behavioral or pharmaceutical interventions on behavioral change or skin cancer prevention in solid organ transplant recipients.

Data extraction and synthesis

Risks of bias and evidence certainty were assessed using Cochrane and the GRADE framework.

Results

Twenty trials (n=2,295 participants) were included. It is uncertain whether behavioral interventions improve sun protection behavior (N=3, n= 414, SMD 0.89, 95% CI -0.84-2.62, I² =98%) and knowledge (N=4, n=489, SMD 0.50, 95% CI 0.12-0.87, I²= 76%) as the quality of evidence

1
2 is very low. We are uncertain of the effects of mammalian target of rapamycin inhibitors on the
3
4 incidence of non-melanocytic skin cancer (N=5, n=1080, RR 0.46 95% CI 0.28-0.75, I²=72%) as the
5
6 quality of evidence is very low.
7
8
9
10

11 **Conclusions**

12
13 Behavioral and pharmaceutical preventive interventions may improve sun protective behavior and
14
15 knowledge, and reduce the incidence of non-melanocytic skin cancer, but the overall quality of the
16
17 evidence is very low and insufficient to guide decision-making and clinical practice.
18
19
20
21
22

23 **PROSPERO Registration number**

24
25
26 CRD42017063962
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Strengths and limitations

- A comprehensive review conducted using methods outlined by Cochrane Collaboration including GRADE to assess risk of bias and evidence certainty
- Inclusion of a broad range of interventions, including behavioral to improve sun protection behavior and pharmaceutical (immunosuppression, photodynamic therapy, oral retinoid, nicotinamide and topical immune response modifiers) to evaluate precancerous lesion response and cancer incidence
- Difficulty obtaining an overall summary estimate for many outcomes due to the variability in the analytical methods and reporting in individual studies
- Unable to perform detailed subgroup analyses or assess for publication bias due to small number of studies
- Few trials included the important outcomes of skin cancer and none included melanoma or mortality.

1. INTRODUCTION

Skin cancer, including melanoma and nonmelanoma skin cancer (NMSC), is the most frequently diagnosed malignancy among solid organ transplant recipients, affecting more than 50% of post-transplantation recipients.^{1,2} The cumulative incidence of NMSC increases with time after transplantation, from 5-10% at 2 years to 40-80% at 20 years.²⁻⁴ Compared to the general population, there is a higher rate of squamous cell carcinoma (SCC) to basal cell carcinoma (BCC), with an incidence of 65 to 250 times greater than the age and gender-matched general population.⁵⁻⁸ Once cancer develops, management options are limited as immunotherapy may be unsuitable as it may lead to graft rejection.^{9,10} Although registry data shows improvement in survival rates of transplant recipients as a result of improved transplantation techniques and management of immunosuppression, there is a greater burden of skin cancer and cancer related mortality.¹¹ The excess risk of death from invasive and metastatic skin cancer, such as SCC and melanoma, are three times to nine times higher than the general population, with five-year overall survival of less than 30%.^{6,12-15}

Sun exposure behaviors remain the most significant and modifiable risk factor in the prevention of skin cancers in the general population.¹⁶ However, with the dramatic increase in skin cancers in solid organ transplant recipients, pharmaceuticals have also been used to reduce and delay the development of skin cancer.^{16,17} Current recommendations for preventive strategies have often been extrapolated from guidelines in the general population, which may not be applicable to solid organ transplant recipients.^{18,19} For example, frequent skin self-examination and annual to biannual total body skin examination are generally recommended for the general population.¹⁸⁻²⁰ Sun protective behaviors including use of sunscreen, protective clothing and limiting sun exposure during peak hours of high UV index days are potential measures for skin cancer prevention.^{3,4,14}

1
2 Further, alteration of maintenance immunosuppression such as conversion to mammalian target
3
4 of rapamycin inhibitors (mTORi) and secondary prevention using retinoid acitretin are
5
6 recommended for management of skin cancers in high risk transplant recipients.²⁰
7
8
9

10
11 The aim of this study is determine the effectiveness of interventions that promote behavioral
12
13 change and skin cancer prevention in solid organ transplant recipients.
14
15
16

17 **2. METHODS**

18
19
20
21 This systematic review followed a pre-specified protocol registered in PROSPERO
22
23 (CRD42017063962) and is reported in accordance with the Preferred Reporting Items for
24
25 Systematic Reviews and Meta-analyses (PRISMA) checklist.²¹ The study was exempt from approval
26
27 from an ethics' board.
28
29
30
31

32 **2.1 Inclusion criteria**

33
34 All randomized controlled trials (RCTs) or quasi RCTs (allocated to trial arms by investigators) of
35
36 interventions for skin cancer prevention (both melanoma and non-melanoma skin cancer) in solid
37
38 organ transplant recipients were included. Behavioral interventions defined as any strategy used
39
40 to promote sun protective behavior including passive (e.g. pamphlets), active (e.g. group
41
42 workshops, counselling, dermatology clinic) and provision of sun protective equipment; and
43
44 pharmaceutical interventions (switch to mTOR inhibitors, photodynamic therapy, immune
45
46 response modifiers, nicotinamide and oral retinoids) and studies that reported skin cancer related
47
48 outcomes as their primary outcomes were included. Studies that did not report these outcomes as
49
50 primary end-points were excluded. Studies of interventions for the treatment of skin cancer were
51
52 excluded.
53
54
55
56
57
58
59
60

2.2 Search strategies

We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and CINAHL from inception to November 2019 without language restriction, using search strategies designed by a specialist information manager (see Medline search strategy in Figure S1). Reference lists of included studies were also searched.

2.3 Data extraction

Titles and abstracts were reviewed by two independent authors (LJJ & LL) and those that did not meet the inclusion criteria were excluded. Full text articles were reviewed by 3 independent reviewers (LJJ, VS, LL) and any disagreements were resolved by discussion. Data on study design, geographic location, sample size, type of transplant, measurement of interventions, interventions and comparators were extracted. We sought unclear or missing information from authors where possible.

2.4 Outcome measures

The pre-specified outcome measures were incidence of precancerous and cancerous lesions, sun protection behavior (including use of sunscreen, use of protective clothing including hats and sunglasses, shade and sun avoidance), knowledge and attitude, skin self-examination, sun exposure (including skin irritation, sunburn) and biologic measures (including measurement of melanin index and sun damage assessment).

2.5 Risk of bias and quality of evidence

The risk of bias was assessed independently by LJJ and VS using the Cochrane risk of bias tool.²²

The domains included in the assessment were: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, trial registration and industry involvement. Each criterion was

1 assigned a judgment of high, low or unclear risk of bias. Intention to treat and lost to follow up
2
3
4 were also assessed for each study. The quality of the evidence informing summary estimates for
5
6
7 each outcome was then assessed by LJJ using the Grading of Recommendations Assessment
8
9 Development and Evaluation (GRADE) guidelines.²³
10

11 12 13 **2.6 Data synthesis and statistical analyses**

14
15 Continuous outcomes were summarized as mean difference (MD) or standardized mean
16
17 difference (SMD) and dichotomous outcomes as relative risk (RR). A MD/SMD greater than zero
18
19 and/or a RR greater than 1 could be interpreted as favoring the intervention group relative to the
20
21 control, unless specified elsewhere. Risk estimates were reported with 95% confidence intervals
22
23 (CI), using random-effects meta-analysis. We quantified the heterogeneity using the I^2 statistic. An
24
25 I^2 value of <25% was considered to represent low heterogeneity and >75% as high heterogeneity.
26
27
28 When sufficient data were available, possible sources of heterogeneity were investigated using
29
30 subgroup analysis based on pre-specified study characteristics including sample size, trial duration,
31
32 setting and overall risk of bias. Funnel plots were planned to evaluate small study effects when at
33
34 least ten studies were included in meta-analysis. All analyses were conducted using Review
35
36 Manager version 5.3 software.
37
38
39
40
41
42
43
44

45 **2.7 Patient and public involvement**

46
47
48 There was no patient or public involvement.
49

50 51 **3. RESULTS**

52 **3.1 Study selection**

53
54
55 The literature search identified 1280 articles, of which, 1201 were excluded after abstract and title
56
57 review. Full text assessment of 79 studies found 22 eligible articles for inclusion (Figure 1).
58
59
60

3.2 Studies characteristics

We included 22 reports of 20 RCTs, including 2,295 participants (Figure 1). The study characteristics are summarized in Table 1 and Table 2. The median number of participants was 44 (range 17 to 830) and the median follow-up duration was 10 months (range 1 day to 60 months). All studies included kidney transplant recipients, with some also including heart transplant recipients (n=1), liver, heart, pancreas, lung, heart/lung and other transplants (n=1), and lung and liver transplant recipients (n=2). In total, 15 of 21 (76%) studies provided sufficient data for the meta-analyses. Six studies did not meet final criteria for meta-analysis as they had the same sample of participants (n=1),²⁴ or did not provide data that was able to be meta-analyzed (n=5).²⁵⁻²⁹

3.3 Risk of bias and quality of the evidence

Overall studies had either high or unclear risk of bias for at least one domain (Figure 2; Figure S2). Random sequence generation and allocation concealment were unclear in most studies (n=12, 60%). Blinding of participants was not done in most studies (n=16, 80%) and blinding of outcome assessors was only reporting in half of the studies (n=10). Intention to treat analyses were used in 6 (30%) studies and 6 studies (30%) had a high loss to follow-up. A total of 3 (15%) studies had incomplete outcome data, and all studies were at low risk for selective reporting. Seven studies (35%) reported industry involvement in authorship, design, or data analysis, and of the 16 trials requiring trial registration, only 9 (56%) reported accordingly.

The overall quality of the evidence was very low for all outcomes (Table S1) due to limitations in study design, heterogeneity in the intervention and outcomes measures, the very small sample size of individual studies and the small number of studies for each specific outcome. Obtaining an

1
2 overall summary estimate was difficult for many outcomes due to the variability in the analytical
3
4 methods and reporting in individual studies. In particular, assessment of reporting of sun
5
6 protection behavior and sun protection knowledge was not possible as outcomes were
7
8 inconsistent and there was large diversity of interventions used (e.g. written education material
9
10 versus a mobile app program). Furthermore, formal testing of publication bias was not performed
11
12 due to insufficient data.
13
14
15

16 17 **3.4 Interventions**

18
19 The interventions in the included studies were grouped in three broad categories, behavioral
20
21 (n=6), switch to mTOR inhibitors (n=6), and other pharmaceutical interventions (photodynamic
22
23 therapy, immune response modifiers, oral retinoids and nicotinamide) (n=9). Studies of behavioral
24
25 interventions used passive methods of delivery including written educational material (n=2), both
26
27 written educational material and text messages (n=1), mobile app programs (n=2) and a video
28
29 (n=1).
30
31
32
33
34
35
36

37 All six studies of immunosuppression compared mTORis (sirolimus) to calcineurin inhibitors (CNI)
38
39 based therapies.
40
41
42

43 Four of the eight studies of other pharmaceutical interventions assessed the effect of
44
45 photodynamic therapy using methyl aminolevinate creams compared to placebo (n=1), no
46
47 treatment to contralateral area (n=2) or a topical immune response modifier cream (n=1). Three
48
49 studies assessed oral retinoid using acitretin compared to placebo (n=1), lower dose (n=1) or a
50
51 drug free period (n=1), one study assessed nicotinamide compared to placebo and a single study
52
53 assessed the benefits of topical immune response modifier compared to placebo in kidney
54
55 transplant recipients.
56
57
58
59
60

3.5 Effect of behavioural interventions on sun protection outcomes

Sun protection behavior

Sun protection behavior, defined as hours spent outdoors per week, use of sunscreen, wearing protective clothing and seeking shade, was assessed in three trials³⁰⁻³². Educational workbooks,³⁰ educational workbooks and text messages³¹ and a mobile app program³² were compared with standard care. Patients who received behavioral interventions reported improved sun protection behavior scores³⁰⁻³² (3 studies, 414 participants, SMD 0.89, 95% CI -0.84-2.62, I² 98%) (Table 3; Figure 3). We are uncertain of the effects of behavioural interventions on sun protection behavior due to very low quality of evidence. A single trial assessed a standardised and validated educational workbook and found an improvement in the proportion of participants engaging in skin self-examination after one month (75 participants, RR 4.14, 95% CI 2.22-7.72).³³ One trial assessed a mobile app program and reported a reduction in daily hours spent outdoors among the intervention group (170 participants, MD -6.12, 95% CI -7.11 to -5.13).³²

Sun protection knowledge

The effectiveness of educational workbooks, text messages, mobile app programs and videos on sun protection knowledge was assessed in 6 studies^{24 28 30-33}, four of which provided data for a meta-analysis. There was an improvement in knowledge scores (4 studies, 489 participants, SMD 0.50, 95% CI 0.12-0.87, I² 76%) in the intervention group compared to standard care (Figure 4).³⁰⁻³³ One study compared an interactive visual representation of the educational program with standard information pamphlets and found that knowledge of sun protection improved among those who received the educational video.²⁸

Sun protection attitude

Three studies assessed sun protective attitude after receiving an educational workbook, text messages or a mobile app program over a period of 0.5 months to 1.5 months.³¹⁻³³ Compared to standard care, there was an overall improvement in scores of concern about developing cancer (3 studies, 348 participants, SMD 1.85, 95% CI 1.59-2.11, I² 96%).³¹⁻³³ Two studies involving 273 participants reported an improvement in scores of understanding the personal risk of skin cancer (SMD 0.61, 95% CI -0.60-1.82, I² 96%), adherence to sun protection (SMD 0.77 95% CI -0.14-1.68, I² 92%) and willingness or intention to change behavior (SMD 1.70, 95% CI -1.68-5.07, I² 99%).^{31 32} We are uncertain of the effects of behavioural interventions on sun protection attitude due to very low quality of evidence. A single study involving 75 participants also reported an improvement in scores of ability to recognize a potential skin cancer (MD 1.80, 95% CI 1.35-2.25), importance of skin self-examination (MD 1.05, 95% CI 0.61-1.49) and having a partner help for skin self-examination (MD 1.59, 95% CI 1.10-2.08).³³ Another single study reported an improvement in the importance of engaging in sun protection (measured using 5-point Likert scale) (101 participants, MD 7.00, 95% CI 2.94-11.06).³¹

Skin complications and biologic measures

Two trials of behavioral interventions in 271 kidney transplant recipients compared a mobile app or an educational workbook and text messages to standard care on reported skin complications and biologic measures of sun exposure.^{31 32} The intervention group experienced a reduced incidence of skin irritation (a culturally relevant term for sun exposure³⁴) (RR 1.00, 95% CI 0.89-1.13, I² 95%) or sunburn (RR 3.19, 95% CI 2.47-4.10, I² 99%). They also had a decreased melanin index (right forearm, SMD -0.42, 95% CI -0.66 to -0.18; cheek SMD -0.25, 95% CI -0.64 to -0.15) and reduced severity of sun damage (SMD -0.13, 95% CI -0.40 to 0.13) on sun exposed areas (measured using clinical images of chronic sun damage and scored 1-10).

3.6 Effect of pharmaceutical interventions on skin cancer prevention

The incidence and responses of pre-cancerous lesions were measured only in trials of pharmaceutical interventions (Table 4). These included the switch to mTOR inhibitors (n=1),³⁵ photodynamic therapy (n=2)^{36 37} and immune response modifiers (n=1)³⁸ to current treatment or placebo. The incidence of non-melanocytic skin cancers (NMSC) was assessed in nine pharmaceutical studies.^{1 35 38-44} None included melanoma as an outcome.

Topical/local interventions

One trial of 14 participants compared an immune response modifier, 5% imiquimod cream with placebo and found a reduction in the incidence of skin dysplasia (RR 2.14, 95% CI 0.31-14.65), skin atypia (RR 3.00, 95% CI 0.47-19.35), and viral warts (RR 7.00, 95% CI 0.46-106.10).³⁸

One Danish study of 26 kidney transplant recipients compared photodynamic therapy with no treatment and reported a relative reduction by approximately 40% in the incidence of NMSC on the treated area (RR 0.59, 95% CI 0.34-21.03, p 0.06).⁴⁴ A lower incidence of SCC was also reported in one trial comparing two areas of skin using an immune response modifier and placebo (14 participants, RR 0.09, 95% CI 0.001-1.70).³⁸ Two trials comparing photodynamic therapy to an immune response modifier or photodynamic therapy to placebo in recipients with diagnosed keratoses reported a complete response rate of 60% compared to 24% in the control group (50 participants, RR 5.03, 95% CI 0.14-176.17, I² 85%).^{36 37} We are uncertain of the effects of photodynamic therapy on incidence of precancerous lesions due to very low quality of evidence. Further, one trial which was not included in the meta-analysis, reported a higher cumulative

1
2 incidence of actinic keratosis lesions in untreated skin (63%) compared with skin treated by
3
4 photodynamic therapy (28%).²⁷
5
6
7
8

9 Systemic interventions

10
11
12
13

14 mTORis therapy reduced the incidence of NMSC compared to CNIs maintenance therapy (5 trials,
15
16 1082 participants, RR 0.46, 95% CI 0.28-0.75, I² 72%) (Figure 5).^{1 35 39 41 43} However evidence was
17
18 limited due to short follow-up periods, variability in dosing of mTORis and significant rates of loss
19
20 to follow up, and therefore we are uncertain of the effects of mTORis on skin cancer incidence due
21
22 to very low quality of evidence. A single trial involving 21 patients reported a reduction in the
23
24 overall incidence of SCC by 49% in the conversion arm, but reported a drop out rate of 77% and
25
26 follow-up time of less than 2 years.²⁵ Further, a single trial which compared mTORi conversion
27
28 from CNI based therapy reported a significant improvement in skin dysplasia (32 participants, RR
29
30 24.35, 95% CI 1.55-381.99).³⁵
31
32
33
34
35
36
37
38

39 Two trials comparing an oral retinoid, acitretin, with placebo or a drug free period reported an
40
41 increased lower risk of both SCCs and BCCs (46 participants, RR 0.40, 95% CI 0.19-0.85, p 0.02; RR
42
43 0.50, 95% CI 0.14-1.76)⁴² or development of a new skin cancer (19 participants, RR 0.22, 95% CI
44
45 0.06-0.90). However, there were no differences in the incidence of new SCCs.⁴⁰ One trial, which
46
47 was not included in the meta-analysis, showed approximately a 50% reduction in the incidence of
48
49 actinic keratosis which compared a high dose to a low dose of acitretin.²⁶
50
51
52
53
54

55 One Australian trial of 22 kidney transplant recipients compared nicotinamide with placebo and
56
57 reported an estimated relative rate difference of 0.35 (95% CI -0.62 to 0.74), 0.67 (95% CI -0.40 to
58
59 0.90) and 0.07 (95% CI -1.51 to 0.65) for NMSC, BCCs and SCCs respectively.²⁹
60

3.7 Subgroup analysis

Study size, trial duration, setting and risk of bias did not modify the effects of CNIs and mTORIs on skin cancer incidences (Figure S3). Sources of heterogeneity for other treatment effects could not be explored due to insufficient data.

4 DISCUSSION

Skin cancers (both non-melanoma and melanoma) are major causes of morbidity and mortality in solid organ transplant recipients. Despite this, trials of interventions aimed at preventing skin cancer in solid organ transplant recipients are few in number (20 trials), small with half comprising of 50 patients or less, of short duration (48% have <12 months follow up) and 52% do not include incidence of skin cancer as an outcome. Our review included 22 reports of 20 trials involving 2,295 transplant recipients, who were predominately kidney transplant recipients. The studies covered a broad range of interventions, including behavioral to improve sun protection behavior and pharmaceutical (immunosuppression, photodynamic therapy, oral retinoid, nicotinamide and topical immune response modifiers) to evaluate precancerous lesion response and cancer incidence. None of the behavioral intervention studies included precancerous lesions or skin cancer incidence as outcomes. Although interventions showed plausible improvements to sun protection behaviors, precancerous lesion responses and cancer incidence, there was considerable variability across interventions types, variability in outcomes assessed and outcome estimates. Overall, the current evidence for interventions for skin cancer prevention in solid organ transplant recipients is of very low quality and is insufficient to guide decision-making and clinical practice.

Although behavioral interventions appeared to improve sun protection attitude, knowledge and behavior, there were inconsistencies detected and none of these studies included skin cancer as

1
2 an outcome. Due to limited number of studies, we were unable to compare specific behavioral
3
4 interventions (e.g. mobile app vs. written education) to ascertain the most effective method of
5
6 delivering sun protection education. While there may be some modest benefits in the reduction in
7
8 cancer incidence (for NMSC) among solid organ transplant recipients who were converted to
9
10 mTORIs compared to those on CNI maintenance, there was substantial heterogeneity across the
11
12 studies that was unable to be explained by subgroup analyses. Heterogeneity may be attributed to
13
14 the absence of long term follow up, large discontinuation rates owing to adverse events and
15
16 variability in the doses of mTORIs. Pharmaceutical interventions (switch to mTOR inhibitors,
17
18 photodynamic therapy, immune response modifiers) showed a reduction in precancerous lesions
19
20 compared to standard care or a comparator group. However uncertainty exists in the treatment
21
22 effects and there were too few studies, interventions were incomparable, follow-up times were
23
24 variable and considerable loss to follow up for some studies to conclude that the benefits are
25
26 sustainable.
27
28
29
30
31
32
33
34
35

36 Previous systematic reviews have evaluated the impact of behavioral interventions on skin cancer
37
38 prevention in the general population,⁴⁵ and concluded that computer programs may increase sun
39
40 protective behaviors, and 'appearance-focused' interventions may decrease sun tanning and UV
41
42 exposure in adolescents and young women, respectively. Reviews conducted in other populations
43
44 at high-risk including outdoor workers,⁴⁶ family history, personal history and phenotypic factors⁴⁷
45
46 have found similar improvement in sun protective behaviors, including use of sunscreen, as well as
47
48 a decreased incidence of keratoses. A systematic review of the benefits and harms of oral
49
50 retinoids for the prevention of skin cancer among high risk transplant recipients led to inconclusive
51
52 results on the effect of acitretin due to the small number of included trials.⁴⁸
53
54
55
56
57
58
59
60

1
2 Despite the inclusion of all interventions aimed at the prevention of skin cancer in solid organ
3
4 transplant recipients and the comprehensive systematic search for eligible studies, there are some
5
6 potential limitations. Due to the heterogeneity of the studies, the high risk of bias, the potential
7
8 for reporting bias and imprecision in the point estimates of individual studies, there is a high
9
10 degree of uncertainty in the estimate of the effect of skin cancer prevention interventions. All
11
12 studies of behavioral interventions were undertaken in United States, with 4 by the same authors,
13
14 whilst most pharmacological intervention studies were conducted in Europe. There were also
15
16 large discontinuation rates owing to adverse events in trials of mTORIs. Further, given the small
17
18 number of studies included in the meta-analysis, we were unable to perform any detailed
19
20 subgroup analyses to explore heterogeneity or assess for publication bias. While we were unable
21
22 to show and assess publication bias using standard statistical tests, we would suggest the
23
24 observed heterogeneity may also be attributed to potential publication and reporting biases. It is
25
26 difficult to quantify the extent of such bias in this review, but one would expect research with
27
28 'positive' findings that indicate an intervention works, such as behavioral interventions improve
29
30 sun protection, are more likely to be published more than one, in high impact journals and more
31
32 likely to be cited. Finally, few trials included patient important outcomes associated with skin
33
34 cancer and none included melanoma or mortality.
35
36
37
38
39
40
41
42
43
44
45

46 The use of pharmaceutical and immunosuppression therapy remains complex. Not only has mTORI
47
48 therapy shown benefits in lowering the risk of skin cancer, early conversion to mTORI therapy
49
50 from CNIs has also shown promising effects in reducing cancer rates.^{49 50} On the contrary, overall
51
52 mortality is higher and discontinuation following adverse events is more common in patients who
53
54 receive mTORI therapy.^{49 50} Several RCTs showed a higher rate of patients reporting adverse
55
56 events or drug discontinuation with sirolimus,^{1 41 43} demonstrating concern of its clinical
57
58 usefulness.⁴⁹ Nicotinamide may also offer benefits to reducing skin cancer incidence by 20% and is
59
60

1
2 relatively safe with minimal side effects. The protective effect of nicotinamide on skin cancer
3
4 incidence in kidney transplant recipients is currently being explored in a phase 3 randomised
5
6 controlled trial.
7
8
9

10
11 Although behavioral change is a simple strategy, long-term adherence remains challenging.

12
13 While behavioral counseling has been shown to increase sun protective behaviors in non-
14
15 transplant populations,⁴⁵ there is no direct evidence to show that the behavioral change led to a
16
17 reduction in morbidity and mortality. Previous studies have suggested that transplant recipients
18
19 do not practice sun protective behaviors regularly,⁵¹⁻⁵³ were less likely to use sunscreen⁵⁴ and that
20
21 patients have to perceive skin cancer as being an important risk to be motivated to change
22
23 behavior.^{55 56} However, studies on risk perception of transplant recipients remain conflicting.

24
25 Given this complexity and the observed inconsistencies in the existing trials, process evaluations
26
27 including facilitators and barriers to behavioral change should be included in future trials. Such
28
29 evaluations could include the use of qualitative methodology to support the trial design, ascertain
30
31 the perspectives of participants on the intervention and evaluate the implementation.^{57 58}
32
33
34
35
36
37
38
39
40

41 We suggest that further strategies for skin cancer prevention in transplant recipients require a
42
43 multifaceted and individualized approach. Transplant recipients are likely to benefit from early
44
45 implementation of education, particularly before transplantation occurs and recipients may be
46
47 preoccupied with other health needs related to transplantation. Although recipients understand
48
49 the importance of ongoing education for the ability to self-manage their disease, they may
50
51 experience difficulty in concentrating and learning new knowledge, and are often unable to look
52
53 beyond their graft and the anxiety/fear of graft loss.⁵⁹⁻⁶¹ Interventions should be integrated into
54
55 routine appointments and tailored to meet the individual needs of patients. This would be best
56
57
58
59
60

1
2 achieved through a shared decision-making approach to identify the patient's preferences and
3
4 priorities and thereby enhance the likelihood of success of self-management and prevention.⁶²
5
6
7

8
9 Additional large-scale and high-quality RCTs are needed to demonstrate the effectiveness of
10
11 interventions used to prevent skin cancer in transplant recipients in terms of patient important
12
13 outcomes, in particular morbidity and mortality associated with skin cancer. Determining patient's
14
15 preferences for prevention and management of skin cancer are also warranted to ensure
16
17 interventions and outcomes for trials are relevant to patient needs and priorities and better
18
19 support patient-centered treatment decisions.⁶³ Evidence of the efficacy of sun protective
20
21 behavior interventions need to be strengthened, with use of measures that are homogenous,
22
23 reliable and validated.
24
25
26
27
28
29

30
31 Preventative measures including behavioral, switch to mTOR inhibitors and other pharmaceuticals
32
33 may improve skin cancer outcomes for solid organ transplant recipients. However, the overall
34
35 quality of evidence is of very low and insufficient to guide decision-making and clinical practice.
36
37 Future robust studies that are well powered, have long-term follow up, and use clinical and
38
39 patient important outcome measures in a consistent manner are required to therefore optimize
40
41 outcomes for solid organ transplant recipients.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. *N Engl J Med* 2012;367(4):329-39.
2. Harwood CA, Mesher D, McGregor JM, et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. *Am J Transplant* 2013;13(1):119-29. doi: 10.1111/j.1600-6143.2012.04292.x [published Online First: 2012/10/18]
3. Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. *Br J Dermatol* 2002;147(5):950-6. [published Online First: 2002/11/02]
4. Ulrich C, Kanitakis J, Stockfleth E, et al. Skin cancer in organ transplant recipients--where do we stand today? *Am J Transplant* 2008;8(11):2192-8. doi: 10.1111/j.1600-6143.2008.02386.x [published Online First: 2008/09/11]
5. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med* 2003;348(17):1681-91. doi: 10.1056/NEJMra022137 [published Online First: 2003/04/25]
6. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. *J Am Acad Dermatol* 2002;47(1):1-20. doi: <https://doi.org/10.1067/mjd.2002.125579>
7. Garrett GL, Blanc PD, Boscardin J, et al. Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. *JAMA Dermatol* 2017;153(3):296-303. doi: 10.1001/jamadermatol.2016.4920 [published Online First: 2017/01/18]
8. Green AC, Olsen CM. Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. *Acta Derm Venereol* 2015;95(8):923-27.
9. Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. *J Immunother Cancer* 2019;7(1):106.
10. Hassan NA, Abudayyeh A, Shah M, et al. The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature: American Society of Clinical Oncology, 2018.

- 1 11. Au EH, Chapman JR, Craig JC, et al. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and
2 after Kidney Transplant. *J Am Soc Nephrol* 2019;30(3):471-80.
- 3
4
5 12. Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ
6 transplant recipients: a multicenter collaborative study. *Arch Dermatol* 2003;139(3):301-6. [published
7
8
9 Online First: 2003/03/08]
- 10
11
12 13. ANZDATA Registry. 38th Report, Chapter 10: Cancer. Adelaide, Australia. : Australia and New Zealand
13
14 Dialysis and Transplant Registry, 2016.
- 15
16
17 14. Chapman JR, Webster AC, Wong G. Cancer in the Transplant Recipient. *Cold Spring Harb Perspect Med*
18
19 2013;3(7):a015677. doi: 10.1101/cshperspect.a015677
- 20
21
22 15. Garrett GL, Lowenstein SE, Singer JP, et al. Trends of skin cancer mortality after transplantation in the
23
24 United States: 1987 to 2013. *J Am Acad Dermatol* 2016;75(1):106-12. doi: 10.1016/j.jaad.2016.02.1155
25
26 [published Online First: 2016/04/14]
- 27
28
29 16. Ibrahim SF, Brown MD. Tanning and cutaneous malignancy. *Dermatologic Surgery* 2008;34(4):460-74.
30
31 doi: 10.1111/j.1524-4725.2007.34092.x [published Online First: 2008/02/06]
- 32
33
34 17. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant
35
36 recipients. *Clin Transplant* 2005;19(6):726-34. doi: 10.1111/j.1399-0012.2005.00412.x [published Online
37
38 First: 2005/11/30]
- 39
40
41 18. Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence?
42
43 *Clin J Am Soc Nephrol* 2008;3 Suppl 2:S87-S100. doi: 10.2215/CJN.03320807
- 44
45
46 19. Acuna SA, Huang JW, Scott AL, et al. Cancer Screening Recommendations for Solid Organ Transplant
47
48 Recipients: A Systematic Review of Clinical Practice Guidelines. *Am J Transplant* 2017;17(1):103-14. doi:
49
50 10.1111/ajt.13978 [published Online First: 2016/08/31]
- 51
52
53 20. Chadban SJ, Barraclough KA, Campbell SB, et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO
54
55 Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *Nephrology* 2012;17(3):204-14. doi:
56
57 10.1111/j.1440-1797.2011.01559.x
- 58
59
60

- 1 21. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-
2
3 Analyses: The PRISMA Statement. *PLOS Medicine* 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097
4
5 22. edited by Julian PTH, Sally G. Cochrane handbook for systematic reviews of interventions: Chichester,
6
7 West Sussex ; Hoboken NJ : John Wiley & Sons 2008.
8
9
10 23. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and
11
12 strength of recommendations. *BMJ* 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD [published
13
14 Online First: 2008/04/26]
15
16
17 24. Robinson JK, Friedewald JJ, Desai A, et al. Response across the health-literacy spectrum of kidney
18
19 transplant recipients to a sun-protection education program delivered on tablet computers: randomized
20
21 controlled trial. *JMIR Cancer* 2015;1(2):e8.
22
23
24 25. Carroll RP, Hester J, Wood KJ, et al. Conversion to sirolimus in kidney transplant recipients with
25
26 squamous cell cancer and changes in immune phenotype. *Nephrol Dial Transplant* 2013;28(2):462-65.
27
28
29 26. de Sevaux RG, Smit JV, de Jong EM, et al. Acitretin treatment of premalignant and malignant skin
30
31 disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of
32
33 acitretin. *J Am Acad Dermatol* 2003;49(3):407-12. [published Online First: 2003/09/10]
34
35
36
37 27. Togsverd-Bo K, Omland SH, Wulf HC, et al. Primary prevention of skin dysplasia in renal transplant
38
39 recipients with photodynamic therapy: a randomized controlled trial. *Am J Transplant* 2015;15(11):2986-
40
41
42 90. doi: <https://dx.doi.org/10.1111/ajt.13358>
43
44
45 28. Trinh N, Novice K, Lekakh O, et al. Use of a brief educational video administered by a portable video
46
47 device to improve skin cancer knowledge in the outpatient transplant population. *Dermatologic Surgery*
48
49 2014;40(11):1233-9. doi: <https://dx.doi.org/10.1097/DSS.000000000000148>
50
51
52 29. Chen AC, Martin AJ, Dalziell RA, et al. A phase II randomized controlled trial of nicotinamide for skin
53
54 cancer chemoprevention in renal transplant recipients. *Br J Dermatol* 2016;175(5):1073-75. doi:
55
56 10.1111/bjd.14662 [published Online First: 2016/10/30]
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30. Clowers-Webb HE, Christenson LJ, Phillips PK, et al. Educational outcomes regarding skin cancer in organ transplant recipients: Randomized intervention of intensive vs standard education. *Arch Dermatol* 2006;142(6):712-8. doi: 10.1001/archderm.142.6.712 [published Online First: 2006/06/21]
31. Robinson JK, Guevara Y, Gaber R, et al. Efficacy of a sun protection workbook for kidney transplant recipients: a randomized controlled trial of a culturally sensitive educational intervention. *Am J Transplant* 2014;14(12):2821-29.
32. Robinson JK, Friedewald JJ, Desai A, et al. A randomized controlled trial of a mobile medical app for kidney transplant recipients: effect on use of sun protection. *Transplant Direct* 2016;2(1):1.
33. Robinson JK, Turrisi R, Mallett KA, et al. Efficacy of an educational intervention with kidney transplant recipients to promote skin self-examination for squamous cell carcinoma detection. *Arch Dermatol* 2011;147(6):689-95. doi: <https://dx.doi.org/10.1001/archdermatol.2011.10>
34. Robinson JK, Joshi KM, Ortiz S, et al. Melanoma knowledge, perception, and awareness in ethnic minorities in Chicago: recommendations regarding education. *Psychooncology* 2011;20(3):313-20. doi: 10.1002/pon.1736 [published Online First: 2010/09/30]
35. Salgo R, Gossman J, fer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. *Am J Transplant* 2010;10(6):1385-93.
36. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. *Br J Dermatol* 2004;151(1):196-200.
37. Togsverd-Bo K, Halldin C, Sandberg C, et al. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients – a randomized intra-individual controlled trial. *Br J Dermatol* 2017 doi: 10.1111/bjd.15884

- 1 38. Brown VL, Atkins CL, Ghali L, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin
2
3 dysplasia in high-risk renal transplant recipients: Randomized, double-blind, placebo-controlled trial. *Arch*
4
5 *Dermatol* 2005;141(8):985-93.
6
7
8 39. Alberu J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted
9
10 to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
11
12 *Transplantation* 2011;92(3):303-10.
13
14
15 40. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic
16
17 skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled
18
19 study. *J Clin Oncol* 1995;13(8):1933-8. doi: 10.1200/jco.1995.13.8.1933 [published Online First:
20
21 1995/08/01]
22
23
24 41. Campbell S, Walker R, Tai S, et al. Randomized controlled trial of sirolimus for renal transplant
25
26 recipients at high risk for nonmelanoma skin cancer. *Am J Transplant* 2012;12(5):1146-56.
27
28
29 42. George R, Weightman W, Russ GR, et al. Acitretin for chemoprevention of non-melanoma skin cancers
30
31 in renal transplant recipients. *Austral J Dermatol* 2002;43(4):269-73.
32
33
34 43. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al. Two-year randomized controlled
35
36 prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive
37
38 squamous cell carcinomas to sirolimus. *J Clin Oncol* 2013;31(10):1317-23.
39
40
41 44. Wulf HC, Pavel S, Stender I, et al. Topical photodynamic therapy for prevention of new skin lesions in
42
43 renal transplant recipients. *Acta Derm Venereol* 2006;86(1):25-28.
44
45
46 45. Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the
47
48 U.S. Preventive Services Task Force. *Ann Intern Med* 2011;154(3):190-201. doi: 10.7326/0003-4819-154-3-
49
50 201102010-00009 [published Online First: 2011/02/02]
51
52
53 46. Horsham C, Auster J, Sendall MC, et al. Interventions to decrease skin cancer risk in outdoor workers:
54
55 update to a 2007 systematic review. *BMC Res Notes* 2014;7:10. doi: 10.1186/1756-0500-7-10 [published
56
57 Online First: 2014/01/09]
58
59
60

- 1
2
3 47. Wu YP, Aspinwall LG, Conn BM, et al. A systematic review of interventions to improve adherence to
4 melanoma preventive behaviors for individuals at elevated risk. *Prev Med* 2016;88:153-67. doi:
5 10.1016/j.ypmed.2016.04.010 [published Online First: 2016/04/20]
6
7
8 48. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant
9 recipients: a systematic review of randomized controlled trials. *Br J Dermatol* 2005;152(3):518-23. doi:
10 10.1111/j.1365-2133.2005.06347.x [published Online First: 2005/03/25]
11
12
13 49. Howard MD, Su JC, Chong AH. Skin cancer following solid organ transplantation: a review of risk factors
14 and models of care. *Am J Clin Dermatol* 2018;19(4):585-97.
15
16
17 50. Lim W, Eris J, Kanellis J, et al. A systematic review of conversion from calcineurin inhibitor to
18 mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant
19 recipients. *Am J Transplant* 2014;14(9):2106-19.
20
21
22 51. Iannacone MR, Pandeya N, Isbel N, et al. Sun Protection Behavior in Organ Transplant Recipients in
23 Queensland, Australia. *Dermatology* 2015;231(4):360-6. doi: 10.1159/000439428 [published Online First:
24 2015/09/30]
25
26
27 52. Imko-Walczuk B, Graczyk M, Korban M, et al. Impact of Skin Cancer Awareness on Prophylactic
28 Behavior Among Renal Transplant Recipients. *Transplant Proc* 2016;48(5):1526-31. doi:
29 10.1016/j.transproceed.2015.11.040 [published Online First: 2016/08/09]
30
31
32 53. Thomas BR, Barnabas A, Agarwal K, et al. Patient perception of skin-cancer prevention and risk after
33 liver transplantation. *Clin Exp Dermatol* 2013;38(8):851-6. doi: 10.1111/ced.12159 [published Online First:
34 2013/06/21]
35
36
37 54. Robinson JK, Rigel DS. Sun protection attitudes and behaviors of solid-organ transplant recipients.
38 *Dermatologic Surgery* 2004;30(4 Pt 2):610-5. doi: 10.1111/j.1524-4725.2004.30145.x [published Online
39 First: 2004/04/06]
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 55. Robinson JK, Friedewald J, Gordon EJ. Perceptions of Risk of Developing Skin Cancer for Diverse
2
3 Audiences: Enhancing Relevance of Sun Protection to Reduce the Risk. *J Cancer Educ* 2016;31(1):153-7. doi:
4
5 10.1007/s13187-015-0885-1 [published Online First: 2015/07/26]
6
7 56. Skiveren J, Mortensen EL, Haedersdal M. Sun protective behaviour in renal transplant recipients. A
8
9 qualitative study based on individual interviews and the Health Belief Model. *J Dermatolog Treat*
10
11 2010;21(6):331-6. doi: 10.3109/09546630903410166 [published Online First: 2010/06/10]
12
13
14 57. Lewin S, Glenton C, Oxman AD. Use of qualitative methods alongside randomised controlled trials of
15
16 complex healthcare interventions: methodological study. *BMJ* 2009;339:b3496. doi: 10.1136/bmj.b3496
17
18 [published Online First: 2009/09/12]
19
20
21 58. Oakley A, Strange V, Bonell C, et al. Process evaluation in randomised controlled trials of complex
22
23 interventions. *BMJ* 2006;332(7538):413-6. doi: 10.1136/bmj.332.7538.413 [published Online First:
24
25 2006/02/18]
26
27
28 59. Buldukoglu K, Kulakac O, Kececioglu N, et al. Recipients' perceptions of their transplanted kidneys.
29
30 *Transplantation* 2005;80(4):471-6. [published Online First: 2005/08/27]
31
32
33 60. Jamieson NJ, Hanson CS, Josephson MA, et al. Motivations, Challenges, and Attitudes to Self-
34
35 management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. *Am J Kidney Dis*
36
37 2016;67(3):461-78. doi: 10.1053/j.ajkd.2015.07.030 [published Online First: 2015/09/16]
38
39
40 61. Urstad KH, Wahl AK, Andersen MH, et al. Renal recipients' educational experiences in the early post-
41
42 operative phase--a qualitative study. *Scand J Caring Sci* 2012;26(4):635-42. doi: 10.1111/j.1471-
43
44 6712.2012.00972.x [published Online First: 2012/03/16]
45
46
47 62. Gordon EJ, Butt Z, Jensen SE, et al. Opportunities for shared decision making in kidney transplantation.
48
49 *Am J Transplant* 2013;13(5):1149-58. doi: 10.1111/ajt.12195 [published Online First: 2013/03/16]
50
51
52 63. O'Hare AM, Rodriguez RA, Bowling CB. Caring for patients with kidney disease: shifting the paradigm
53
54 from evidence-based medicine to patient-centered care. *Nephrol Dial Transplant* 2016;31(3):368-75. doi:
55
56 10.1093/ndt/gfv003 [published Online First: 2015/02/01]
57
58
59
60

1 64. Dantal J, Morelon E, Rostaing L, et al. Sirolimus for Secondary Prevention of Skin Cancer in Kidney
2
3 Transplant Recipients: 5-Year Results. *Journal of Clinical Oncology* 2018;36(25):2612-20. doi:
4
5 10.1200/jco.2017.76.6691
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of included studies (n=20)

Characteristics	N (%)
Type of transplant	
Kidney	16 (80)
Multiple*	4 (20)
Sex	
≥ 50% Male	18 (90)
< 50% Male	1 (5)
Not specified	1 (5)
Age (mean)	
< 60	10 (50)
≥ 60	5 (25)
Not specified	5 (25)
Sample size	
10 – 50	11 (55)
50 – 100	3 (15)
100 – 200	4 (20)
>200	2 (10)
Setting	
Single center	8 (40)
Multi center	11 (55)
Not specified	1 (5)
Country of origin	
Australia	3 (15)
Denmark	4 (20)
France	1 (5)
Germany	1 (5)
Netherlands	2 (10)
New Zealand	2 (10)
Switzerland	1 (5)
Sweden	1 (5)
United Kingdom	3 (15)
United States	6 (30)
Other†	1 (5)
Intervention Type	
Behavioral	5 (25)
Switch to mTOR inhibitors	6 (30)
Photodynamic therapy	4 (20)
Oral retinoid	3 (15)
Nictotinamide	1 (5)
Topical immune response modifier	1 (5)
Duration of follow up	
<12 months	9 (45)
12 months	4 (20)
24 months	5 (25)
>24 months	1 (5)
Not specified	1 (5)
Year of publication	
1995 – 1999	1 (5)
2000 – 2004	3 (15)
2005 – 2009	4 (20)
2010 – 2014	8 (40)
2015 – 2017	4 (20)

* Kidney, liver and lung (n=2); kidney and heart (n=1); Kidney and multiple other types (n=1) – see text

† 111 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, United States), South Africa, and South America (Argentina, Brazil, Chile)

Table 2. Characteristics of individual studies

Study	N	Type of transplant	Setting	Type of intervention	Measures	Intervention	Comparator	Primary outcomes	Time (mths)
Behavioral interventions (n=6)									
4 Clowers- 5 Webb 6 2006 ³⁰	202	Kidney, liver, heart, pancreas, lung, heart/lung, other [§]	Single centre, United States	Behavioral	Self-reported questionnaire	Repetitive written material	Standard care	Knowledge & behavior	10
8 Robinson 9 2011 ³³	75	Kidney	United States	Behavioral	Self-reported questionnaire	Workbook	Standard care	Knowledge & behavior	1
10 Robinson 11 2014 ³¹	101	Kidney	Single centre, United States	Behavioral	Self-reported questionnaire	Workbook Text messages	Standard care	Knowledge & behavior	1.5
14 Robinson 15 2015 ^{24†}	170	Kidney	Multi-centre, United States	Behavioral	Self-reported questionnaire	Mobile app program	Standard care	Knowledge & behavior	0.5
17 Robinson 18 2016 ³²	170	Kidney	Multi-centre, United States	Behavioral	Self-reported questionnaire	Mobile app program	Standard care	Knowledge & behavior	1.5
21 Trinh 22 2014 ^{28*}	100	Kidney, liver, lung	Single centre, United States	Behavioral	Self-reported questionnaire	Video	Pamphlet	Knowledge	1 day
Switch to mTOR inhibitors (n=7)									
25 Alberu 26 2011 ³⁹	830	Kidney	Multi centre [§]	Switch to mTOR inhibitors	Investigator reported adverse events	Conversion to sirolimus	CNI	Cancer incidence	24
29 Campbell 30 2012 ⁴¹	86	Kidney	Multi centre, Australia, New Zealand, United States	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	CNI	Cancer incidence	12
34 Carroll 35 2013 ^{25*}	32	Kidney	Multi centre, UK	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to prednisolone & sirolimus	CNI/AZA	Cancer incidence	24
37 Euvrard 38 2012 ¹⁶⁴	120	Kidney	Multi centre, France	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	CNI	Cancer incidence	24
40 Hoogendijk- 41 van den 42 Akker	155	Kidney	Multi centre, Netherlands, UK	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	AZA/MMF/ CNI	Cancer incidence	24

2013⁴³

1 Salgo 2 2010 ³⁵ 3 4	44	Kidney	Single centre, Germany	Switch to mTOR inhibitors	Physical examination +/- biopsy Clinical photographs	Conversion to sirolimus and prednisone	AZA/MMF/ CNI	Precancerous skin dysplasia incidence	12
5 Pharmaceutical interventions – Photodynamic therapy (n=4); oral retinoids (n=3); nicotinamide (n=1); 5% imiquimod cream (n=1)									
6 Bavinck 7 1995 ⁴⁰ 8 9 10 11	44	Kidney	Multi centre, Netherlands	Oral retinoid	Physical examination +/- biopsy	Acitretin	Placebo	Cancer incidence precancerous lesion reduction	6
12 Brown 13 2005 ³⁸ 14 15 16 17	21	Kidney	Multi centre, UK	Topical immune response modifier cream	Physical examination +/- biopsy Clinical mapping and photographs	5% Imiquimod cream	Placebo	Reduction of precancerous lesions	4
18 Chen 19 2016 ^{29*} 20 21	22	Kidney	Single centre, Australia	Nicotinamide	Physical examination	Nicotinamide	Placebo	Cancer incidence	6
22 de Sevaux 23 2003 ^{26*} 24 25	26	Kidney	Single centre, Netherlands	Oral retinoid	Physical examination +/- biopsy	High dose acitretin	Low dose acitretin	Cancer and precancerous incidence	12
26 Dragieva 27 2004 ³⁶ 28 29	17	Kidney, heart	Single centre, Switzerland	Photodynamic therapy	Physical examination +/- biopsy Clinical photographs	Methyl aminolevulinate cream	Placebo	Precancerous lesion response	4
30 George 31 2002 ⁴² 32 33	23	Kidney	Multi centre, Australia	Oral retinoid	Physical examination Annual radiological evaluation	Acitretin	Drug free period	Cancer incidence	24
34 Togsverd- 35 Bo 2015 ^{27*†} 36 37	25	Kidney	Single centre, Denmark	Photodynamic therapy	Physical examination Clinical photographs	Methyl aminolevulinate cream	No treatment contralateral area	Actinic keratosis incidence	36
38 Togsverd- 39 Bo 2017 ^{37†} 40 41	35	Kidney, lung, liver	Multi-centre, Denmark and Sweden	Photodynamic therapy	Physical examination Questionnaire/Diary	Methyl aminolevulinate cream	5% imiquimoid cream	Actinic keratosis lesion response	6

32

Wulf 2006 ^{44†}	27	Kidney	Multi centre, Denmark and Netherlands	Photodynamic therapy	Clinical mapping and photographs	Methyl aminolevulinate cream	No treatment contralateral area	Cancer incidence	12
-----------------------------	----	--------	---	-------------------------	-------------------------------------	------------------------------------	---------------------------------------	---------------------	----

*Excluded from analyses – no meaningful data to extract

†Randomized controlled areas of skin on individuals

‡Excluded from analyses – same participants as Robinson 2016

§11 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, United States), South Africa, and South America (Argentina, Brazil, Chile)

Abbreviations: CNI, Calcineurin inhibitor; AZA, Azathioprine; MMF, Mycophenolate mofetil

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

Table 3. Effect of behavioral interventions on sun protection outcomes

Outcome	Studies	Participants	Weighted MD ^a /SMD ^b [95% CI]	Relative risk	P	I ²	Intervention	Comparator
BEHAVIORAL INTERVENTION (n=5)								
SUN PROTECTION BEHAVIOR								
General sun protection behavior	3	414	0.89 [-0.84, 2.62]		0.31	98%	Workbook, text messages, mobile app program	Standard care
Skin self-examination								
1 month after visit	1	75		4.14 [2.22, 7.72]	<0.001	90%	Workbook	Standard care
If checked, concerned	1	42		6.43 [0.42, 98.58]	0.18	99%		
If concerned, saw dermatologist	1	12		Not estimable ^c		99%		
Decrease daily hours outdoors	1	170	-6.12 [-7.11, -5.13] ^d		<0.001	99%	Mobile app program	Standard care
SUN PROTECTION KNOWLEDGE								
	4	489	0.50 [0.12, 0.87]		0.01	76%	Workbook, text messages, mobile app program	Standard care
SUN PROTECTION ATTITUDE								
Concern about developing skin cancer	3	348	1.88 [0.96, 2.80]		<0.001	92%	Workbook, text messages, mobile app program	Standard care
Recognise personal risk	2	273	0.61 [-0.60, 1.82]		0.32	96%	Workbook and text messages, mobile app program	Standard care
Confidence in ability to perform sun protection	2	273	0.77 [-0.14, 1.68]		0.10	92%		
Willingness/intention to change behavior	2	273	1.70 [-1.68, 5.07]		0.32	99%		
Knowledge of significance of skin cancer, relevance of sun protection, risk of having a tan	1	101	7.00 [2.94, 11.06]		0.001	99%	Workbook and text messages	Standard care
Confidence in ability to recognise a skin cancer	1	75	1.80 [1.35, 2.25]		<0.001	99%	Workbook	Standard care
Importance of skin self-examination	1	75	1.05 [0.61, 1.49]		<0.001	99%		
Importance of partner help for skin self-examination	1	75	1.59 [1.10, 2.08]		<0.001	99%		

COMPLICATIONS

1	Skin irritation								
2	None	2	271	1.00 [0.89, 1.13]	0.95	95%	Workbook and text messages, mobile app program	Standard care	
3	> 1	2	271	0.77 [0.43, 1.36]	0.36	89%			
4	Sunburn (past week)								
5	None	2	271	3.19 [2.47, 4.10]	<0.001	99%			
6	> 1	2	271	2.68 [1.81, 3.96]	<0.001	95%			

BIOLOGIC MEASURES

10	Melanin index - RU arm (sun protected)	2	271	0.12 [-0.12, 0.35]	0.34	0%	Workbook and text messages, mobile app program	Standard care
11	Melanin index - R forearm (sun exposed)	2	271	-0.42 [-0.66, -0.18] ^d	0.001	0%		
12	Cheek (sun exposed)	2	271	-0.25 [-0.64, 0.15] ^d	0.22	61%		
13	Sun damage assessment - R forearm	2	271	-0.13 [-0.40, 0.13] ^d	0.33	16%		

^aMean difference

^bStandardised mean difference

^cUnable to estimate due to absence of comparator group

^dReduction of outcome of interest represents an improvement

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

For peer review only

Table 4. Effect of pharmaceutical interventions on skin cancer prevention

Outcome	Studies	Participants	Relative risk	P	I ²	Intervention	Comparator
SWITH TO mTOR INHIBITORS (n=5)							
<u>PRE-CANCEROUS LESIONS</u>							
Skin dysplasia							
Any improvement	1	32	24.35 [1.55, 381.99]	0.02	0	Sirolimus	CNI ^b
Unchanged	1	32	0.85 [0.28, 2.61]	0.78	0		
Any worsening	1	32	0.04 [0.00, 0.66]	0.02	0		
<u>CANCEROUS LESIONS</u>							
SCC ^d /BCC ^e incidence	5	1082	0.46 [0.28, 0.75]	0.002	72%	Sirolimus	CNI
≥1 SCC	1	53	0.64 (0.35, 1.17)	0.15	N/A		
Skin cancer (excluding SCC)	1	53	0.74 (0.49, 1.14)	0.17	N/A		
Skin cancer (including SCC)	1	53	0.85 (0.61, 1.17)	0.32	N/A		
Skin cancer with BCC	1	53	0.89 (0.45, 1.78)	0.75	N/A		
PHOTODYNAMIC THERAPY (n=3)							
<u>PRE-CANCEROUS LESIONS</u>							
Actinic keratosis reduction (1-2 sessions)							
Complete response	2	50 ^a	5.03 [0.14, 176.17]	0.37	85%	MAL ^c	Placebo, Imiquimod 5% cream
Partial response	1	17 ^a	7.00 [0.39, 125.99]	0.19	N/A	MAL	Placebo
No reduction	1	17 ^a	0.09 [0.02, 0.40]	0.002	N/A		
<u>CANCEROUS LESIONS</u>	1	26 ^a	0.59 [0.34, 1.03]	0.06	N/A	MAL	No treatment
IMMUNE RESPONSE MODIFIERS (n=1)							
<u>PRE-CANCEROUS LESIONS</u>							
Reduced skin atypia							
	1	14 ^a	3.00 [0.47, 19.35]	0.25	N/A	Imiquimod 5% cream	Placebo
Reduced dysplasia	1	14 ^a	2.14 [0.31, 14.65]	0.44	N/A		
Reduced keratoses	1	14 ^a	2.14 [0.31, 14.65]	0.44	N/A		
Reduced no. viral warts	1	14 ^a	7.00 [0.46, 106.10]	0.16	N/A		

CANCEROUS LESIONS

SCC incidence

1	Treated (cream vs. placebo)	1	14 ^a	0.09 [0.01, 1.70]	0.11	N/A	Imiquimod 5% cream	Placebo
2								
3								
4	Untreated (control site)	1	14 ^a	0.43 [0.08, 2.37]	0.33	N/A		
5								

ORAL RETINOIDS (n=2)

CANCEROUS LESIONS

Decreased incidence:

10	> 1 SCC	1	46 ^a	0.40 [0.19, 0.85]	0.02	N/A	Acitretin	Drug free period
11								
12	> 1 BCC	1	46 ^a	0.50 [0.14, 1.76]	0.28	N/A		
13								
14	New skin cancer	1	19 ^a	0.22 [0.06, 0.90]	0.03	N/A	Acitretin	Placebo
15								

^aControl is the contralateral or similar area of skin on the same participant

^bCalcineurin inhibitor

^cMethyl aminolaevulinate cream

^dSquamous cell carcinoma

^eBasal cell carcinoma

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

For peer review only

1
2
3 **Figure legends**
4

5
6 Figure 1. Study selection
7

8 Figure 2. Risk of bias of included studies
9


10 Figure 3. Behavioral interventions – Sun protection behavior (general)
11

12 Figure 4. Behavioral interventions – Sun protection knowledge
13

14 Figure 5. Switch to mTOR inhibitors – Non melanoma skin cancer incidence
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


Figure 1. PRISMA Flowchart



209x297mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Risk of bias in included studies




297x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




209x279mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



209x279mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



209x279mm (300 x 300 DPI)

Figure S1. Search Strategy

1. exp Neoplasms, Basal Cell/
2. basal cell carcinoma.ti,ab.
3. exp Neoplasms, Squamous Cell/
4. squamous cell carcinoma.ti,ab.
5. nonmelanom*.ti,ab.
6. non melanom*.ti,ab.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Melanoma/
9. melanoma*.ti,ab.
10. Skin Neoplasms/
11. skin cancer*.ti,ab.
12. 8 or 9 or 10 or 11
13. 7 or 12
14. exp Organ Transplantation/
15. solid organ transplant*.mp.
16. transplant recipient*.tw.
17. exp Immunosuppression/
18. Immunocompromised Host/
19. 14 or 15 or 16 or 17 or 18
20. 13 and 19
21. randomized controlled trial.pt.
22. controlled clinical trial.pt.
23. randomized.ab.
24. placebo.ab.
25. Clinical Trials as Topic/
26. randomly.ab.
27. (crossover or cross-over).tw.
28. trial.ti.
29. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. Animals/ not (animals/ and Humans/)

1 31. 29 not 30

2
3 32. 20 and 31
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure S2. Risk of bias and key findings in individual studies

Study, year	Random sequence generation	Allocation concealment	Blinding participants & personnel	Blinding outcome assessors	Incomplete outcome data	Selective reporting	Intervention & comparator	Outcome RR/MD/SMD (95% CI)	
Behavioral Interventions (n=6)									
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Clowers-Webb 2006 ³⁰	Unclear	Unclear	High	Unclear	High	Low	Repetitive written material vs. standard care	General behavior SMD -0.30 (-0.63, 0.03) Knowledge SMD 0.07 (-0.26, 0.40)
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44	Robinson 2011 ³³	Unclear	Unclear	Unclear	Unclear	Low	Low	Workbook vs. standard care	Skin self examination (1 month) RR 4.14 (2.22, 7.72) Knowledge SMD 1.05 (0.57, 1.54) Concern about developing cancer SMD 0.95 (0.47, 1.43) Confidence to recognize cancer MD 1.80 (1.35, 2.25) Importance of skin self-examination MD 1.05 (0.61, 1.49) Importance of partner to help for skin self-examination MD 1.59 (1.10, 2.08)
45 46	Robinson 2014 ³¹	Low	Low	High	Low	Low	Low	Workbook & text messages vs. standard care	General behavior SMD 0.32 (-0.07, 0.71) Knowledge SMD 0.65 (0.25, 1.05) Concern about developing cancer SMD 2.73 (2.19, 3.27) Recognize personal risk SMD -0.01 (0.40, 0.38) Confidence in sun protection SMD 0.30 (-0.09, 0.68) Willingness/intention to change behaviour SMD -0.02 (-0.41, 0.36) Importance of skin cancer/sun protection/having a tan MD 7.00 (2.94, 11.06) Skin irritation none RR 1.37 (1.16, 1.63) Skin irritation >1 RR 0.15 (0.03, 0.61) Sunburn none RR 1.30 (1.12, 1.52) Sunburn >1 RR 0.17 (0.04, 0.72) Melanin index - RU arm (sun protected) SMD 0.23

(-0.17, 0.62)

Melanin index - R forearm (sun exposed) SMD -

0.37 (-0.76, 0.02)

Cheek (sun exposed) SMD -0.03 (-0.42, 0.36)

Sun damage assessment - R forearm SMD -0.30 (-

0.69, 0.09)

General behavior SMD 2.67 (2.26, 3.09)

Daily hours outdoors MD -6.12 (-7.11, -5.13)

Knowledge SMD 0.33 (0.03, 0.64)

Concern about developing cancer SMD 1.97 (1.61,

2.34)

Recognize personal risk SMD 1.22 (0.90, 1.55)

Confidence in sun protection SMD 1.23 (0.09, 1.56)

Willingness/intention to change behaviour SMD

3.42 (2.94, 3.89)

Skin irritation none RR 0.82 (0.69, 0.96)

Skin irritation >1 RR 1.64 (0.79, 3.40)

Sunburn none RR 40.44 (10.27, 159.27)

Sunburn >1 RR 4.83 (2.95, 7.90)

Melanin index - RU arm (sun protected) SMD 0.05

(-0.2, 0.35)

Melanin index - R forearm (sun exposed) SMD -

0.46 (-0.76, -0.15)

Cheek (sun exposed) SMD -0.43 (-0.73, -0.12)

Sun damage assessment - R forearm SMD -0.02 (-

0.33, 0.28)

Video vs. pamphlet

Cancer incidence RR 0.27 (0.14, 0.54)

Cancer incidence RR 0.70 (0.51, 0.95)

Cancer incidence RR 0.63 (0.50, 0.81)

Protected by copyright: http://bmjopen.bmj.com/

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Robinson 2016 ³²	Unclear	Low	High	Low	Low	Low	Mobile app program vs. standard care
Trinh 2014 ^{28*}	Low	Unclear	Unclear	Unclear	Low	Low	Video vs. pamphlet
Switch to mTOR inhibitors (n=6)							
Alberu 2011 ³⁹	Low	Unclear	High	High	Low	Low	Sirolimus vs. CNI
Campbell 2009 ⁴¹	Low	Low	High	Low	Low	Low	Sirolimus vs. CNI
Carroll 2013 ^{25*}	Unclear	Unclear	High	Low	Low	Low	Sirolimus vs. CNI/AZA
Euvrard 2012 ¹	Unclear	Unclear	High	Unclear	Low	Low	Sirolimus vs. CNI

1 2 3 4	Hoogendijk- van den Akker 2013 ⁴³	Unclear	Low	High	Low	High	Low	Sirolimus vs CNI/MMF/AZA	Cancer incidence RR 0.13 (0.02, 0.99)
5 6 7 8 9 10	Salgo 2010 ³⁵	Unclear	Unclear	High	Low	High	Low	Sirolimus vs CNI/MMF/AZA	Cancer incidence RR 0.13 (0.02, 0.95) Skin dysplasia Any improvement RR 24.35 (1.55, 381.99) Unchanged RR 0.85 (0.28, 2.61) Any worsening RR 0.04 (0.00, 0.66)
11	Pharmaceutical interventions – Photodynamic therapy (n=4); oral retinoids (n=3); 5% imiquimod cream (n=1)								
12 13 14	Bavinck 1995 ⁴⁰	Unclear	Unclear	Low	Unclear	Low	Low	Acitretin vs. placebo	Cancer incidence RR 0.22 (0.06, 0.90)
15 16 17 18 19 20 21 22 23	Brown 2005 ³⁸	Unclear	Unclear	Low	Low	Low	Low	5% Imiquimod cream vs. placebo	Cancer incidence SCC treated RR 0.09 (0.01, 1.70) SCC untreated RR 0.43 (0.08, 2.37) Reduced skin atypia RR 3.00 (0.47, 19.35) Reduced dysplasia RR 2.14 (0.31, 14.65) Reduced keratosis RR 2.14 (0.31, 14.65) Reduced no. viral warts RR 07.00 (0.46, 106.10)
24 25	Chen 2016 ²⁹	Low	Unclear	Low	Low	Low	Low	Nicotinamide vs. placebo	
26 27 28 29	de Sevaux 2003 ²⁶	Unclear	Low	High	Unclear	Low	Low	High dose acitretin vs. low dose acitretin	
30 31 32 33 34	Dragieva 2004 ³⁶	Unclear	Unclear	Low	Unclear	Low	Low	Methyl aminolevulinate cream vs. placebo	Actinic keratosis reduction Complete response RR 27.00 (1.73, 420.67) Partial reduction RR 7.00 (0.39, 125.99) No reduction RR 0.09 (0.02, 0.40)
35 36 37 38	George 2002 ⁴²	Unclear	Unclear	High	Unclear	Low	Low	Acitretin vs. drug free period	Cancer incidence >1 SCC RR 0.40 (0.19, 0.85) >1 SCC RR 0.50 (0.14, 1.76)
39 40 41 42 43 44	Togsverd-Bo 2015 ^{27*}	Low	Low	Unclear	Low	Low	Low	Methyl aminolevulinate cream vs. no treatment	

1	Togsverd-Bo 2017 ^{37†}	Low	Low	High	Unclear	Low	Low	Methyl aminolevulinate cream vs. 5% Imiquimod cream	Actinic keratosis reduction Complete response RR 1.42 (0.81, 2.48)
2									
3									
4									
5	Wulf 2006 ^{44†}	Low	High	High	Low	Low	Low	Methyl aminolevulinate cream vs. no treatment	Cancer incidence RR 0.59 (0.34, 1.03)
6									
7									
8									
9									

10 *Excluded from analyses – no meaningful data to extract

11 †Randomized controlled areas of skin on individuals

12 ‡Excluded from analyses – same participants as Robinson 2016

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Quality of assessment (Decrease in quality score)						
Number of studies	Risk of bias/Quality of evidence	Inconsistency	Indirectness	Imprecision	Publication bias	Quality
Sun protection behavior						
35 RCTs ^{24 30-33}	Serious study limitations (-1) Randomisation unclear ^{24 30 32 33} Participants not blinded or well described ^{24 30-33} Concealment of allocation not described. ^{30 33}	Important inconsistency (-1) Analysed in subgroups. heterogeneity (I ² =99%) ³⁰⁻³²	Indirectness (-1) Diverse interventions (written vs. electronic), varying duration (2 weeks to 10 months) Same sample of participants ^{24 32}	Serious imprecision (-1) Small sample size, CIs crosses the null	Uncertain Unable to determine. Small number of studies, large heterogeneity	Very low
Sun protection knowledge						
6 RCTs ^{24 28 30-33}	Serious limitations (-1) Randomisation unclear ^{24 30 32 33} Participants not blinded or well described ^{24 28 30-33} Concealment of allocation not described ^{28 33}	Important inconsistency (-1) Heterogeneity (I ² 85%)	Indirectness (-1) Diverse interventions (written vs. electronic), varying duration (1 day to 10 months) Same sample ^{24 32}	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity	Very low
Sun protection attitude						
4 RCTs ^{24 31-33}	Serious limitations (-1) Randomisation unclear ^{24 32 33} Participants not blinded or well described ^{24 31-33} Concealment of allocation	Important inconsistency (-1) Wide variation in the effect estimates, heterogeneity (I ² 97%).	Indirectness (-1) Diverse interventions (written vs. electronic), Similar duration. Same sample ^{24 32}	Serious imprecision (-1) Small sample size, small number of events	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low

6/bmjopen-
 7 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

not described^{32 33}**Complications (skin irritation, sunburn)**

2 RCTs ^{31 32}	Serious limitations (-1) Participants not blinded ^{31 32}	Important inconsistency (-1) Heterogeneity ($I^2=95-99\%$) Analysed in subgroups. Similar effect estimates.	Indirectness (-1) Diverse interventions (written vs. electronic), similar duration.	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low
-------------------------	--	---	---	--	---	-----------------

Biologic measures (melanin index, sun damage)

2 RCTs ^{31 32}	Serious limitations (-1) Randomisation unclear ³² Participants not blinded ^{31 32}	Important inconsistency (-1) Analysed in subgroups. Heterogeneity ($I^2 60\%$)	Indirectness (-1) Different interventions (written vs. electronic), similar duration.	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low
-------------------------	---	---	---	--	---	-----------------

Pre-cancerous incidence

4 RCTs ^{27 35-38}	Serious limitations (-1) Randomisation or allocation unclear ^{35 36 38} Participants not blinded or well described ^{27 35-38}	Important inconsistency (-1) Analysed in subgroups.	Indirectness (-1) Diverse interventions, varying duration	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Large heterogeneity.	Very low
----------------------------	--	---	---	--	--	-----------------


Cancer incidence

10 RCTs ^{1 29 35 38-44}	Serious limitations (-1) Randomisation unclear ^{1 40 42 43} Allocation concealment not used or unclear ^{1 29 39 40 42 44} Participants not blinded. ^{1 35 39 41-44}	Important inconsistency (-1) Majority of participants came from 1 study ³⁹ Small sample ^{1 29 35 38 40-44}	Indirectness (-1) Diverse interventions (immunosuppression, photodynamic therapy, immune response modifier, retinoid, nicotinamide), varying duration	Serious imprecision (-1) Majority of participants from one trial (n=551), small number of events	Uncertain Unable to determine. Large heterogeneity.	Very low
----------------------------------	--	---	---	--	--	-----------------

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Figure S3. Subgroup analyses of immunosuppression conversion interventions on skin cancer incidence





PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICCO, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-14
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-14
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16-17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	2

1136/bmjopen-2019-029265 on May 20, 2020. Downloaded from http://bmjopen.bmj.com/ on April 27, 2024 by guest. Protected by copyright.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Behavioral and pharmaceutical interventions for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029265.R3
Article Type:	Original research
Date Submitted by the Author:	20-Mar-2020
Complete List of Authors:	James, Laura; University of Sydney, Saglimbene, Valeria; The University of Sydney, Sydney School of Public Health Wong, Germaine; The Children's Hospital at Westmead, Centre for Kidney Research Tong, Allison; The University of Sydney, Sydney School of Public Health Luu, Laurence; The University of Sydney, Sydney School of Public Health Craig, Jonathan; Flinders University Faculty of Medicine Nursing and Health Sciences, College of Medicine and Public Health, ; The Children's Hospital at Westmead, Centre for Kidney Research Howard, Kirsten; University of Sydney, School of Public Health Howell, Martin; University of Sydney - Camperdown and Darlington Campus, School of Public Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Public health
Keywords:	skin cancer, melanoma, prevention, sun protection, sun protection behaviors

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Behavioral and pharmaceutical interventions for the prevention of skin cancers in solid organ**
5
6 **transplant recipients: a systematic review of randomized controlled trials**
7
8
9

10
11 **Authors full names and highest degree:**
12

13 Laura J. James, MPH^{1,2}, Valeria Saglimbene^{1,2}, MscMed^{1,2}, Germaine Wong, PhD^{1,2,3}, Allison Tong,
14 PhD^{1,2}, Laurence Don Wai Luu, BMedSc^{1,2}, Jonathan C. Craig, PhD⁴, Kirsten Howard, PhD¹, Martin
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Howell, PhD^{1,2}

22 **Institution of each author:**
23

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
¹Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney,
NSW 2006

²Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW 2145

³Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW 2145

⁴College of Medicine and Public Health, Flinders University, Adelaide, Australia

38 **Corresponding author:**
39

40 Laura James

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Centre for Kidney Research

The Children's Hospital at Westmead, Westmead, NSW 2145

Sydney, Australia

Phone: +61 2 9845 1482 Fax: +61 2 9845 1491

Email: laura.james@health.nsw.gov.au

56 **Word count (abstract):** 205

57
58
59
60
Word count (body): 3593

Tables: 4 **Figures:** 5

1
2
3
4 **Key words:** skin cancer, melanoma, prevention, sun protection, sun protection behaviors, health
5
6 behavior
7
8
9
10

11 **Authorship**

12 LJJ, GW, AT, LL, JCC, KH, MH designed the study; LJJ, VS, LL, MH conducted the data extraction and
13
14 analyses; all authors contributed to the interpretation of the analyses. LJJ drafted the manuscript;
15
16 all authors contributed to the writing and review of the manuscript.
17
18
19
20
21
22

23 **Disclosure**

24 The authors declare no conflicts of interest.
25
26
27
28
29
30

31 **Data availability statement**

32 No additional data available.
33
34
35
36
37

38 **Funding**

39 LJJ is supported by the National Health and Medical Research Council (NHMRC) Better Evidence
40
41 and Translation in Chronic Kidney Disease (BEAT-CKD) Program Grant (APP1092957). MH is
42
43 supported by the BEAT-CKD Program Grant (APP1092957). AT is supported by the NHMRC
44
45 Fellowship (APP1106716). The funding organizations had no role in the design and conduct of the
46
47 study; collection, management, analysis and interpretation of the data; preparation, review, or
48
49 approval of the manuscript.
50
51
52
53
54
55
56
57
58
59
60

Abbreviations

AZA, azathioprine

BCC, basal cell carcinoma

CNI, calcineurin inhibitors

CI, confidence intervals

MAL, methyl aminolaevulinate cream

MD, mean difference

MMF, mycophenolate mofetil

mTORI, mammalian target of rapamycin inhibitors

NMSC, non-melanoma skin cancer

RCT, randomized controlled trial

RR, relative risk

SCC, squamous cell carcinoma

SMD, standardized mean difference

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives

Solid organ transplant recipients are at increased risk of skin cancer, affecting more than 50% of recipients. We aimed to determine the effectiveness of interventions for behavioral change for sun protection or skin cancer prevention in solid organ transplant recipients.

Design

Systematic review

Data sources

We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and CINAHL from inception to November 2019.

Eligibility Criteria

We included randomized controlled trials that evaluated the effect of behavioral or pharmaceutical interventions on behavioral change or skin cancer prevention in solid organ transplant recipients.

Data extraction and synthesis

Risks of bias and evidence certainty were assessed using Cochrane and the GRADE framework.

Results

Twenty trials (n=2,295 participants) were included. It is uncertain whether behavioral interventions improve sun protection behavior (N=3, n= 414, SMD 0.89, 95% CI -0.84-2.62, I²

1
2 =98%) and knowledge (N=4, n=489, SMD 0.50, 95% CI 0.12-0.87, I²= 76%) as the quality of evidence
3
4 is very low. We are uncertain of the effects of mammalian target of rapamycin inhibitors on the
5
6 incidence of non-melanocytic skin cancer (N=5, n=1080, RR 0.46 95% CI 0.28-0.75, I²=72%) as the
7
8 quality of evidence is very low.
9
10

11 12 13 14 **Conclusions**

15
16 Behavioral and pharmaceutical preventive interventions may improve sun protective behavior and
17
18 knowledge, and reduce the incidence of non-melanocytic skin cancer, but the overall quality of the
19
20 evidence is very low and insufficient to guide decision-making and clinical practice.
21
22
23
24
25

26 **PROSPERO Registration number**

27
28
29 CRD42017063962
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Strengths and limitations

- A comprehensive review conducted using methods outlined by Cochrane Collaboration including GRADE to assess risk of bias and evidence certainty
- Inclusion of a broad range of interventions, including behavioral to improve sun protection behavior and pharmaceutical (immunosuppression, photodynamic therapy, oral retinoid, nicotinamide and topical immune response modifiers) to evaluate precancerous lesion response and cancer incidence
- Difficulty obtaining an overall summary estimate for many outcomes due to the variability in the analytical methods and reporting in individual studies
- Unable to perform detailed subgroup analyses or assess for publication bias due to small number of studies
- Few trials included the important outcomes of skin cancer and none included melanoma or mortality.

1. INTRODUCTION

Skin cancer, including melanoma and nonmelanoma skin cancer (NMSC), is the most frequently diagnosed malignancy among solid organ transplant recipients, affecting more than 50% of post-transplantation recipients.^{1,2} The cumulative incidence of NMSC increases with time after transplantation, from 5-10% at 2 years to 40-80% at 20 years.²⁻⁴ Compared to the general population, there is a higher rate of squamous cell carcinoma (SCC) to basal cell carcinoma (BCC), with an incidence of 65 to 250 times greater than the age and gender-matched general population.⁵⁻⁸ Once cancer develops, management options are limited as immunotherapy may be unsuitable as it may lead to graft rejection.^{9,10} Although registry data shows improvement in survival rates of transplant recipients as a result of improved transplantation techniques and management of immunosuppression, there is a greater burden of skin cancer and cancer related mortality.¹¹ The excess risk of death from invasive and metastatic skin cancer, such as SCC and melanoma, are three times to nine times higher than the general population, with five-year overall survival of less than 30%.^{6,12-15}

Sun exposure behaviors remain the most significant and modifiable risk factor in the prevention of skin cancers in the general population.¹⁶ However, with the dramatic increase in skin cancers in solid organ transplant recipients, pharmaceuticals have also been used to reduce and delay the development of skin cancer.^{16,17} Current recommendations for preventive strategies have often been extrapolated from guidelines in the general population, which may not be applicable to solid organ transplant recipients.^{18,19} For example, frequent skin self-examination and annual to biannual total body skin examination are generally recommended for the general population.¹⁸⁻²⁰ Sun protective behaviors including use of sunscreen, protective clothing and limiting sun exposure during peak hours of high UV index days are potential measures for skin cancer prevention.^{3,4,14}

1
2 Further, alteration of maintenance immunosuppression such as conversion to mammalian target
3
4 of rapamycin inhibitors (mTORi) and secondary prevention using retinoid acitretin are
5
6 recommended for management of skin cancers in high risk transplant recipients.²⁰
7
8
9

10
11 The aim of this study is determine the effectiveness of interventions that promote behavioral
12
13 change and skin cancer prevention in solid organ transplant recipients.
14
15
16

17 **2. METHODS**

18
19
20
21 This systematic review followed a pre-specified protocol registered in PROSPERO
22
23 (CRD42017063962) and is reported in accordance with the Preferred Reporting Items for
24
25 Systematic Reviews and Meta-analyses (PRISMA) checklist.²¹ The study was exempt from approval
26
27 from an ethics' board.
28
29
30
31

32 **2.1 Inclusion criteria**

33
34 All randomized controlled trials (RCTs) or quasi RCTs (allocated to trial arms by investigators) of
35
36 interventions for skin cancer prevention (both melanoma and non-melanoma skin cancer) in solid
37
38 organ transplant recipients were included. Behavioral interventions defined as any strategy used
39
40 to promote sun protective behavior including passive (e.g. pamphlets), active (e.g. group
41
42 workshops, counselling, dermatology clinic) and provision of sun protective equipment; and
43
44 pharmaceutical interventions (switch to mTOR inhibitors, photodynamic therapy, immune
45
46 response modifiers, nicotinamide and oral retinoids) and studies that reported skin cancer related
47
48 outcomes as their primary outcomes were included. Studies that did not report these outcomes as
49
50 primary end-points were excluded. Studies of interventions for the treatment of skin cancer were
51
52 excluded.
53
54
55
56
57
58
59
60

2.2 Search strategies

We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and CINAHL from inception to November 2019 without language restriction, using search strategies designed by a specialist information manager (see Medline search strategy in Figure S1). Reference lists of included studies were also searched.

2.3 Data extraction

Titles and abstracts were reviewed by two independent authors (LJJ & LL) and those that did not meet the inclusion criteria were excluded. Full text articles were reviewed by 3 independent reviewers (LJJ, VS, LL) and any disagreements were resolved by discussion. Data on study design, geographic location, sample size, type of transplant, measurement of interventions, interventions and comparators were extracted. We sought unclear or missing information from authors where possible.

2.4 Outcome measures

The pre-specified outcome measures were incidence of precancerous and cancerous lesions, sun protection behavior (including use of sunscreen, use of protective clothing including hats and sunglasses, shade and sun avoidance), knowledge and attitude, skin self-examination, sun exposure (including skin irritation, sunburn) and biologic measures (including measurement of melanin index and sun damage assessment).

2.5 Risk of bias and quality of evidence

The risk of bias was assessed independently by LJJ and VS using the Cochrane risk of bias tool.²²

The domains included in the assessment were: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, trial registration and industry involvement. Each criterion was

1 assigned a judgment of high, low or unclear risk of bias. Intention to treat and lost to follow up
2
3
4 were also assessed for each study. The quality of the evidence informing summary estimates for
5
6
7 each outcome was then assessed by LJJ using the Grading of Recommendations Assessment
8
9 Development and Evaluation (GRADE) guidelines.²³
10

11 12 13 **2.6 Data synthesis and statistical analyses**

14
15 Continuous outcomes were summarized as mean difference (MD) or standardized mean
16
17 difference (SMD) and dichotomous outcomes as relative risk (RR). A MD/SMD greater than zero
18
19 and/or a RR greater than 1 could be interpreted as favoring the intervention group relative to the
20
21 control, unless specified elsewhere. Risk estimates were reported with 95% confidence intervals
22
23 (CI), using random-effects meta-analysis. We quantified the heterogeneity using the I^2 statistic. An
24
25 I^2 value of <25% was considered to represent low heterogeneity and >75% as high heterogeneity.
26
27
28 When sufficient data were available, possible sources of heterogeneity were investigated using
29
30 subgroup analysis based on pre-specified study characteristics including sample size, trial duration,
31
32 setting and overall risk of bias. Funnel plots were planned to evaluate small study effects when at
33
34 least ten studies were included in meta-analysis. All analyses were conducted using Review
35
36 Manager version 5.3 software.
37
38
39
40
41
42
43
44

45 **2.7 Patient and public involvement**

46
47
48 There was no patient or public involvement.
49

50 51 **3. RESULTS**

52 **3.1 Study selection**

53
54
55
56
57 The literature search identified 1280 articles, of which, 1201 were excluded after abstract and title
58
59 review. Full text assessment of 79 studies found 22 eligible articles for inclusion (Figure 1).
60

3.2 Studies characteristics

We included 22 reports of 20 RCTs, including 2,295 participants (Figure 1). The study characteristics are summarized in Table 1 and Table 2. The median number of participants was 44 (range 17 to 830) and the median follow-up duration was 10 months (range 1 day to 60 months). All studies included kidney transplant recipients, with some also including heart transplant recipients (n=1), liver, heart, pancreas, lung, heart/lung and other transplants (n=1), and lung and liver transplant recipients (n=2). In total, 15 of 21 (76%) studies provided sufficient data for the meta-analyses. Six studies did not meet final criteria for meta-analysis as they had the same sample of participants (n=1),²⁴ or did not provide data that was able to be meta-analyzed (n=5).²⁵⁻²⁹

3.3 Risk of bias and quality of the evidence

Overall studies had either high or unclear risk of bias for at least one domain (Figure 2; Figure S2). Random sequence generation and allocation concealment were unclear in most studies (n=12, 60%). Blinding of participants was not done in most studies (n=16, 80%) and blinding of outcome assessors was only reporting in half of the studies (n=10). Intention to treat analyses were used in 6 (30%) studies and 6 studies (30%) had a high loss to follow-up. A total of 3 (15%) studies had incomplete outcome data, and all studies were at low risk for selective reporting. Seven studies (35%) reported industry involvement in authorship, design, or data analysis, and of the 16 trials requiring trial registration, only 9 (56%) reported accordingly.

The overall quality of the evidence was very low for all outcomes (Table S1) due to limitations in study design, heterogeneity in the intervention and outcomes measures, the very small sample size of individual studies and the small number of studies for each specific outcome. Obtaining an

1
2 overall summary estimate was difficult for many outcomes due to the variability in the analytical
3
4 methods and reporting in individual studies. In particular, assessment of reporting of sun
5
6 protection behavior and sun protection knowledge was not possible as outcomes were
7
8 inconsistent and there was large diversity of interventions used (e.g. written education material
9
10 versus a mobile app program). Furthermore, formal testing of publication bias was not performed
11
12 due to insufficient data.
13
14
15

16 17 **3.4 Interventions**

18
19 The interventions in the included studies were grouped in three broad categories, behavioral
20
21 (n=6), switch to mTOR inhibitors (n=6), and other pharmaceutical interventions (photodynamic
22
23 therapy, immune response modifiers, oral retinoids and nicotinamide) (n=9). Studies of behavioral
24
25 interventions used passive methods of delivery including written educational material (n=2), both
26
27 written educational material and text messages (n=1), mobile app programs (n=2) and a video
28
29 (n=1).
30
31
32
33
34
35
36

37 All six studies of immunosuppression compared mTORis (sirolimus) to calcineurin inhibitors (CNI)
38
39 based therapies.
40
41
42

43 Four of the eight studies of other pharmaceutical interventions assessed the effect of
44
45 photodynamic therapy using methyl aminolevinate creams compared to placebo (n=1), no
46
47 treatment to contralateral area (n=2) or a topical immune response modifier cream (n=1). Three
48
49 studies assessed oral retinoid using acitretin compared to placebo (n=1), lower dose (n=1) or a
50
51 drug free period (n=1), one study assessed nicotinamide compared to placebo and a single study
52
53 assessed the benefits of topical immune response modifier compared to placebo in kidney
54
55 transplant recipients.
56
57
58
59
60

3.5 Effect of behavioural interventions on sun protection outcomes

Sun protection behavior

Sun protection behavior, defined as hours spent outdoors per week, use of sunscreen, wearing protective clothing and seeking shade, was assessed in three trials³⁰⁻³². Educational workbooks,³⁰ educational workbooks and text messages³¹ and a mobile app program³² were compared with standard care. Patients who received behavioral interventions reported improved sun protection behavior scores³⁰⁻³² (3 studies, 414 participants, SMD 0.89, 95% CI -0.84-2.62, I² 98%) (Table 3; Figure 3). We are uncertain of the effects of behavioural interventions on sun protection behavior due to very low quality of evidence. A single trial assessed a standardised and validated educational workbook and found an improvement in the proportion of participants engaging in skin self-examination after one month (75 participants, RR 4.14, 95% CI 2.22-7.72).³³ One trial assessed a mobile app program and reported a reduction in daily hours spent outdoors among the intervention group (170 participants, MD -6.12, 95% CI -7.11 to -5.13).³²

Sun protection knowledge

The effectiveness of educational workbooks, text messages, mobile app programs and videos on sun protection knowledge was assessed in 6 studies^{24 28 30-33}, four of which provided data for a meta-analysis. There was an improvement in knowledge scores (4 studies, 489 participants, SMD 0.50, 95% CI 0.12-0.87, I² 76%) in the intervention group compared to standard care (Figure 4).³⁰⁻³³ One study compared an interactive visual representation of the educational program with standard information pamphlets and found that knowledge of sun protection improved among those who received the educational video.²⁸

Sun protection attitude

Three studies assessed sun protective attitude after receiving an educational workbook, text messages or a mobile app program over a period of 0.5 months to 1.5 months.³¹⁻³³ Compared to standard care, there was an overall improvement in scores of concern about developing cancer (3 studies, 348 participants, SMD 1.85, 95% CI 1.59-2.11, I² 96%).³¹⁻³³ Two studies involving 273 participants reported an improvement in scores of understanding the personal risk of skin cancer (SMD 0.61, 95% CI -0.60-1.82, I² 96%), adherence to sun protection (SMD 0.77 95% CI -0.14-1.68, I² 92%) and willingness or intention to change behavior (SMD 1.70, 95% CI -1.68-5.07, I² 99%).^{31 32} We are uncertain of the effects of behavioural interventions on sun protection attitude due to very low quality of evidence. A single study involving 75 participants also reported an improvement in scores of ability to recognize a potential skin cancer (MD 1.80, 95% CI 1.35-2.25), importance of skin self-examination (MD 1.05, 95% CI 0.61-1.49) and having a partner help for skin self-examination (MD 1.59, 95% CI 1.10-2.08).³³ Another single study reported an improvement in the importance of engaging in sun protection (measured using 5-point Likert scale) (101 participants, MD 7.00, 95% CI 2.94-11.06).³¹

Skin complications and biologic measures

Two trials of behavioral interventions in 271 kidney transplant recipients compared a mobile app or an educational workbook and text messages to standard care on reported skin complications and biologic measures of sun exposure.^{31 32} The intervention group experienced a reduced incidence of skin irritation (a culturally relevant term for sun exposure³⁴) (RR 1.00, 95% CI 0.89-1.13, I² 95%) or sunburn (RR 3.19, 95% CI 2.47-4.10, I² 99%). They also had a decreased melanin index (right forearm, SMD -0.42, 95% CI -0.66 to -0.18; cheek SMD -0.25, 95% CI -0.64 to -0.15) and reduced severity of sun damage (SMD -0.13, 95% CI -0.40 to 0.13) on sun exposed areas (measured using clinical images of chronic sun damage and scored 1-10).

3.6 Effect of pharmaceutical interventions on skin cancer prevention

The incidence and responses of pre-cancerous lesions were measured only in trials of pharmaceutical interventions (Table 4). These included the switch to mTOR inhibitors (n=1),³⁵ photodynamic therapy (n=2)^{36 37} and immune response modifiers (n=1)³⁸ to current treatment or placebo. The incidence of non-melanocytic skin cancers (NMSC) was assessed in nine pharmaceutical studies.^{1 35 38-44} None included melanoma as an outcome.

Topical/local interventions

One trial of 14 participants compared an immune response modifier, 5% imiquimod cream with placebo and found a reduction in the incidence of skin dysplasia (RR 2.14, 95% CI 0.31-14.65), skin atypia (RR 3.00, 95% CI 0.47-19.35), and viral warts (RR 7.00, 95% CI 0.46-106.10).³⁸

One Danish study of 26 kidney transplant recipients compared photodynamic therapy with no treatment and reported a relative reduction by approximately 40% in the incidence of NMSC on the treated area (RR 0.59, 95% CI 0.34-21.03, p 0.06).⁴⁴ A lower incidence of SCC was also reported in one trial comparing two areas of skin using an immune response modifier and placebo (14 participants, RR 0.09, 95% CI 0.001-1.70).³⁸ Two trials comparing photodynamic therapy to an immune response modifier or photodynamic therapy to placebo in recipients with diagnosed keratoses reported a complete response rate of 60% compared to 24% in the control group (50 participants, RR 5.03, 95% CI 0.14-176.17, I² 85%).^{36 37} We are uncertain of the effects of photodynamic therapy on incidence of precancerous lesions due to very low quality of evidence. Further, one trial which was not included in the meta-analysis, reported a higher cumulative

1
2 incidence of actinic keratosis lesions in untreated skin (63%) compared with skin treated by
3
4 photodynamic therapy (28%).²⁷
5
6
7
8

9 Systemic interventions

10
11
12
13

14 mTORis therapy reduced the incidence of NMSC compared to CNIs maintenance therapy (5 trials,
15
16 1082 participants, RR 0.46, 95% CI 0.28-0.75, I² 72%) (Figure 5).^{1 35 39 41 43} However evidence was
17
18 limited due to short follow-up periods, variability in dosing of mTORis and significant rates of loss
19
20 to follow up, and therefore we are uncertain of the effects of mTORis on skin cancer incidence due
21
22 to very low quality of evidence. A single trial involving 21 patients reported a reduction in the
23
24 overall incidence of SCC by 49% in the conversion arm, but reported a drop out rate of 77% and
25
26 follow-up time of less than 2 years.²⁵ Further, a single trial which compared mTORi conversion
27
28 from CNI based therapy reported a significant improvement in skin dysplasia (32 participants, RR
29
30 24.35, 95% CI 1.55-381.99).³⁵
31
32
33
34
35
36
37
38

39 Two trials comparing an oral retinoid, acitretin, with placebo or a drug free period reported an
40
41 increased lower risk of both SCCs and BCCs (46 participants, RR 0.40, 95% CI 0.19-0.85, p 0.02; RR
42
43 0.50, 95% CI 0.14-1.76)⁴² or development of a new skin cancer (19 participants, RR 0.22, 95% CI
44
45 0.06-0.90). However, there were no differences in the incidence of new SCCs.⁴⁰ One trial, which
46
47 was not included in the meta-analysis, showed approximately a 50% reduction in the incidence of
48
49 actinic keratosis which compared a high dose to a low dose of acitretin.²⁶
50
51
52
53
54

55 One Australian trial of 22 kidney transplant recipients compared nicotinamide with placebo and
56
57 reported an estimated relative rate difference of 0.35 (95% CI -0.62 to 0.74), 0.67 (95% CI -0.40 to
58
59 0.90) and 0.07 (95% CI -1.51 to 0.65) for NMSC, BCCs and SCCs respectively.²⁹
60

3.7 Subgroup analysis

Study size, trial duration, setting and risk of bias did not modify the effects of CNIs and mTORIs on skin cancer incidences (Figure S3). Sources of heterogeneity for other treatment effects could not be explored due to insufficient data.

4 DISCUSSION

Skin cancers (both non-melanoma and melanoma) are major causes of morbidity and mortality in solid organ transplant recipients. Despite this, trials of interventions aimed at preventing skin cancer in solid organ transplant recipients are few in number (20 trials), small with half comprising of 50 patients or less, of short duration (48% have <12 months follow up) and 52% do not include incidence of skin cancer as an outcome. Our review included 22 reports of 20 trials involving 2,295 transplant recipients, who were predominately kidney transplant recipients. The studies covered a broad range of interventions, including behavioral to improve sun protection behavior and pharmaceutical (immunosuppression, photodynamic therapy, oral retinoid, nicotinamide and topical immune response modifiers) to evaluate precancerous lesion response and cancer incidence. None of the behavioral intervention studies included precancerous lesions or skin cancer incidence as outcomes. Although interventions showed plausible improvements to sun protection behaviors, precancerous lesion responses and cancer incidence, there was considerable variability across interventions types, variability in outcomes assessed and outcome estimates. Overall, the current evidence for interventions for skin cancer prevention in solid organ transplant recipients is of very low quality and is insufficient to guide decision-making and clinical practice.

Although behavioral interventions appeared to improve sun protection attitude, knowledge and behavior, there were inconsistencies detected and none of these studies included skin cancer as

1
2 an outcome. Due to limited number of studies, we were unable to compare specific behavioral
3
4 interventions (e.g. mobile app vs. written education) to ascertain the most effective method of
5
6 delivering sun protection education. While there may be some modest benefits in the reduction in
7
8 cancer incidence (for NMSC) among solid organ transplant recipients who were converted to
9
10 mTORIs compared to those on CNI maintenance, there was substantial heterogeneity across the
11
12 studies that was unable to be explained by subgroup analyses. Heterogeneity may be attributed to
13
14 the absence of long term follow up, large discontinuation rates owing to adverse events and
15
16 variability in the doses of mTORIs. Pharmaceutical interventions (switch to mTOR inhibitors,
17
18 photodynamic therapy, immune response modifiers) showed a reduction in precancerous lesions
19
20 compared to standard care or a comparator group. However uncertainty exists in the treatment
21
22 effects and there were too few studies, interventions were incomparable, follow-up times were
23
24 variable and considerable loss to follow up for some studies to conclude that the benefits are
25
26 sustainable.
27
28
29
30
31
32
33
34
35

36 Previous systematic reviews have evaluated the impact of behavioral interventions on skin cancer
37
38 prevention in the general population,⁴⁵ and concluded that computer programs may increase sun
39
40 protective behaviors, and 'appearance-focused' interventions may decrease sun tanning and UV
41
42 exposure in adolescents and young women, respectively. Reviews conducted in other populations
43
44 at high-risk including outdoor workers,⁴⁶ family history, personal history and phenotypic factors⁴⁷
45
46 have found similar improvement in sun protective behaviors, including use of sunscreen, as well as
47
48 a decreased incidence of keratoses. A systematic review of the benefits and harms of oral
49
50 retinoids for the prevention of skin cancer among high risk transplant recipients led to inconclusive
51
52 results on the effect of acitretin due to the small number of included trials.⁴⁸
53
54
55
56
57
58
59
60

1
2 Despite the inclusion of all interventions aimed at the prevention of skin cancer in solid organ
3
4 transplant recipients and the comprehensive systematic search for eligible studies, there are some
5
6 potential limitations. Due to the heterogeneity of the studies, the high risk of bias, the potential
7
8 for reporting bias and imprecision in the point estimates of individual studies, there is a high
9
10 degree of uncertainty in the estimate of the effect of skin cancer prevention interventions. All
11
12 studies of behavioral interventions were undertaken in United States, with 4 by the same authors,
13
14 whilst most pharmacological intervention studies were conducted in Europe. There were also
15
16 large discontinuation rates owing to adverse events in trials of mTORIs. Further, given the small
17
18 number of studies included in the meta-analysis, we were unable to perform any detailed
19
20 subgroup analyses to explore heterogeneity or assess for publication bias. While we were unable
21
22 to show and assess publication bias using standard statistical tests, we would suggest the
23
24 observed heterogeneity may also be attributed to potential publication and reporting biases. It is
25
26 difficult to quantify the extent of such bias in this review, but one would expect research with
27
28 'positive' findings that indicate an intervention works, such as behavioral interventions improve
29
30 sun protection, are more likely to be published more than one, in high impact journals and more
31
32 likely to be cited. Finally, few trials included patient important outcomes associated with skin
33
34 cancer and none included melanoma or mortality.
35
36
37
38
39
40
41
42
43
44
45

46 The use of pharmaceutical and immunosuppression therapy remains complex. Not only has mTORI
47
48 therapy shown benefits in lowering the risk of skin cancer, early conversion to mTORI therapy
49
50 from CNIs has also shown promising effects in reducing cancer rates.^{49 50} On the contrary, overall
51
52 mortality is higher and discontinuation following adverse events is more common in patients who
53
54 receive mTORI therapy.^{49 50} Several RCTs showed a higher rate of patients reporting adverse
55
56 events or drug discontinuation with sirolimus,^{1 41 43} demonstrating concern of its clinical
57
58 usefulness.⁴⁹ Nicotinamide may also offer benefits to reducing skin cancer incidence by 20% and is
59
60

1
2 relatively safe with minimal side effects. The protective effect of nicotinamide on skin cancer
3
4 incidence in kidney transplant recipients is currently being explored in a phase 3 randomised
5
6 controlled trial.
7
8
9

10
11 Although behavioral change is a simple strategy, long-term adherence remains challenging.

12
13 While behavioral counseling has been shown to increase sun protective behaviors in non-
14
15 transplant populations,⁴⁵ there is no direct evidence to show that the behavioral change led to a
16
17 reduction in morbidity and mortality. Previous studies have suggested that transplant recipients
18
19 do not practice sun protective behaviors regularly,⁵¹⁻⁵³ were less likely to use sunscreen⁵⁴ and that
20
21 patients have to perceive skin cancer as being an important risk to be motivated to change
22
23 behavior.^{55 56} However, studies on risk perception of transplant recipients remain conflicting.

24
25 Given this complexity and the observed inconsistencies in the existing trials, process evaluations
26
27 including facilitators and barriers to behavioral change should be included in future trials. Such
28
29 evaluations could include the use of qualitative methodology to support the trial design, ascertain
30
31 the perspectives of participants on the intervention and evaluate the implementation.^{57 58}
32
33
34
35
36
37
38
39
40

41 We suggest that further strategies for skin cancer prevention in transplant recipients require a
42
43 multifaceted and individualized approach. Transplant recipients are likely to benefit from early
44
45 implementation of education, particularly before transplantation occurs and recipients may be
46
47 preoccupied with other health needs related to transplantation. Although recipients understand
48
49 the importance of ongoing education for the ability to self-manage their disease, they may
50
51 experience difficulty in concentrating and learning new knowledge, and are often unable to look
52
53 beyond their graft and the anxiety/fear of graft loss.⁵⁹⁻⁶¹ Interventions should be integrated into
54
55 routine appointments and tailored to meet the individual needs of patients. This would be best
56
57
58
59
60

1
2 achieved through a shared decision-making approach to identify the patient's preferences and
3
4 priorities and thereby enhance the likelihood of success of self-management and prevention.⁶²
5
6
7

8
9 Additional large-scale and high-quality RCTs are needed to demonstrate the effectiveness of
10
11 interventions used to prevent skin cancer in transplant recipients in terms of patient important
12
13 outcomes, in particular morbidity and mortality associated with skin cancer. Determining patient's
14
15 preferences for prevention and management of skin cancer are also warranted to ensure
16
17 interventions and outcomes for trials are relevant to patient needs and priorities and better
18
19 support patient-centered treatment decisions.⁶³ Evidence of the efficacy of sun protective
20
21 behavior interventions need to be strengthened, with use of measures that are homogenous,
22
23 reliable and validated.
24
25
26
27
28
29

30
31 Preventative measures including behavioral, switch to mTOR inhibitors and other pharmaceuticals
32
33 may improve skin cancer outcomes for solid organ transplant recipients. However, the overall
34
35 quality of evidence is of very low and insufficient to guide decision-making and clinical practice.
36
37 Future robust studies that are well powered, have long-term follow up, and use clinical and
38
39 patient important outcome measures in a consistent manner are required to therefore optimize
40
41 outcomes for solid organ transplant recipients.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. *N Engl J Med* 2012;367(4):329-39.
2. Harwood CA, Mesher D, McGregor JM, et al. A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population. *Am J Transplant* 2013;13(1):119-29. doi: 10.1111/j.1600-6143.2012.04292.x [published Online First: 2012/10/18]
3. Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. *Br J Dermatol* 2002;147(5):950-6. [published Online First: 2002/11/02]
4. Ulrich C, Kanitakis J, Stockfleth E, et al. Skin cancer in organ transplant recipients--where do we stand today? *Am J Transplant* 2008;8(11):2192-8. doi: 10.1111/j.1600-6143.2008.02386.x [published Online First: 2008/09/11]
5. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med* 2003;348(17):1681-91. doi: 10.1056/NEJMra022137 [published Online First: 2003/04/25]
6. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. *J Am Acad Dermatol* 2002;47(1):1-20. doi: <https://doi.org/10.1067/mjd.2002.125579>
7. Garrett GL, Blanc PD, Boscardin J, et al. Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. *JAMA Dermatol* 2017;153(3):296-303. doi: 10.1001/jamadermatol.2016.4920 [published Online First: 2017/01/18]
8. Green AC, Olsen CM. Increased risk of melanoma in organ transplant recipients: systematic review and meta-analysis of cohort studies. *Acta Derm Venereol* 2015;95(8):923-27.
9. Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. *J Immunother Cancer* 2019;7(1):106.
10. Hassan NA, Abudayyeh A, Shah M, et al. The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature: American Society of Clinical Oncology, 2018.

- 1 11. Au EH, Chapman JR, Craig JC, et al. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and
2 after Kidney Transplant. *J Am Soc Nephrol* 2019;30(3):471-80.
- 3
4
5 12. Martinez JC, Otley CC, Stasko T, et al. Defining the clinical course of metastatic skin cancer in organ
6 transplant recipients: a multicenter collaborative study. *Arch Dermatol* 2003;139(3):301-6. [published
7
8
9 Online First: 2003/03/08]
- 10
11
12 13. ANZDATA Registry. 38th Report, Chapter 10: Cancer. Adelaide, Australia. : Australia and New Zealand
13
14 Dialysis and Transplant Registry, 2016.
- 15
16
17 14. Chapman JR, Webster AC, Wong G. Cancer in the Transplant Recipient. *Cold Spring Harb Perspect Med*
18
19 2013;3(7):a015677. doi: 10.1101/cshperspect.a015677
- 20
21
22 15. Garrett GL, Lowenstein SE, Singer JP, et al. Trends of skin cancer mortality after transplantation in the
23
24 United States: 1987 to 2013. *J Am Acad Dermatol* 2016;75(1):106-12. doi: 10.1016/j.jaad.2016.02.1155
25
26 [published Online First: 2016/04/14]
- 27
28
29 16. Ibrahim SF, Brown MD. Tanning and cutaneous malignancy. *Dermatologic Surgery* 2008;34(4):460-74.
30
31 doi: 10.1111/j.1524-4725.2007.34092.x [published Online First: 2008/02/06]
- 32
33
34 17. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant
35
36 recipients. *Clin Transplant* 2005;19(6):726-34. doi: 10.1111/j.1399-0012.2005.00412.x [published Online
37
38 First: 2005/11/30]
- 39
40
41 18. Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence?
42
43 *Clin J Am Soc Nephrol* 2008;3 Suppl 2:S87-S100. doi: 10.2215/CJN.03320807
- 44
45
46 19. Acuna SA, Huang JW, Scott AL, et al. Cancer Screening Recommendations for Solid Organ Transplant
47
48 Recipients: A Systematic Review of Clinical Practice Guidelines. *Am J Transplant* 2017;17(1):103-14. doi:
49
50 10.1111/ajt.13978 [published Online First: 2016/08/31]
- 51
52
53 20. Chadban SJ, Barraclough KA, Campbell SB, et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO
54
55 Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *Nephrology* 2012;17(3):204-14. doi:
56
57 10.1111/j.1440-1797.2011.01559.x
- 58
59
60

- 1 21. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-
2
3 Analyses: The PRISMA Statement. *PLOS Medicine* 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097
4
5 22. edited by Julian PTH, Sally G. Cochrane handbook for systematic reviews of interventions: Chichester,
6
7 West Sussex ; Hoboken NJ : John Wiley & Sons 2008.
8
9
10 23. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and
11
12 strength of recommendations. *BMJ* 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD [published
13
14 Online First: 2008/04/26]
15
16
17 24. Robinson JK, Friedewald JJ, Desai A, et al. Response across the health-literacy spectrum of kidney
18
19 transplant recipients to a sun-protection education program delivered on tablet computers: randomized
20
21 controlled trial. *JMIR Cancer* 2015;1(2):e8.
22
23
24 25. Carroll RP, Hester J, Wood KJ, et al. Conversion to sirolimus in kidney transplant recipients with
25
26 squamous cell cancer and changes in immune phenotype. *Nephrol Dial Transplant* 2013;28(2):462-65.
27
28
29 26. de Sevaux RG, Smit JV, de Jong EM, et al. Acitretin treatment of premalignant and malignant skin
30
31 disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of
32
33 acitretin. *J Am Acad Dermatol* 2003;49(3):407-12. [published Online First: 2003/09/10]
34
35
36
37 27. Togsverd-Bo K, Omland SH, Wulf HC, et al. Primary prevention of skin dysplasia in renal transplant
38
39 recipients with photodynamic therapy: a randomized controlled trial. *Am J Transplant* 2015;15(11):2986-
40
41
42 90. doi: <https://dx.doi.org/10.1111/ajt.13358>
43
44
45 28. Trinh N, Novice K, Lekakh O, et al. Use of a brief educational video administered by a portable video
46
47 device to improve skin cancer knowledge in the outpatient transplant population. *Dermatologic Surgery*
48
49 2014;40(11):1233-9. doi: <https://dx.doi.org/10.1097/DSS.000000000000148>
50
51
52 29. Chen AC, Martin AJ, Dalziell RA, et al. A phase II randomized controlled trial of nicotinamide for skin
53
54 cancer chemoprevention in renal transplant recipients. *Br J Dermatol* 2016;175(5):1073-75. doi:
55
56 10.1111/bjd.14662 [published Online First: 2016/10/30]
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30. Clowers-Webb HE, Christenson LJ, Phillips PK, et al. Educational outcomes regarding skin cancer in organ transplant recipients: Randomized intervention of intensive vs standard education. *Arch Dermatol* 2006;142(6):712-8. doi: 10.1001/archderm.142.6.712 [published Online First: 2006/06/21]
31. Robinson JK, Guevara Y, Gaber R, et al. Efficacy of a sun protection workbook for kidney transplant recipients: a randomized controlled trial of a culturally sensitive educational intervention. *Am J Transplant* 2014;14(12):2821-29.
32. Robinson JK, Friedewald JJ, Desai A, et al. A randomized controlled trial of a mobile medical app for kidney transplant recipients: effect on use of sun protection. *Transplant Direct* 2016;2(1):1.
33. Robinson JK, Turrisi R, Mallett KA, et al. Efficacy of an educational intervention with kidney transplant recipients to promote skin self-examination for squamous cell carcinoma detection. *Arch Dermatol* 2011;147(6):689-95. doi: <https://dx.doi.org/10.1001/archdermatol.2011.10>
34. Robinson JK, Joshi KM, Ortiz S, et al. Melanoma knowledge, perception, and awareness in ethnic minorities in Chicago: recommendations regarding education. *Psychooncology* 2011;20(3):313-20. doi: 10.1002/pon.1736 [published Online First: 2010/09/30]
35. Salgo R, Gossman J, fer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. *Am J Transplant* 2010;10(6):1385-93.
36. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. *Br J Dermatol* 2004;151(1):196-200.
37. Togsverd-Bo K, Halldin C, Sandberg C, et al. Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients – a randomized intra-individual controlled trial. *Br J Dermatol* 2017 doi: 10.1111/bjd.15884

- 1 38. Brown VL, Atkins CL, Ghali L, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin
2
3 dysplasia in high-risk renal transplant recipients: Randomized, double-blind, placebo-controlled trial. *Arch*
4
5 *Dermatol* 2005;141(8):985-93.
6
7
- 8 39. Alberu J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted
9
10 to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
11
12 *Transplantation* 2011;92(3):303-10.
13
14
- 15 40. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic
16
17 skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled
18
19 study. *J Clin Oncol* 1995;13(8):1933-8. doi: 10.1200/jco.1995.13.8.1933 [published Online First:
20
21 1995/08/01]
22
23
- 24 41. Campbell S, Walker R, Tai S, et al. Randomized controlled trial of sirolimus for renal transplant
25
26 recipients at high risk for nonmelanoma skin cancer. *Am J Transplant* 2012;12(5):1146-56.
27
28
- 29 42. George R, Weightman W, Russ GR, et al. Acitretin for chemoprevention of non-melanoma skin cancers
30
31 in renal transplant recipients. *Austral J Dermatol* 2002;43(4):269-73.
32
33
- 34 43. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al. Two-year randomized controlled
35
36 prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive
37
38 squamous cell carcinomas to sirolimus. *J Clin Oncol* 2013;31(10):1317-23.
39
40
- 41 44. Wulf HC, Pavel S, Stender I, et al. Topical photodynamic therapy for prevention of new skin lesions in
42
43 renal transplant recipients. *Acta Derm Venereol* 2006;86(1):25-28.
44
45
- 46 45. Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the
47
48 U.S. Preventive Services Task Force. *Ann Intern Med* 2011;154(3):190-201. doi: 10.7326/0003-4819-154-3-
49
50 201102010-00009 [published Online First: 2011/02/02]
51
52
- 53 46. Horsham C, Auster J, Sendall MC, et al. Interventions to decrease skin cancer risk in outdoor workers:
54
55 update to a 2007 systematic review. *BMC Res Notes* 2014;7:10. doi: 10.1186/1756-0500-7-10 [published
56
57 Online First: 2014/01/09]
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
47. Wu YP, Aspinwall LG, Conn BM, et al. A systematic review of interventions to improve adherence to melanoma preventive behaviors for individuals at elevated risk. *Prev Med* 2016;88:153-67. doi: 10.1016/j.ypmed.2016.04.010 [published Online First: 2016/04/20]
48. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. *Br J Dermatol* 2005;152(3):518-23. doi: 10.1111/j.1365-2133.2005.06347.x [published Online First: 2005/03/25]
49. Howard MD, Su JC, Chong AH. Skin cancer following solid organ transplantation: a review of risk factors and models of care. *Am J Clin Dermatol* 2018;19(4):585-97.
50. Lim W, Eris J, Kanellis J, et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. *Am J Transplant* 2014;14(9):2106-19.
51. Iannacone MR, Pandeya N, Isbel N, et al. Sun Protection Behavior in Organ Transplant Recipients in Queensland, Australia. *Dermatology* 2015;231(4):360-6. doi: 10.1159/000439428 [published Online First: 2015/09/30]
52. Imko-Walczuk B, Graczyk M, Korban M, et al. Impact of Skin Cancer Awareness on Prophylactic Behavior Among Renal Transplant Recipients. *Transplant Proc* 2016;48(5):1526-31. doi: 10.1016/j.transproceed.2015.11.040 [published Online First: 2016/08/09]
53. Thomas BR, Barnabas A, Agarwal K, et al. Patient perception of skin-cancer prevention and risk after liver transplantation. *Clin Exp Dermatol* 2013;38(8):851-6. doi: 10.1111/ced.12159 [published Online First: 2013/06/21]
54. Robinson JK, Rigel DS. Sun protection attitudes and behaviors of solid-organ transplant recipients. *Dermatologic Surgery* 2004;30(4 Pt 2):610-5. doi: 10.1111/j.1524-4725.2004.30145.x [published Online First: 2004/04/06]

- 1 55. Robinson JK, Friedewald J, Gordon EJ. Perceptions of Risk of Developing Skin Cancer for Diverse
2
3 Audiences: Enhancing Relevance of Sun Protection to Reduce the Risk. *J Cancer Educ* 2016;31(1):153-7. doi:
4
5 10.1007/s13187-015-0885-1 [published Online First: 2015/07/26]
6
7 56. Skiveren J, Mortensen EL, Haedersdal M. Sun protective behaviour in renal transplant recipients. A
8
9 qualitative study based on individual interviews and the Health Belief Model. *J Dermatolog Treat*
10
11 2010;21(6):331-6. doi: 10.3109/09546630903410166 [published Online First: 2010/06/10]
12
13
14 57. Lewin S, Glenton C, Oxman AD. Use of qualitative methods alongside randomised controlled trials of
15
16 complex healthcare interventions: methodological study. *BMJ* 2009;339:b3496. doi: 10.1136/bmj.b3496
17
18 [published Online First: 2009/09/12]
19
20
21 58. Oakley A, Strange V, Bonell C, et al. Process evaluation in randomised controlled trials of complex
22
23 interventions. *BMJ* 2006;332(7538):413-6. doi: 10.1136/bmj.332.7538.413 [published Online First:
24
25 2006/02/18]
26
27
28 59. Buldukoglu K, Kulakac O, Kececioglu N, et al. Recipients' perceptions of their transplanted kidneys.
29
30 *Transplantation* 2005;80(4):471-6. [published Online First: 2005/08/27]
31
32
33 60. Jamieson NJ, Hanson CS, Josephson MA, et al. Motivations, Challenges, and Attitudes to Self-
34
35 management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. *Am J Kidney Dis*
36
37 2016;67(3):461-78. doi: 10.1053/j.ajkd.2015.07.030 [published Online First: 2015/09/16]
38
39
40 61. Urstad KH, Wahl AK, Andersen MH, et al. Renal recipients' educational experiences in the early post-
41
42 operative phase--a qualitative study. *Scand J Caring Sci* 2012;26(4):635-42. doi: 10.1111/j.1471-
43
44 6712.2012.00972.x [published Online First: 2012/03/16]
45
46
47 62. Gordon EJ, Butt Z, Jensen SE, et al. Opportunities for shared decision making in kidney transplantation.
48
49 *Am J Transplant* 2013;13(5):1149-58. doi: 10.1111/ajt.12195 [published Online First: 2013/03/16]
50
51
52 63. O'Hare AM, Rodriguez RA, Bowling CB. Caring for patients with kidney disease: shifting the paradigm
53
54 from evidence-based medicine to patient-centered care. *Nephrol Dial Transplant* 2016;31(3):368-75. doi:
55
56 10.1093/ndt/gfv003 [published Online First: 2015/02/01]
57
58
59
60

1 64. Dantal J, Morelon E, Rostaing L, et al. Sirolimus for Secondary Prevention of Skin Cancer in Kidney
2
3 Transplant Recipients: 5-Year Results. *Journal of Clinical Oncology* 2018;36(25):2612-20. doi:
4
5 10.1200/jco.2017.76.6691
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Characteristics of included studies (n=20)

Characteristics	N (%)
Type of transplant	
Kidney	16 (80)
Multiple*	4 (20)
Sex	
≥ 50% Male	18 (90)
< 50% Male	1 (5)
Not specified	1 (5)
Age (mean)	
< 60	10 (50)
≥ 60	5 (25)
Not specified	5 (25)
Sample size	
10 – 50	11 (55)
50 – 100	3 (15)
100 – 200	4 (20)
>200	2 (10)
Setting	
Single center	8 (40)
Multi center	11 (55)
Not specified	1 (5)
Country of origin	
Australia	3 (15)
Denmark	4 (20)
France	1 (5)
Germany	1 (5)
Netherlands	2 (10)
New Zealand	2 (10)
Switzerland	1 (5)
Sweden	1 (5)
United Kingdom	3 (15)
United States	6 (30)
Other†	1 (5)
Intervention Type	
Behavioral	5 (25)
Switch to mTOR inhibitors	6 (30)
Photodynamic therapy	4 (20)
Oral retinoid	3 (15)
Nictotinamide	1 (5)
Topical immune response modifier	1 (5)
Duration of follow up	
<12 months	9 (45)
12 months	4 (20)
24 months	5 (25)
>24 months	1 (5)
Not specified	1 (5)
Year of publication	
1995 – 1999	1 (5)
2000 – 2004	3 (15)
2005 – 2009	4 (20)
2010 – 2014	8 (40)
2015 – 2017	4 (20)

* Kidney, liver and lung (n=2); kidney and heart (n=1); Kidney and multiple other types (n=1) – see text

† 111 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, United States), South Africa, and South America (Argentina, Brazil, Chile)

Table 2. Characteristics of individual studies

Study	N	Type of transplant	Setting	Type of intervention	Measures	Intervention	Comparator	Primary outcomes	Time (mths)
Behavioral interventions (n=6)									
4 Clowers- 5 Webb 6 2006 ³⁰	202	Kidney, liver, heart, pancreas, lung, heart/lung, other [§]	Single centre, United States	Behavioral	Self-reported questionnaire	Repetitive written material	Standard care	Knowledge & behavior	10
8 Robinson 9 2011 ³³	75	Kidney	United States	Behavioral	Self-reported questionnaire	Workbook	Standard care	Knowledge & behavior	1
10 Robinson 11 2014 ³¹	101	Kidney	Single centre, United States	Behavioral	Self-reported questionnaire	Workbook Text messages	Standard care	Knowledge & behavior	1.5
14 Robinson 15 2015 ^{24†}	170	Kidney	Multi-centre, United States	Behavioral	Self-reported questionnaire	Mobile app program	Standard care	Knowledge & behavior	0.5
17 Robinson 18 2016 ³²	170	Kidney	Multi-centre, United States	Behavioral	Self-reported questionnaire	Mobile app program	Standard care	Knowledge & behavior	1.5
21 Trinh 22 2014 ^{28*}	100	Kidney, liver, lung	Single centre, United States	Behavioral	Self-reported questionnaire	Video	Pamphlet	Knowledge	1 day
Switch to mTOR inhibitors (n=7)									
25 Alberu 26 2011 ³⁹	830	Kidney	Multi centre [§]	Switch to mTOR inhibitors	Investigator reported adverse events	Conversion to sirolimus	CNI	Cancer incidence	24
29 Campbell 30 2012 ⁴¹	86	Kidney	Multi centre, Australia, New Zealand, United States	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	CNI	Cancer incidence	12
34 Carroll 35 2013 ^{25*}	32	Kidney	Multi centre, UK	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to prednisolone & sirolimus	CNI/AZA	Cancer incidence	24
37 Euvrard 38 2012 ¹⁶⁴	120	Kidney	Multi centre, France	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	CNI	Cancer incidence	24
40 Hoogendijk- 41 van den 42 Akker	155	Kidney	Multi centre, Netherlands, UK	Switch to mTOR inhibitors	Physical examination +/- biopsy	Conversion to sirolimus	AZA/MMF/ CNI	Cancer incidence	24

6/mjopen-2024-029265 on 17 May 2024 by guest. Protected by copyright. Downloaded from <http://bmjopen.bmj.com/>

2013⁴³

1 Salgo 2 2010 ³⁵ 3 4	44	Kidney	Single centre, Germany	Switch to mTOR inhibitors	Physical examination +/- biopsy Clinical photographs	Conversion to sirolimus and prednisone	AZA/MMF/ CNI	Precancerous skin dysplasia incidence	12
5 Pharmaceutical interventions – Photodynamic therapy (n=4); oral retinoids (n=3); nicotinamide (n=1); 5% imiquimod cream (n=1)									
6 Bavinck 7 1995 ⁴⁰ 8 9 10 11	44	Kidney	Multi centre, Netherlands	Oral retinoid	Physical examination +/- biopsy	Acitretin	Placebo	Cancer incidence precancerous lesion reduction	6
12 Brown 13 2005 ³⁸ 14 15 16 17	21	Kidney	Multi centre, UK	Topical immune response modifier cream	Physical examination +/- biopsy Clinical mapping and photographs	5% Imiquimod cream	Placebo	Reduction of precancerous lesions	4
18 Chen 19 2016 ^{29*} 20 21	22	Kidney	Single centre, Australia	Nicotinamide	Physical examination	Nicotinamide	Placebo	Cancer incidence	6
22 de Sevaux 23 2003 ^{26*} 24 25	26	Kidney	Single centre, Netherlands	Oral retinoid	Physical examination +/- biopsy	High dose acitretin	Low dose acitretin	Cancer and precancerous incidence	12
26 Dragieva 27 2004 ³⁶ 28 29	17	Kidney, heart	Single centre, Switzerland	Photodynamic therapy	Physical examination +/- biopsy Clinical photographs	Methyl aminolevulinate cream	Placebo	Precancerous lesion response	4
30 George 31 2002 ⁴² 32 33	23	Kidney	Multi centre, Australia	Oral retinoid	Physical examination Annual radiological evaluation	Acitretin	Drug free period	Cancer incidence	24
34 Togsverd- 35 Bo 2015 ^{27*†} 36 37	25	Kidney	Single centre, Denmark	Photodynamic therapy	Physical examination Clinical photographs	Methyl aminolevulinate cream	No treatment contralateral area	Actinic keratosis incidence	36
38 Togsverd- 39 Bo 2017 ^{37†} 40 41	35	Kidney, lung, liver	Multi-centre, Denmark and Sweden	Photodynamic therapy	Physical examination Questionnaire/Diary	Methyl aminolevulinate cream	5% imiquimoid cream	Actinic keratosis lesion response	6

32

Wulf 2006 ^{44†}	27	Kidney	Multi centre, Denmark and Netherlands	Photodynamic therapy	Clinical mapping and photographs	Methyl aminolevulinate cream	No treatment contralateral area	Cancer incidence	12
-----------------------------	----	--------	---	-------------------------	-------------------------------------	------------------------------------	---------------------------------------	---------------------	----

*Excluded from analyses – no meaningful data to extract

‡Randomized controlled areas of skin on individuals

‡Excluded from analyses – same participants as Robinson 2016

§11 centres in Asia, Australia, Europe, the Middle East, North America (Canada, Mexico, United States), South Africa, and South America (Argentina, Brazil, Chile)

Abbreviations: CNI, Calcineurin inhibitor; AZA, Azathioprine; MMF, Mycophenolate mofetil

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

Table 3. Effect of behavioral interventions on sun protection outcomes

Outcome	Studies	Participants	Weighted MD ^a /SMD ^b [95% CI]	Relative risk	P	I ²	Intervention	Comparator
BEHAVIORAL INTERVENTION (n=5)								
SUN PROTECTION BEHAVIOR								
General sun protection behavior	3	414	0.89 [-0.84, 2.62]		0.31	98%	Workbook, text messages, mobile app program	Standard care
Skin self-examination								
1 month after visit	1	75		4.14 [2.22, 7.72]	<0.001	90%	Workbook	Standard care
If checked, concerned	1	42		6.43 [0.42, 98.58]	0.18	99%		
If concerned, saw dermatologist	1	12		Not estimable ^c		99%		
Decrease daily hours outdoors	1	170	-6.12 [-7.11, -5.13] ^d		<0.001	99%	Mobile app program	Standard care
SUN PROTECTION KNOWLEDGE								
	4	489	0.50 [0.12, 0.87]		0.01	76%	Workbook, text messages, mobile app program	Standard care
SUN PROTECTION ATTITUDE								
Concern about developing skin cancer	3	348	1.88 [0.96, 2.80]		<0.001	92%	Workbook, text messages, mobile app program	Standard care
Recognise personal risk	2	273	0.61 [-0.60, 1.82]		0.32	96%	Workbook and text messages, mobile app program	Standard care
Confidence in ability to perform sun protection	2	273	0.77 [-0.14, 1.68]		0.10	92%		
Willingness/intention to change behavior	2	273	1.70 [-1.68, 5.07]		0.32	99%		
Knowledge of significance of skin cancer, relevance of sun protection, risk of having a tan	1	101	7.00 [2.94, 11.06]		0.001	99%	Workbook and text messages	Standard care
Confidence in ability to recognise a skin cancer	1	75	1.80 [1.35, 2.25]		<0.001	99%	Workbook	Standard care
Importance of skin self-examination	1	75	1.05 [0.61, 1.49]		<0.001	99%		
Importance of partner help for skin self-examination	1	75	1.59 [1.10, 2.08]		<0.001	99%		

COMPLICATIONS

1	Skin irritation								
2	None	2	271	1.00 [0.89, 1.13]	0.95	95%	Workbook and text messages, mobile app program	Standard care	
3	> 1	2	271	0.77 [0.43, 1.36]	0.36	89%			
4	Sunburn (past week)								
5	None	2	271	3.19 [2.47, 4.10]	<0.001	99%			
6	> 1	2	271	2.68 [1.81, 3.96]	<0.001	95%			

BIOLOGIC MEASURES

10	Melanin index - RU arm (sun protected)	2	271	0.12 [-0.12, 0.35]	0.34	0%	Workbook and text messages, mobile app program	Standard care
11	Melanin index - R forearm (sun exposed)	2	271	-0.42 [-0.66, -0.18] ^d	0.001	0%		
12	Cheek (sun exposed)	2	271	-0.25 [-0.64, 0.15] ^d	0.22	61%		
13	Sun damage assessment - R forearm	2	271	-0.13 [-0.40, 0.13] ^d	0.33	16%		

^aMean difference

^bStandardised mean difference

^cUnable to estimate due to absence of comparator group

^dReduction of outcome of interest represents an improvement

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

For peer review only

Table 4. Effect of pharmaceutical interventions on skin cancer prevention

Outcome	Studies	Participants	Relative risk	P	I ²	Intervention	Comparator
SWITH TO mTOR INHIBITORS (n=5)							
<u>PRE-CANCEROUS LESIONS</u>							
Skin dysplasia							
Any improvement	1	32	24.35 [1.55, 381.99]	0.02	0.0	Sirolimus	CNI ^b
Unchanged	1	32	0.85 [0.28, 2.61]	0.78	0.0		
Any worsening	1	32	0.04 [0.00, 0.66]	0.02	0.0		
<u>CANCEROUS LESIONS</u>							
SCC ^d /BCC ^e incidence	5	1082	0.46 [0.28, 0.75]	0.002	72%	Sirolimus	CNI
≥1 SCC	1	53	0.64 (0.35, 1.17)	0.15	N/A		
Skin cancer (excluding SCC)	1	53	0.74 (0.49, 1.14)	0.17	N/A		
Skin cancer (including SCC)	1	53	0.85 (0.61, 1.17)	0.32	N/A		
Skin cancer with BCC	1	53	0.89 (0.45, 1.78)	0.75	N/A		
PHOTODYNAMIC THERAPY (n=3)							
<u>PRE-CANCEROUS LESIONS</u>							
Actinic keratosis reduction (1-2 sessions)							
Complete response	2	50 ^a	5.03 [0.14, 176.17]	0.37	85%	MAL ^c	Placebo, Imiquimod 5% cream
Partial response	1	17 ^a	7.00 [0.39, 125.99]	0.19	N/A	MAL	Placebo
No reduction	1	17 ^a	0.09 [0.02, 0.40]	0.002	N/A		
<u>CANCEROUS LESIONS</u>	1	26 ^a	0.59 [0.34, 1.03]	0.06	N/A	MAL	No treatment
IMMUNE RESPONSE MODIFIERS (n=1)							
<u>PRE-CANCEROUS LESIONS</u>							
Reduced skin atypia							
	1	14 ^a	3.00 [0.47, 19.35]	0.25	N/A	Imiquimod 5% cream	Placebo
Reduced dysplasia	1	14 ^a	2.14 [0.31, 14.65]	0.44	N/A		
Reduced keratoses	1	14 ^a	2.14 [0.31, 14.65]	0.44	N/A		
Reduced no. viral warts	1	14 ^a	7.00 [0.46, 106.10]	0.16	N/A		

CANCEROUS LESIONS

SCC incidence

1	Treated (cream vs. placebo)	1	14 ^a	0.09 [0.01, 1.70]	0.11	N/A	Imiquimod 5% cream	Placebo
2								
3								
4	Untreated (control site)	1	14 ^a	0.43 [0.08, 2.37]	0.33	N/A		
5								

ORAL RETINOIDS (n=2)

CANCEROUS LESIONS

Decreased incidence:

10	> 1 SCC	1	46 ^a	0.40 [0.19, 0.85]	0.02	N/A	Acitretin	Drug free period
11								
12	> 1 BCC	1	46 ^a	0.50 [0.14, 1.76]	0.28	N/A		
13								
14	New skin cancer	1	19 ^a	0.22 [0.06, 0.90]	0.03	N/A	Acitretin	Placebo
15								

^aControl is the contralateral or similar area of skin on the same participant

^bCalcineurin inhibitor

^cMethyl aminolaevulinate cream

^dSquamous cell carcinoma

^eBasal cell carcinoma

6/bmjopen-2019-029265 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

For peer review only

1
2
3 **Figure legends**
4

5
6 Figure 1. Study selection
7

8 Figure 2. Risk of bias of included studies
9


10 Figure 3. Behavioral interventions – Sun protection behavior (general)
11

12
13 Figure 4. Behavioral interventions – Sun protection knowledge
14

15 Figure 5. Switch to mTOR inhibitors – Non melanoma skin cancer incidence
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


Figure 1. PRISMA Flowchart



209x297mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Risk of bias in included studies




297x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




209x279mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



209x279mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



209x279mm (300 x 300 DPI)

Figure S1. Search Strategy

1. exp Neoplasms, Basal Cell/
2. basal cell carcinoma.ti,ab.
3. exp Neoplasms, Squamous Cell/
4. squamous cell carcinoma.ti,ab.
5. nonmelanom*.ti,ab.
6. non melanom*.ti,ab.
7. 1 or 2 or 3 or 4 or 5 or 6
8. Melanoma/
9. melanoma*.ti,ab.
10. Skin Neoplasms/
11. skin cancer*.ti,ab.
12. 8 or 9 or 10 or 11
13. 7 or 12
14. exp Organ Transplantation/
15. solid organ transplant*.mp.
16. transplant recipient*.tw.
17. exp Immunosuppression/
18. Immunocompromised Host/
19. 14 or 15 or 16 or 17 or 18
20. 13 and 19
21. randomized controlled trial.pt.
22. controlled clinical trial.pt.
23. randomized.ab.
24. placebo.ab.
25. Clinical Trials as Topic/
26. randomly.ab.
27. (crossover or cross-over).tw.
28. trial.ti.
29. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
30. Animals/ not (animals/ and Humans/)

1 31. 29 not 30

2
3 32. 20 and 31
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure S2. Risk of bias and key findings in individual studies

Study, year	Random sequence generation	Allocation concealment	Blinding participants & personnel	Blinding outcome assessors	Incomplete outcome data	Selective reporting	Intervention & comparator	Outcome RR/MD/SMD (95% CI)
Behavioral Interventions (n=6)								
7 Clowers-Webb 8 2006 ³⁰ 9 10	Unclear	Unclear	High	Unclear	High	Low	Repetitive written material vs. standard care	General behavior SMD -0.30 (-0.63, 0.03) Knowledge SMD 0.07 (-0.26, 0.40)
11 Robinson 12 2011 ³³ 13 14 15 16 17 18 19 20 21 22 23 24	Unclear	Unclear	Unclear	Unclear	Low	Low	Workbook vs. standard care	Skin self examination (1 month) RR 4.14 (2.22, 7.72) Knowledge SMD 1.05 (0.57, 1.54) Concern about developing cancer SMD 0.95 (0.47, 1.43) Confidence to recognize cancer MD 1.80 (1.35, 2.25) Importance of skin self-examination MD 1.05 (0.61, 1.49) Importance of partner to help for skin self-examination MD 1.59 (1.10, 2.08)
25 Robinson 26 2014 ³¹ 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44	Low	Low	High	Low	Low	Low	Workbook & text messages vs. standard care	General behavior SMD 0.32 (-0.07, 0.71) Knowledge SMD 0.65 (0.25, 1.05) Concern about developing cancer SMD 2.73 (2.19, 3.27) Recognize personal risk SMD -0.01 (0.40, 0.38) Confidence in sun protection SMD 0.30 (-0.09, 0.68) Willingness/intention to change behaviour SMD -0.02 (-0.41, 0.36) Importance of skin cancer/sun protection/having a tan MD 7.00 (2.94, 11.06) Skin irritation none RR 1.37 (1.16, 1.63) Skin irritation >1 RR 0.15 (0.03, 0.61) Sunburn none RR 1.30 (1.12, 1.52) Sunburn >1 RR 0.17 (0.04, 0.72) Melanin index - RU arm (sun protected) SMD 0.23

1 2 3 4	Hoogendijk- van den Akker 2013 ⁴³	Unclear	Low	High	Low	High	Low	Sirolimus vs CNI/MMF/AZA	Cancer incidence RR 0.13 (0.02, 0.99)
5 6 7 8 9 10	Salgo 2010 ³⁵	Unclear	Unclear	High	Low	High	Low	Sirolimus vs CNI/MMF/AZA	Cancer incidence RR 0.13 (0.02, 0.95) Skin dysplasia Any improvement RR 24.35 (1.55, 381.99) Unchanged RR 0.85 (0.28, 2.61) Any worsening RR 0.04 (0.00, 0.66)
11	Pharmaceutical interventions – Photodynamic therapy (n=4); oral retinoids (n=3); 5% imiquimod cream (n=1)								
12 13 14	Bavinck 1995 ⁴⁰	Unclear	Unclear	Low	Unclear	Low	Low	Acitretin vs. placebo	Cancer incidence RR 0.22 (0.06, 0.90)
15 16 17 18 19 20 21 22 23	Brown 2005 ³⁸	Unclear	Unclear	Low	Low	Low	Low	5% Imiquimod cream vs. placebo	Cancer incidence SCC treated RR 0.09 (0.01, 1.70) SCC untreated RR 0.43 (0.08, 2.37) Reduced skin atypia RR 3.00 (0.47, 19.35) Reduced dysplasia RR 2.14 (0.31, 14.65) Reduced keratosis RR 2.14 (0.31, 14.65) Reduced no. viral warts RR 07.00 (0.46, 106.10)
24 25	Chen 2016 ²⁹	Low	Unclear	Low	Low	Low	Low	Nicotinamide vs. placebo	
26 27 28 29	de Sevaux 2003 ²⁶	Unclear	Low	High	Unclear	Low	Low	High dose acitretin vs. low dose acitretin	
30 31 32 33 34	Dragieva 2004 ³⁶	Unclear	Unclear	Low	Unclear	Low	Low	Methyl aminolevulinate cream vs. placebo	Actinic keratosis reduction Complete response RR 27.00 (1.73, 420.67) Partial reduction RR 7.00 (0.39, 125.99) No reduction RR 0.09 (0.02, 0.40)
35 36 37 38	George 2002 ⁴²	Unclear	Unclear	High	Unclear	Low	Low	Acitretin vs. drug free period	Cancer incidence >1 SCC RR 0.40 (0.19, 0.85) >1 SCC RR 0.50 (0.14, 1.76)
39 40 41 42 43 44	Togsverd-Bo 2015 ^{27*}	Low	Low	Unclear	Low	Low	Low	Methyl aminolevulinate cream vs. no treatment	

1	Togsverd-Bo 2017 ^{37†}	Low	Low	High	Unclear	Low	Low	Methyl aminolevulinate cream vs. 5% Imiquimod cream	Actinic keratosis reduction Complete response RR 1.42 (0.81, 2.48)
2									
3									
4									
5	Wulf 2006 ^{44†}	Low	High	High	Low	Low	Low	Methyl aminolevulinate cream vs. no treatment	Cancer incidence RR 0.59 (0.34, 1.03)
6									
7									
8									
9									

10 *Excluded from analyses – no meaningful data to extract
 11 †Randomized controlled areas of skin on individuals
 12 ‡Excluded from analyses – same participants as Robinson 2016

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

6/bmjopen-2019-029266 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

Table S1. Assessment of quality of studies using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system.

Quality of assessment (Decrease in quality score)						
Number of studies	Risk of bias/Quality of evidence	Inconsistency	Indirectness	Imprecision	Publication bias	Quality
Sun protection behavior						
5 RCTs ^{24 30-33}	Serious study limitations (-1) Randomisation unclear ^{24 30 32 33} Participants not blinded or well described ^{24 30-33} Concealment of allocation not described. ^{30 33}	Important inconsistency (-1) Analysed in subgroups. heterogeneity (I ² =99%) ³⁰⁻³²	Indirectness (-1) Diverse interventions (written vs. electronic), varying duration (2 weeks to 10 months) Same sample of participants ^{24 32}	Serious imprecision (-1) Small sample size, CIs crosses the null	Uncertain Unable to determine. Small number of studies, large heterogeneity	Very low
Sun protection knowledge						
6 RCTs ^{24 28 30-33}	Serious limitations (-1) Randomisation unclear ^{24 30 32 33} Participants not blinded or well described ^{24 28 30-33} Concealment of allocation not described ^{28 33}	Important inconsistency (-1) Heterogeneity (I ² 85%)	Indirectness (-1) Diverse interventions (written vs. electronic), varying duration (1 day to 10 months) Same sample ^{24 32}	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity	Very low
Sun protection attitude						
4 RCTs ^{24 31-33}	Serious limitations (-1) Randomisation unclear ^{24 32 33} Participants not blinded or well described ^{24 31-33} Concealment of allocation	Important inconsistency (-1) Wide variation in the effect estimates, heterogeneity (I ² 97%).	Indirectness (-1) Diverse interventions (written vs. electronic), Similar duration. Same sample ^{24 32}	Serious imprecision (-1) Small sample size, small number of events	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low

7 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

not described^{32 33}

Complications (skin irritation, sunburn)

2 RCTs ^{31 32}	Serious limitations (-1) Participants not blinded ^{31 32}	Important inconsistency (-1) Heterogeneity (I ² =95-99%) Analysed in subgroups. Similar effect estimates.	Indirectness (-1) Diverse interventions (written vs. electronic), similar duration.	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low
-------------------------	--	--	---	--	---	-----------------

Biologic measures (melanin index, sun damage)

2 RCTs ^{31 32}	Serious limitations (-1) Randomisation unclear ³² Participants not blinded ^{31 32}	Important inconsistency (-1) Analysed in subgroups. Heterogeneity (I ² 60%)	Indirectness (-1) Different interventions (written vs. electronic), similar duration.	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Small number of studies, large heterogeneity.	Very low
-------------------------	---	---	---	--	---	-----------------

Pre-cancerous incidence

4 RCTs ^{27 35-38}	Serious limitations (-1) Randomisation or allocation unclear ^{35 36 38} Participants not blinded or well described ^{27 35-38}	Important inconsistency (-1) Analysed in subgroups.	Indirectness (-1) Diverse interventions, varying duration	Serious imprecision (-1) Small sample size	Uncertain Unable to determine. Large heterogeneity.	Very low
----------------------------	--	---	---	--	--	-----------------

Cancer incidence


10 RCTs ^{1 29 35 38-44}	Serious limitations (-1) Randomisation unclear ^{1 40 42 43} Allocation concealment not used or unclear ^{1 29 39 40 42 44} Participants not blinded. ^{1 35 39 41-44}	Important inconsistency (-1) Majority of participants came from 1 study ³⁹ Small sample ^{1 29 35 38 40-44}	Indirectness (-1) Diverse interventions (immunosuppression, photodynamic therapy, immune response modifier, retinoid, nicotinamide), varying duration	Serious imprecision (-1) Majority of participants from one trial (n=551), small number of events	Uncertain Unable to determine. Large heterogeneity.	Very low
----------------------------------	--	---	---	--	--	-----------------

6/bmjopen-2019-029266 on 17 May 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Figure S3. Subgroup analyses of immunosuppression conversion interventions on skin cancer incidence





PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICCO, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10-14
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10-14
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	9
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14-15
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16-17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	2

1136/bmjopen-2019-029265 on May 2020. Downloaded from http://bmjopen.bmj.com/ on April 27, 2024 by guest. Protected by copyright.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>